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Summary 
Cancer is a major cause of morbidity and mortality in today’s world, affecting populations in all 
countries and all regions. Although no drug or treatment able to cure cancer in all of its forms and 
variations was found so far, the clinical advancements of 20
th
 and 21
st
 century provided a number of 
effective drugs for specific types of cancers and had a significant effect on the survival and the 
quality of life of patients. One of these drugs, the platinum-based complex cisplatin, achieved 
almost 100% cure rate of testicular cancer, not only saving lives of thousands of patients every year 
but also overturning a paradigm of medicinal chemistry – it was the first metal-based anticancer 
drug used in the clinic. The success of cisplatin encouraged the search for new metal-based 
anticancer agents, which soon expanded to other metals, such as ruthenium. During the last three 
decades, numerous ruthenium-based compounds with interesting anticancer properties were 
prepared and thoroughly investigated, two of which (NAMI-A and KP1019) were ultimately 
introduced into clinical trials, showing the potential of ruthenium complexes in cancer therapy. 
The goal of the presented thesis was to investigate the properties of dinuclear arene ruthenium 
thiolato-bridged complexes and to establish their potential as anticancer drugs. In the first part of 
the thesis, several monothiolato, dithiolato and trithiolato complexes were synthesized and 
evaluated for their stability and reactivity with biological substrates. The results were correlated 
with the in vitro anticancer activity of the three types of complexes and showed the most stable 
trithiolato complexes to be the most active against ovarian cancer cell lines. Subsequently, the most 
active trithiolato derivative, diruthenium-1, was thoroughly investigated in vitro and in vivo to 
establish the mode of action of this complex, showing its promising ability to influence the tumor 
growth and to prolong the survival of tumor-bearing mice.  
In the second part of this thesis, three series of conjugates of the mixed trithiolato complexes 
were synthesized to demonstrate the potential of the coupling of dinuclear arene ruthenium 
complexes with biologically active organic molecules. Thus, the thiolato-bridged complexes were 
coupled with propargyl bromide, the resulting conjugates being available for the 1,3-Huisgen 
addition with tumor targeting compounds. Conjugates with ibuprofen were synthesized to 
investigate the effect of the antiinflamatory agent on the activity and selectivity of the resulting 
complexes towards cancer cells. Finally, conjugates of dinuclear trithiolato arene ruthenium 
complexes with alkylating agent chlorambucil were synthesized to show the effect of the two 
different modes of action of the conjugates on their activity in vitro and in vivo.  
These results demonstrate the potential of the dinuclear thiolato-bridged arene ruthenium 
complexes as a versatile platform for the synthesis of anticancer agents with variable biological 
properties and modes of action.  
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Chapter 1:  Introduction 
1.1  Cancer 
 “… the renegade cells that form a tumor are the result of normal development gone awry. In 
spite of extraordinary safeguards taken by the organism to prevent their appearance, cancer cells 
somehow learn to thrive. Normal cells are carefully programmed to collaborate with one another in 
constructing the diverse tissues that make possible organismic survival. Cancer cells have a quite 
different and more focused agenda. They appear to be motivated by only one consideration: making 
more copies of themselves.”  
From The Biology of Cancer, R. Weinberg, Garland Science, 2
nd
 edition, 2014. 
 
The adult human body is composed of approximately 10
15
 cells, many of which are required to 
divide and differentiate rapidly, in order to sustain their population and preserve the function of the 
tissue they form. Cells that have the capacity for division and differentiation are called stem cells. It 
can be calculated that there are about 10
12 
divisions per day in these stem cell compartments. Yet in 
spite of this enormous production of new cells, the majority of divisions proceeds without errors, 
owing to hundreds of genes that intricately control the process. Normal tissue growth requires a 
balance between the activity of the genes that promote cell proliferation and those that suppress it. It 
also relies on the activities of genes that signal when damaged cells should undergo apoptosis. In 
cancer cells, however, genetic mutations accumulated over time in their DNA are the cause of the 
suppression of some of those control mechanisms and signaling pathways, leading to malignant 
cells that grow and divide in an uncontrolled manner, invading normal tissues and organs and 
eventually spreading throughout the body. This growth and spreading of malignant cells is called 
cancer [1-4].  
Cancer is a major cause of morbidity and mortality in today’s world, with approximately 14 
million new cases and 8 million cancer-related deaths in 2012, affecting populations in all countries 
and all regions. Among men, the five most common sites of cancer diagnosed in 2012 were lung 
(16.7% of the total), prostate (15.0%), colorectum (10.0%), stomach (8.5%) and liver (7.5%). 
Among women, the most common incident sites of cancer were breast (25.2%), colorectum (9.2%), 
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lung (8.7%), cervix (7.9%) and stomach (4.8%) [5-6]. Figure 1 shows the incidence and mortality of 
the most common cancers in the world [5]. 
 
Figure 1 - Cancer incidence and mortality rates per 100 000 by major sites in 2012 [5] 
 
Since cancer can result from abnormal proliferation of any of the different kinds of cells in the 
body, there are more than a hundred distinct types of cancer, which can vary substantially in their 
behavior and response to treatment [4]. A summary of the overall pathological classification scheme 
of tumor types is presented in Figure 2. However, the entire spectrum of tumors that appear in 
various organs and tissues is difficult to capture in a single classification scheme, since it requires 
the use of histological features of tumors together with information about their tissues of origin, 
differentiation states and biological behavior. The scheme presented here allows the classification 
of the majority of human tumors [1]. 
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Figure 2 - Classification of human tumors 
 
The great majority of the commonly occurring cancers are caused by factors or agents that are 
external to the body and that somehow attack and corrupt its tissues. Those factors include lifestyle, 
diet, occupational exposure, viruses and carcinogens (substances causing cancer) [1].  
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Figure 3 – Examples of carcinogenic compounds 
 
The development of cancer proceeds in three stages - initiation, promotion and malignant 
transformation. The initiators, such as some alkylating agents or polycyclic hydrocarbons, induce 
the first mutagenic changes to the cell, which then needs to undergo multiple other mutations before 
the cancer really develops. Agents called promoters are usually responsible for this. Promoters do 
not cause cancer by themselves; they increase cell division, which is required for the outgrowth of a 
proliferative cell population during early stages of tumor development. Promotion has no effect on 
cells that have not undergone initiation. Thus, several factors, often the combination of a susceptible 
cell and a carcinogen, are needed to cause cancer. Examples of tumor promoters are free radicals, 
hormones or immune system suppressors. The malignant transformation is then the process by 
which the first lesions, caused by initiators and promoters, are transformed into malignant cancers. 
This step can be caused by the same agents as the initiation. Some agents, such as certain polycyclic 
hydrocarbons or aromatic amines (Figure 3) are complete carcinogens, that is to say they are both 
initiators and promoters, being able to start cancer on their own [1,4,8]. 
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Figure 4 - Progression of cancer depending on different treatment approaches [9] 
 
In order to successfully cure cancer, it is necessary eliminate all of the cancerous cells in the 
body of the host (patient) and to eliminate any possibility of recurrence. To achieve this, a com-
bination of approaches is often adopted – at first, surgical intervention is used to remove as much of 
the solid tumor as possible, followed by radiation therapy and several cycles of chemotherapy to kill 
all the remaining cancer cells in the body. The effectiveness of this approach, largely dependent on 
the early diagnosis of the disease, is demonstrated in Figure 4. 
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1.2  Chemotherapy 
The term chemotherapy was coined at the beginning of 20
th
 century by the famous German 
clinician Paul Ehrlich, who defined it as the use of chemicals to treat disease [10]. The original 
meaning of the world was rather broad, referring to the treatment of any disease by a chemical 
agent. In today’s usage, chemotherapy refers mainly to the treatment of cancer, the original 
meaning is expressed by the word pharmacotherapy. 
 The first anticancer chemotherapeutic agents were developed based on the observation made 
during the World War II – the troops that were exposed to mustard gas showed notably depleted 
bone marrow and lymph nodes. This encouraged pharmacologists Alfred Gilman and Louis 
Goodman in 1943 to examine the potential therapeutic effects of the nitrogen mustard (Figure 5) on 
mice bearing transplanted lymphoid tumor. They observed clear regression of the tumor and 
followed up with an experiment on a human patient, obtaining the same surprising result. 
 
Figure 5 - Nitrogen mustard HN2, mechlorethamine 
 
This discovery led to the development of structural analogues of nitrogen mustards, with the aim 
of designing agents with lower general toxicity while preserving the anticancer effect of the 
compounds, at the time unparalleled. Several related alkylating agents were thus developed, 
including modern orally available drugs such as chlorambucil or cyclophosphamide [10]. 
The success of alkylating agents in 1940s followed by studies on tetrahydrofolate metabolism 
inhibitors proved for the first time that a chemical compound can be used to treat and possibly even 
cure cancer, an achievement many scientists at the time considered improbable at best [10]. Soon 
after, new targets for chemotherapeutic drugs started to be discovered and new families of cytotoxic 
compounds were developed, some of which ultimately proved highly efficient in treatment of 
various cancers. The overview of different types of chemotherapeutic agent in current clinical use is 
given below [11-12]. 
 
Introduction   
   
7 
Alkylating Agents 
Alkylating agents, in a medicinal sense, are compounds capable of interacting with DNA 
nucleobases. They are either electrophiles or generate electrophiles in vivo to produce 
polarized molecules that bind to the nucleophilic nitrogen of a nucleobase. This binding 
results in cross-linking or strand-breaking reactions that hinder the correct DNA replication 
and bring about, by various cellular mechanisms, the programmed death of the cell – 
apoptosis. Chlorambucil, cyclophosphamide or busulfan are examples of alkylating agents, 
the platinum chemotherapeutics cisplatin, oxaliplatin and carboplatin also belong to this 
group. 
Antimetabolites 
Low-molecular-weight compounds that exert their effect by virtue of their similarity with 
naturally occurring metabolites involved in nucleic acid synthesis are called anti–
metabolites. Their similarity allows them to be incorporated in the nucleic acid and produce 
errors that inhibit DNA replication, other antimetabolites can influence critical enzymes 
involved in nucleic acid synthesis. The most often used antimetabolites are purine or 
pyrimidine analogs such as mercaptopurine, fludarabine or fluorouracil, or folic acid analogs 
such as methotrexate [1]. 
Natural Products 
The natural products include mitotic inhibitors vincristine and vinblastine, found in the plant 
Cataranthus roseus, products from Podophyllum peltatum and Camphoteca accuminata 
affecting enzymes topoisomerase I and II, antitumor antibiotics, or antimicrobial compounds 
produced by Streptomyces species affecting the function and synthesis of nucleic acids. 
Examples of clinically used drugs include doxorubicin, paclitaxel, vincristine or topotecan. 
Hormones and Hormone Antagonists 
Clinically active anticancer hormones and hormone antagonists include steroid estrogens, 
progestins, androgens, corticoids and their synthetic derivatives, nonsteroidal synthetic 
compounds with steroid or steroid-antagonist activity, hypothalamic-pituitary analogs, and 
thyroid hormones. Each agent has diverse effects, whose relative roles are only partially 
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understood and can vary between tumor types. Examples of hormones and hormone 
antagonists are prednisone, tamoxifen or letrozole. 
Molecularly Targeted Agents 
Recent advances in oncology and the increased understanding of molecular events that are 
responsible for the development of cancer have made possible the development of new 
drugs with specific molecular targets. These highly specific drugs take advantage of the 
modern drug development approaches and are able to selectively influence specific enzymes 
in cancer cells or induce an immunological response of the organism against cancer cells. 
Imatinib or cetuximab are examples of molecularly targeted agents. 
Other Chemotherapeutic Drugs 
Other chemical agents with various ways of influencing cancer cells have been used in 
clinic, for example growth factor binding inhibitors (suramin), cytoprotectors (amifostine), 
somatostatin analogs (octreotide) or photosensitizing agents (porfimer). 
 
In order to completely cure a patient of cancer, it is necessary to eradicate all the cancer cells 
present in the body, since even a single remaining cell is able to continue the uncontrolled division 
that defines cancer and can therefore cause a complete relapse of the disease [10]. Unfortunately, 
most tumors are heterogeneous, meaning that they contain populations of different cells, each 
population possessing different sensitivity to given chemotherapy treatment. This presents a 
significant problem inasmuch as, even if the majority of the tumor cells is killed by a 
chemotherapeutic agent, the remaining cells that are resistant to this treatment will continue to grow 
and the tumor will no longer respond to the treatment.  As a measure to overcome this natural drug 
resistance, multidrug protocols were developed and applied with success. The first multidrug 
protocol was used in 1960s and was called ‘VAMP’ – an abbreviation of four anticancer drugs 
vincristine, amethopterin, 6-mercaptopurine and prednisone that constituted the treatment. This 
program increased the remission rate of acute lymphotic leukemia to 60%, proving that 
combinations of drugs with different cellular targets can be beneficial for the success of 
chemotherapy [13].  
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As the understanding of cancer biology increases, new multi-drug treatment programs are 
developed, clearly showing the superiority of this approach over single-drug treatments. In order to 
address the issue of drug resistance of many cancers and to successfully fight all the existing types 
of the disease, new drugs with novel modes of action need to be developed and applied in the clinic, 
possibly in combination with other, already known agents [14]. 
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1.3  Metal-Based Chemotherapeutics 
Inorganic compounds have been used in medicine for almost 5000 years. As far back as 3000 
years before Christ, the Egyptians used copper to sterilize water. Other precious metals such as gold 
and silver were used by Chinese, Egyptian, Greek, Indian and Arabic healers in cures of various 
sorts. Iron and zinc remedies were used since around 1500 BC. During the Renaissance period in 
Europe, mercurous chloride found use as a diuretic and was widely utilized along with other 
mercurial diuretics until 1950s. It was only at the beginning of the 19
th
 century, however, that a 
more rational development of medicinal applications of inorganic compounds started to flourish. In 
1908, Paul Ehrlich was the first to document the effectiveness of animal models in screening series 
of compounds to establish their activity against diseases. Using a rabbit model to screen compounds 
against syphilis, he discovered compound 606 (arsphenamine, marketed as Salvarsan), which was 
then used as a successful antisyphilitic, replacing the toxic mercury compounds used previously. 
Other metal-containing compounds of value were discovered and used in medicine during the 19
th
 
century, such as K[Au(CN)2] for the treatment of tuberculosis, pentavalent antimony compounds for 
the treatment of leishmaniasis [15] or gold complexes (mostly thiolates) against rheumatoid arthritis 
[16-18]. 
The first metal complex ever to be used in the field of anticancer chemotherapy was cis-
diamminedichloridoplatinum(II), or cisplatin, whose anticancer properties were discovered 
serendipitously in 1965 [19] and which was approved for clinical use in 1978 [20]. Since then, 
platinum complexes are the most widely studied metal complexes in the field of cancer 
chemotherapy, but complexes of other platinum metals such as ruthenium, rhodium, palladium, 
osmium and iridium are also subject to detailed studies [21-22]. Only platinum complexes have so 
far been applied in the clinical practice, although several complexes of ruthenium as well as of 
some other metals (Fe, Zn, Ga, Mo, or Au) are currently undergoing clinical trials [23-24].  
 
1.3.1  Platinum Compounds 
Although platinum was probably known and used already in ancient times [25], the first 
European reference to the element 78 appears in 1557 in the works of the Julius Caesar Scaliger as a 
description of an unknown noble metal found near Mexico, "which no fire nor any Spanish artifice 
has yet been able to liquefy". Pre-Columbian Indians apparently used white alloys of gold and 
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platinum, from which they made many little artifacts [26]. Being a subject of intensive studies in 
18
th
 and 19
th
 century, platinum gradually found applications in jewelry, in the production of 
laboratory ware, in fuel cell electrodes [27] and later also as part of chemical catalysts and catalytic 
converters in cars. Currently, over 46% of the world production of platinum is used in vehicle 
emission control devices, 31% in jewelry and the rest in other applications, such as electrodes, 
catalysts in chemical industry or anticancer drugs [28]. 
Since the discovery of the biological properties of cisplatin by Rosenberg in 1965 [19], this 
simple inorganic complex has gradually found its way into the clinical practice and has become one 
of the most important drugs in cancer chemotherapy. Today, cisplatin is used in 32 of 78 treatment 
regimens listed in Martindale reference book in combination with a wide variety of other drugs 
including topoisomerase II inhibitors (doxorubicin, etoposide, mytomycin, bleomycin and 
epirubicin), nitrogen mustards (cyclophosphamide, melphalan and ifosfamide), antimetabolites  
(gemcitabine, 5-fluorouracil and methotrexate), vinca alkaloids (vinblastine and vinorelbine) and 
taxols (paclitaxel) [29]. Cisplatin has a central role in the treatment of testicular cancer, for which it 
has a 90% cure rate, with nearly a 100% cure rate for the early stage disease. It is also used in the 
treatment of ovarian, bladder, non-small cell lung and small cell lung cancer, melanoma, 
lymphomas and myelomas [30-31]. The limitations of cisplatin stem from the toxic side-effects of 
the drug, which arise from its indiscriminate uptake into all rapidly dividing cells. These side-
effects include nephrotoxicity, neurotoxicity, myelosuppression, emetogenesis and ototoxicity. 
Some of these problems can be mitigated by supplementary drugs or treatments, such as antiemetics 
or hydration by saline solution [11,32].  
Since 1970s, a plethora of structural analogs of cisplatin has been synthesized in order to find 
compounds with higher selectivity and therefore less severe side-effects as well as compounds 
active against different types of cancer. Insofar only two platinum compounds other than cisplatin 
(carboplatin and oxaliplatin) were approved for the use in the clinic worldwide; three other 
complexes of platinum ledaplatin, lobaplatin and heptaplatin (Figure 6) are used locally in Japan, 
China and Korea, respectively [32].  
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Figure 6 - Structures of clinically used platinum(II) complexes 
 
Apart from square-planar platinum(II) complexes, a large part of the research on platinum 
anticancer drugs concentrated on octahedral platinum(IV) complexes. The rationale is the 
following: The octahedral geometry allows the introduction of two additional ligands, providing 
further tuning of physico-chemical properties and the attachment of targeting ligands. Platinum(IV) 
complexes are also substantially more inert than the platinum(II) complexes and do not bind to 
intracellular proteins or thiols, which can lead to their increased bioavailability compared to 
platinum(II) compounds. Due to their inertness, platinum(IV) drugs are able to get internalized into 
the cancer cells before being reduced to the active platinum(II) species that ultimately bind to the 
DNA. An elegant description of the structure-activity relationship and drug design of platinum(IV) 
drugs based on the recent scientific discoveries is shown in Figure 7 [33]. 
 
Figure 7 - Influence of ligands on the behavior and activity of platinum(IV) complexes [33]. 
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Despite the number of new platinum complexes that have been synthesized and tested for their 
anticancer activity, the problems mentioned previously for cisplatin still remain – the side effects, 
although significantly reduced in modern drugs such as carboplatin, are still an issue and the 
resistance (inherent as well as acquired) of certain cancer cells limit the scope of application of 
platinum drugs [34-36]. Therefore, many research groups have rather focused their efforts on other 
metals then platinum, in order to overcome the aforementioned problems [36]. 
One of the most successful metals in recent anticancer research is ruthenium [37]. 
 
1.3.2  Ruthenium Compounds 
Discovered by Karl Ernst Claus (Karl Karlovich Klaus) in 1844 and named after Ruthenia (the 
latinised name for Russia) in the honor of the country where it was first identified [38], ruthenium 
was in fact the last one of the platinum metals to be discovered. Ruthenium is the element 44 of 
Mendeleev’s periodic table, its molecular weight is 101.07 g∙mol-1, its density is 12.41 g∙cm-3 at 
20°C, and seven isotopes are naturally occurring. The electronic configuration of ruthenium is Kr 
[4d
7
] [5s
1
] [39-40]. Ruthenium is a rare element, contained in the earth’s crust in the concentration 
of about 1 ppb [41], but is relatively inexpensive compared with other group 8 metals [42]. Its 
isolation from platinum group metal ores is described in Figure 8. 
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Figure 8 - Isolation of platinum metals from metal ores [43] 
 
The biological effects of ruthenium compounds have been studied since the mid-1950s [44], but 
these compounds have generally remained disregarded, partly because of their poor water solubility. 
Another reason was the discovery of the anticancer properties of cisplatin in 1965, which has 
inclined the research towards platinum compounds [45]. We can probably consider the pioneering 
work of Clarke in 1980 [46] as the impulse that started the thorough investigations on ruthenium 
complexes and their anticancer properties that last to this day. The main arguments in favor of 
ruthenium are the non-toxicity of the metal, the low general toxicity of most of its compounds, a 
wide range of oxidation state that ruthenium can access under physiological conditions and a very 
similar ligand exchange rate of platinum and ruthenium compounds (in both cases the ligand 
exchange processes are quite slow and may take hours, rates of exchange ranging from 10
-3
 to 10
-2
 
s
-1
, see Figure 9) [41,47].  
Introduction   
   
15 
 
Figure 9 - Ligand exchange of some metal ions [48] 
 
As with platinum, a plethora of coordination complexes of ruthenium have been synthesized and 
studied. Among them, two complexes are currently undergoing clinical trials and can be therefore 
considered to be at the forefront of ruthenium chemotherapy. Those two complexes (Figure 10) are 
[indH]trans-[Ru(N-ind)2Cl4] named KP1019 and [imiH]trans-[Ru(N-imi)(S-dmso)Cl4] named 
NAMI-A (imi being imidazole, dmso  dimethyl sulfoxide and ind indazole) [49].  
 
Figure 10 - Structures of NAMI-A and KP1019 
 
The mode of action of these two potential drugs differs from established platinum-based 
chemotherapeutic agents. The theory of activation by reduction, already postulated by Clarke in 
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1980 [46], states that ruthenium(III) complexes act as prodrugs, being little active and non-toxic. It 
is assumed that once they are delivered into the tumor, the physiological differences between the 
cancerous and healthy tissue (most importantly the reducing environment caused by the increased 
metabolic rate of the tumor cells) lead to the reduction of the Ru(III) complexes to the active Ru(II) 
species [45,50-51]. 
It is now well-recognized that immediately after intravenous administration, ruthenium-based 
anticancer drugs interact with serum proteins, such as albumin and transferrin. Transferrin, which is 
responsible for transporting iron through the body to supply the cells, may particularly serve as a 
natural route for the delivery of the cytotoxic Ru agents to tumor cells as a result of their higher 
demand for iron. Along with transferrin, the most abundant human plasma protein, albumin, 
displays high binding affinity and may contribute to the drug’s cellular uptake via the enhanced 
permeability and retention (EPR) effect, but might also act as a reservoir for the transferrin cycle. 
The binding to proteins and the cellular uptake of the two drugs is followed by the activation by 
reduction, whereupon the compounds exhibit their anticancer properties in cancer cells (Figure 11) 
[50]. 
 
Figure 11 - Mode of action of NAMI-A and KP1019 [50] 
 
Although structurally similar (Figure 10), NAMI-A and KP1019 differ largely in their effects on 
primary solid tumors and metastases. NAMI-A, the first ruthenium anticancer compound to ever 
reach clinical trials [37], failed the usual screenings of putative anticancer agents, such as the 
National Cancer Institute (NCI, USA) screen against a panel of 60 cell lines. On the other hand it 
has been shown to prevent the development and growth of pulmonary metastases in all the solid 
tumors on which it has been tested. Metastases were inhibited independently of their stage of 
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growth. Such behavior is observed in the absence of activity against primary tumors [52]. 
Importantly, NAMI-A is active on lung metastases also when it is dosed by the per oral (p.o.) route. 
Metastases spawned by malignant tumors are responsible for about 90% of deaths from cancer [1], 
NAMI-A was therefore abandoned as a conventional chemotherapeutic agent in favor of its 
development as a selective antimetastatic compound [53]. The investigation of mode of action of 
NAMI-A showed that it undergoes aquation and hydrolysis within minutes in aqueous media at pH 
= 7.4 and 37°C [54], and is practically non-cytotoxic in common cancer cell lines [55]. These 
findings suggest that its activity is not related to DNA binding in the cell nucleus [56-57]. 
Interactions with actin-type proteins on the cell surface [58-59] or with collagens of the 
extracellular matrix [60-61], which preserves it from elimination and gives it prolonged contact 
with the metastatic cells in the lungs, have been suggested as possible mechanisms of anti-
metastatic action of NAMI-A [61]. The recent results of combined phase I/II study of NAMI-A in 
combination with gemcitabine showed rather severe side-effects that were not discovered in the 
preclinical evaluations. The doses of 300 mg/m
2
 and 450 mg/m
2
 caused neutropenia, anemia, 
elevated liver enzymes, transient creatinine elevation, nausea, vomiting, constipation, diarrhea, 
fatigue, and renal toxicity. The combination of NAMI-A with gemcitabine was shown to be less 
active in non-small cell lung cancer patients than gemcitabine alone [62].  
Contrary to NAMI-A, KP1019 is active against a wide range of primary tumors, in particular 
against platinum-resistant colorectal autochthonous tumors [63-64], its IC50 value (50% inhibitory 
concentration) against SW480 cell line being 58.2 µM [65]. KP1019 induces apoptosis 
predominantly by the intrinsic mitochondrial pathway (loss of mitochondrial membrane potential in 
a high percentage of cells) and shows an activity superior to that of 5-fluorouracil in experimental 
therapy of autochthonous colorectal carcinoma. In early clinical trials, no dose-limiting toxicity was 
found, and the state of five out of six patients either stabilized or improved after the treatment with 
KP1019 [66]. Based on the recent results of the clinical evaluations of KP1019, its sodium analog 
NKP-1339 (sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]), has been proposed as the 
lead compound in the further trials. The main reason for the use of NKP-1339 was its higher water 
solubility, which not only facilitates manufacturing and handling of the drug, but also allows 
clinical application of larger doses [67].   
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1.4  Arene Metal Complexes  
The history of arene metal complexes starts with the discovery of ferrocene. In 1952, the groups 
of Ernst Otto Fisher and Geoffrey Wilkinson independently reported the structure of bis–
(cyclopentadienyl) iron, previously prepared by Pauson, for which Mark C. Whiting suggested the 
name ferrocene (Figure 12) [68]. It was the first example of a so-called molecular sandwich 
complex, a type of structure hitherto unknown to chemists. The structure was not immediately 
accepted by the general scientific community (a reviewer of the Journal of the American Chemical 
Society wrote to Woodward in 1952: “We have dispatched your communication to the printers but I 
cannot help feeling that you have been at the hashish again.” [69]), but when other groups 
confirmed the veracity of the structure by X-ray crystallography and molecular orbital theory 
studies, the skepticism disappeared. 
 
Figure 12 - Structure of ferrocene 
 
The first arene metal complex was presumably prepared by Franz Hein in 1918. With the 
intention of preparing triphenylchromium, Hein reacted phenylmagnesium bromide with CrCl3 and 
obtained a mixture of products with surprising properties and of unknown structures. He then spent 
years of work trying to rationalize the unexpected behavior of his phenylchromium compounds, 
which, peculiarly, did not fit his theories. It was only after the discovery of ferrocene, and after the 
general acceptance of sandwich structure, that Harold H. Zeiss and Minoru Tsutsui proposed in 
1953 the following sandwich structure for Heins’ compounds (Figure 13). 
 
Figure 13 – Sandwich structure of Heins’ compound proposed by Zeiss and Tsutsui 
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As with ferrocene, the proposed structure did not convince the scientific community and it was 
not until 1957 that the full paper of Zeiss and Tsutsui was finally accepted. What made the 
publication possible was the synthesis of bis(benzene) chromium (Figure 14) by Ernst Otto Fischer 
and Water Hafner [70] by reacting CrCl3, Al and AlCl3 and reducing the resulting orange solid with 
sodium dithionite in aqueous NaOH [71-72]. 
 
Figure 14 - Structures of bis(benzene) chromium 
 
The discovery of ferrocene, bis(benzene) chromium, and the work on the chemistry of sandwich 
complexes earned Ernst Otto Fisher and Geoffrey Wilkinson a 1973 Nobel Prize in Chemistry [73]. 
 
1.4.1  Arene Ruthenium Complexes  
The first arene ruthenium complex was prepared by Winkhaus and Singer in 1967 by reduction 
of ruthenium trichloride hydrate in the presence of 1,3-cyclohexadiene. This neutral diamagnetic 
complex was obtained as a brown precipitate, for which a polymeric structure (Scheme 1) was first 
proposed [74]. 
 
Scheme 1 – Synthesis of benzene ruthenium dichloride dimer and its proposed polymeric structure 
 
In 1972 Baird and Zelonka showed this polymeric formula to be erroneous and suggested a 
dimeric structure [75], analogous to the complexes [(η5-C5H5)M(μ
2
-Cl)Cl]2 (M = Ir, Rh) published 
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by Maitlis in 1969 [76]. Eventually, in 1974, Bennett confirmed this dimeric structure [(η6-
C6H6)Ru(μ
2
-Cl)Cl]2, in which each ruthenium atom has the oxidation state +II, the two ruthenium 
centers are linked by two chlorido bridges and where the arene is a L3 ligand (Figure 15) [77]. 
 
 
Figure 15 – Structure of benzene ruthenium dichloride dimer 
 
The robust nature of the organometallic scaffold of ruthenium arene compounds presents an 
ideal template for rational drug design. The hydrophilic nature of the metal and the hydrophobic 
nature of the arene ligand make those complexes highly versatile. The arene can be functionalized 
with many types of groups in order to change the solubility of the complex or even to deliver the 
final compound to specific cellular targets, whereas the -ligands can be tuned to change the 
hydrolysis behavior or to achieve charged complexes with increased solubility in water [47,78].  
 The first anticancer arene ruthenium complex was synthetized by Tocher in 1992 by 
coordinating metronidazole [1-β-(hydroxyethyl)-2-methyl-5-nitro-imidazole] to a benzene ruthe–
nium dichlorido fragment, which resulted in a cytotoxicity enhancement [79]. Later on, the field of 
arene ruthenium anticancer complexes was pioneered individually by the groups of Dyson and 
Sadler with their respective prototype compounds [(η6-p-MeC6H4Pr
i
)Ru(P-pta)Cl2] (pta is 1,3,5-
triaza-7-phosphatricyclo[3.3.1.1
3,7
]decane), named RAPTA-C [80], and [(η6-PhC6H5)Ru(en)Cl]
+
 
(en is 1,2-diaminoethane), named RM175 [81] (Figures 16 and 17). 
RAPTA compounds are characterized by a monodentate 1,3,5-triaza-7-phosphatricyclo-
[3.3.1.1
3,7
]decane ligand and a η6-arene ligand bound facially to the metal center (Figure 16). They 
are generally air-stable complexes with good thermodynamic stability. Two lead compounds in the 
series are RAPTA-T, [RuCl2(η
6
-toluene)(pta)] and RAPTA-C [RuCl2(η
6
-p-cymene)(pta)]. Both 
compounds were found to be only poorly toxic towards cancer cells and completely non-toxic to 
non-tumorigenic (healthy) cells in vitro. Like NAMI-A, RAPTA compounds failed the NCI 
screening process [82]. In vivo, RAPTA-T was found to inhibit lung metastases in mice bearing the 
MCa mammary carcinoma, although again with only mild effects on primary tumors. Like    
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NAMI-A, extremely low general toxicity combined with excellent clearance rates was observed 
[52]. RAPTA-C also displays antimetastatic activity [82] and also increases the survival of mice 
bearing Ehrlich Ascites Carcinoma [83]. Further studies of RAPTA-C in vivo showed that it inhibits 
cell growth by triggering G2/M phase arrest leading to apoptosis. Treatment with RAPTA-C also 
upregulates p53, triggering the mitochondrial apoptotic pathway. Moreover, increased cytochrome c 
levels induced by RAPTA-C suggest the activation of procaspase-9, an effect that has been linked 
to apoptosis. These facts indicate that RAPTA-C acts on various molecular pathways and does not 
bind to a single target. Such conclusion is perhaps not unexpected given the relatively simple 
structures of RAPTA complexes, which can bind to many different biomolecules [83].  
 
Figure 16 – Structures of RAPTA-C and RAPTA-T 
 
A number of parameters have been varied in the RAPTA series, using approaches characte–
ristic to medicinal chemistry, in order to improve their efficacy and to test various hypotheses 
regarding their mode of action [52]. Replacement of p-cymene in the RAPTA-C complex with 
different arene ligands such as benzene, toluene and hexamethylbenzene only slightly changes the 
cytotoxic activity [84]. By contrast, the insertion of a cyclopentadienyl system as aromatic ligand 
shows a remarkable cytotoxicity dependence on the substituents at the ring [85]. Substitution of the 
hydrolysis-susceptible chlorido ligands with other anionic ligands such as bromido, iodido and 
isothiocyanato ligands does not result in large differences in terms of cytotoxicity [86]. However, 
certain aquation-resistant RAPTA complexes with chelating diketone (acac) ligands exhibit 
cytotoxicity profiles different to classical RAPTA complexes [87-88]. These observations indicate 
that the speed of aquation is not essential for reactions of RAPTA complexes with biomolecules, 
although it influences their behavior in some cancer cell lines [89]. The replacement of the pta 
ligand by the N-methylated pta-Me
+
 causes the loss of selectivity for cancerous and non-
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tumorigenic cell lines, showing that the water-soluble phosphine pta ligand plays an important role 
for the selectivity of RAPTA compounds [82]. Functionalization of the arene ligand in RAPTA 
complexes has also been used for tumor targeting. The RAPTA scaffold was functionalized by a 
benzaldehyde moiety that can be conjugated to specific target groups and was used to tether 
RAPTA derivatives to human serum albumin via a hydrazone bond that may be cleaved at low pH 
[90]. The significant enhancement in the cytotoxicity of the RAPTA structure following attachment 
to human serum albumin, which leads to increased internalization of the compound, indicates that 
the antimetastatic effect of RAPTA compounds may be due to extracellular events, and that once 
inside the cell, RAPTA compounds are quite cytotoxic. The importance of the extra- and 
intracellular effects of these compounds has yet to be quantified [89]. 
The studies of the Sadler group focused on monofunctional ruthenium(II) arene anticancer 
complexes of the type [(η6-arene)Ru(ethylenediamine)(X)]n+, where X is a leaving group (e.g. Cl). 
In these pseudooctahedral ‘‘piano-stool’’ Ru(II) complexes, a π-bonded arene occupies three 
coordination sites, and the ethylenediamine (en) and X fill the remaining three sites (Figure 17). In 
contrast to the phosphine complexes of the RAPTA family that exhibit only low cytotoxicity in 
vitro but a high metastatic activity in vivo [82], the cationic arene ruthenium complexes containing 
ethylenediamine chelating ligands show very high cytotoxicities in vitro as hexafluorophosphate 
salts, and they are also very active in vivo [47]. 
 
Figure 17 – General structure of Ru(en) complexes and the structure of the RM175 
 
The investigation of the mode of action of these Ru(en) complexes showed that, similarly to 
cisplatin, those complexes bind specifically to guanines of the DNA double-helix and form G7- or 
G8- monoruthenated species as well as G7, G8-diruthenated species [91]. The π-π stacking between 
multiring (biphenyl, dihydroanthracene or tetrahydridoanthracene) arene ligand and the DNA 
nucleobase was also shown to take place and was confirmed by X-ray crystallography [92], 
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although the guanine binding is preferential [93]. Interactions with other biomolecules, such as 
amino acids [94-95], peptides [96], proteins [95], and DNA bases [97] were also observed. These 
interactions were shown to involve, as the first step, the hydrolysis of the ruthenium-halide bond, 
the aqua ligand being then much more reactive towards biomolecules. The influence of structural 
variations on the rate of hydrolysis was therefore extensively studied using different arenes 
(hexamethylbenzene = hmb, para-cymene = p-cym, indane = inda, biphenyl = bip, benzene = bz, 
tetrahydroanthracene = tha and dihydroanthracene = dha) and different leaving groups X (Br, Cl, I, 
N3). The variations of arene ligand showed that the hydrolysis rate decreases with increase in the 
electron accepting ability of the arene (hmb < p-cym < inda ≈ tha ≈ dha < bip < bz), whereas the 
rates of the hydrolysis of the halide and azide complexes followed the order Br ≈ Cl > I > N3. This 
correlated with the cytotoxicities of the studied complexes, generally showing that the complexes 
that readily hydrolyze exhibit high cytotoxicities, those that do not hydrolyze are inactive or weakly 
active [98]. The variations of the bidentate ligand showed that it is vital for the anticancer activity, 
analogs containing two monodentate N-donor ligands instead of the en ligand showed almost no 
activity towards the A2780 ovarian cancer cell line [91]. 
 
1.4.2  Dinuclear Arene Ruthenium Thiolato-Bridged Complexes – State of the Art 
The versatility of arene ruthenium complexes can be exploited to produce a plethora of 
complexes with diverse structural features, which are not limited to classical mononuclear piano-
stool complexes - multinuclear arene ruthenium complexes are also frequently studied. Dinuclear 
complexes with pyridone-derived linkers were synthesized by Hartinger et al. and showed to be 
active against ovarian and colon cancer cell lines [99]. Sadlers’ dinuclear arene ruthenium 
complexes containing 2,3-bis(2-pyridyl)pyrazine (dpp) as doubly chelating ligands have been 
studied for their potential in photodynamic therapy [100]. Water-soluble chloride or 
tetrafluoroborate salts of the cationic trinuclear arene ruthenium clusters [(η6-C6Me6)2(η
6
-
C6H6)Ru3(µ
2
-H)3(µ
3
-O)]
+
 and [(η6-C6Me6)(η
6
-p-MeC6H4Pr
i)(µ6-C6H6)Ru3(µ
2
-H)3(µ
3
-O)]
+
 were 
found to be cytotoxic against human ovarian cancer cells [101]. Biological properties of other 
tetranuclear ruthenium clusters [102-103], as well as of supramolecular arene ruthenium assemblies 
of various geometries were also investigated [45]. 
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Figure 18 – First two examples of dinuclear thiolato-bridged arene ruthenium complexes [104-105] 
 
In 1992, the reaction of the dimeric arene ruthenium dichloride dimers [(η6-arene)2Ru2Cl4] with 
thiols gave rise to the cationic trithiolato complexes of the type [(6-arene)2Ru2(-SR)3]
+
, the first 
examples being the hexamethylbenzene derivative [(6-C6Me6)2Ru(-SC6H5)3]
+
 reported by H. T. 
Schacht et al. [104] and the p-cymene derivative [(6-p­MeC6H4Pr
i
)2Ru(-SC6H5)3]
+
, reported by 
K. Mashima et al. [105], both containing three thiophenolato bridges. The series was completed in 
2003 by the synthesis of the p-bromothiophenolato derivative [(6-p-MeC6H4Pr
i
)2Ru2(-S-p-
C6H4Br)3]
+
 [106-107], the p-methylthiophenolato and p-hydroxythiophenolato derivatives [(6-
arene)2Ru2(-S-p-C6H4X)3]
+
 (arene = C6H6, p-MeC6H4Pr
i
, C6Me6; X = Me, OH) [107], as well as 
the 2-hydroxyethylthiolato derivatives [(6-arene)2Ru2(-SCH2CH2OH)3]
+
 (arene = C6H6, p-
MeC6H4Pr
i
, C6Me6) [108]. The chloride salts of the trithiolato complexes [(
6
-arene)2Ru2(-SR)3]
+
 
were found to be highly cytotoxic for human ovarian cancer cells [109],
 
they are
 
in fact among the 
most active ruthenium anticancer compounds [37,45,84,110]. The IC50 values of these compounds 
are in the nanomolar range for A2780 human ovarian cancer cells and for their cisplatin-resistant 
mutant A2780cisR [111-113]. It was shown that these complexes, the most active derivative being 
the [(6-p-MeC6H4Pr
i
)2Ru2(-S-p-C6H4Bu
t
)3]
+
 (IC50 = 30 nM for both A2780 and A2780cisR cell 
lines) [111], are highly efficient catalysts for the oxidation of glutathione in aqueous solution, which 
may at least partly explain their high cytotoxicity [114]. 
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Scheme 2 - Intermediacy of dithiolato complexes in the formation of trithiolato complexes [115] 
 
The synthesis of the trithiolato complexes [(η6-arene)2Ru2(µ-SR)3]
+
 was recently shown to 
proceed through the intermediacy of the dithiolato complexes [(η6-arene)2Ru2(µ-SR)2Cl2], several 
representatives of which could be isolated and structurally characterized in the case of aliphatic 
thiolato ligands [115] (see Scheme 2). 
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1.5  Aim of this Work 
This thesis aims to investigate the properties of the thiolato-bridged dinuclear arene ruthenium 
complexes synthesized previously in our group. In order to understand the fate of a compound in a 
biological system, the behavior of this compound must be thoroughly studied, starting at first by 
experiments under laboratory conditions, then by in vitro tests on cell lines or specific isolated 
receptors, followed by in vivo studies on animal models, such as mice, rats or rabbits. The 
knowledge of the precise interactions and chemical changes that the complexes undergo in 
biological system is vital to design a successful selective anticancer agent. Therefore, with the 
assistance of research groups from Switzerland (Paul J. Dyson at EPFL, Julien Furrer at the 
University of Bern) and the Czech Republic (Martina Řezáčová at the Charles University in Hradec 
Králové), an effort will be made to study the mode of action of trithiolato complexes, as the reason 
for their high anticancer activity is so far unknown. 
 
The second goal of the presented PhD thesis is to investigate the effect of the coupling of well-
established organic anticancer drugs as well as other molecules with known anticancer properties to 
ruthenium complexes. The benefits of this approach have already been demonstrated in several 
cases, proving that organic compounds with well-defined molecular targets can enhance the 
anticancer activity and selectivity of ruthenium complexes. Conjugates of thiolato-bridged arene 
ruthenium complexes with chemotherapeutic drugs or bioactive molecules will thus be synthesized 
and their biological properties and modes of action will be investigated.  
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Chapter 2:  Properties of Dinuclear Arene Ruthenium Thiolato 
Complexes 
 
The trithiolato dinuclear arene ruthenium complexes were first synthesized in our group in 2003, 
originally for their use as precursors of star-like oligophenylene dendrimers [116]. It was only in 
2010 that their anticancer properties were evaluated in vitro and their high cytotoxicity against 
ovarian cancer cells A2780 and A2780cisR was discovered [117]. Since then, several series of the 
complexes of the general formula [(6-arene)2Ru2(-SR)3]
+
 were prepared and their anticancer 
activity assessed. The IC50 values of all the derivatives are systematically in the nanomolar range 
for both cisplatin-sensitive and cisplatin-resistant cancer cells [111-115,117]. The recently 
discovered dithiolato complexes [115] are less cytotoxic, their IC50 values being in the micromolar 
range.  
Despite the number of synthesized compounds, the reason for the high cytotoxicity of dinuclear 
thiolato arene ruthenium complexes is not yet understood. The only indication for the possible 
mode of action is their ability to catalyze the oxidation of glutathione, an important intracellular 
antioxidant. The ratio between the reduced (GSH) and the oxidized (GSSG) form of the glutathione 
was found to differ in cancer cells and in healthy cells [118] and the depletion of GSH is believed to 
have an effect on the efficacy of the cancer treatment [119], the catalytic activity of the complexes 
could therefore offer a partial explanation for their high anticancer activity.  
In this chapter, the chemical properties, the stability, the reactivity and the in vitro and in vivo 
behavior of the thiolato-bridged arene ruthenium complexes are investigated, with the goal of 
learning the reasons for their cytotoxic properties. 
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2.1  Stepwise Synthesis of Dinuclear Trithiolato Arene Ruthenium Complexes 
Adapted from: D. Stíbal, B. Therrien, F. Giannini, L.E.H. Paul, J. Furrer, G. Süss-Fink, 
Monothiolato-Bridged Dinuclear Arene Ruthenium Complexes: The Missing Link in the Reaction 
of Arene Ruthenium Dichloride Dimers with Thiols, European Journal of Inorganic Chemistry, 
2014, 34, 5925-5931. 
 
2.1.1  General 
The dithiolato complexes reported in 2012 [115] showed that it is possible to isolate 
intermediates in the synthesis of trithiolato complexes, if the conditions and the chemical properties 
of thiols are carefully chosen. Although monothiolato complexes are also expected as intermediates, 
they have never been isolated or observed so far from this reaction. Apart from the chelating amino-
thiolato complexes [(6-p-MeC6H4Pr
i
)2Ru2(-N,S-L)(-Cl)]
+
 (LH = 2-mercapto-1-methylimidazole 
or 4,5-diphenyl-2-mercaptoimidazole) [120] and [(6-C6Me6)2Ru2(-N,S-L)(-Cl)]
+
 (LH = 2-
aminoethylthiol or 2-dimethylaminoethanethiol) [121], the only dinuclear monothiolato arene ruthe-
nium complexes known so far are the dihydrido complexes [(η6-arene)2Ru2(-S-p-C6H4-X)(-H)2]
+
 
(arene = C6Me6, 1,2,4,5-Me4C6H2; X = Me or Br) [122]. 
 
2.1.2  Results 
When we tried to synthesize the known [115] dithiolato complex [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-
SCH2C6H5)2], we found the product to be contaminated by another compound that appeared to be 
the predicted monothiolato intermediate [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-Cl)(-SCH2C6H5)] (1). By 
modifying the reaction conditions, it was possible to obtain this complex as the main product; 
however, in our hands it was not possible to separate the mono- and the dithiolato complexes by 
chromatographic methods. We therefore decreased the reactivity of the thiol by introducing 
electron-withdrawing or sterically demanding substituents. Using the modified reaction conditions, 
monothiolato derivatives 1 – 4 [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-Cl)(-SR)], (R = CH2C6H5, 1, p-
CH2C6H4NO2, 2, C10H15, 3, m-9-B10C2H11, 4) were synthesized. Complexes 1 and 2 are formed in a 
mixture with the corresponding dithiolato complex, while complexes 3 and 4 are obtained free of 
the corresponding dithiolato complex; 3, however, being contaminated with the starting ruthenium 
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para-cymene dichloride dimer. In our hands, it was not possible to eliminate the contaminations of 
1 and 3 by chromatographic methods. Although we managed to grow a single crystal of 1 by vapor 
diffusion, we did not succeed in isolating larger quantities by crystallization. Therefore, only 2 and 
4 could be obtained in an analytically pure form. Complexes 1 – 4 (Figure 19) are orange to red 
solids that are stable in air and well soluble in dichloromethane, methanol and ethanol. 
 
Figure 19 - Monothiolato complexes 1 – 4, the symbols  in the formula of 4 representing the CH groups of the 
carborane 
 
Complexes 1 – 4 have been characterized by 1H and 13C NMR and mass spectroscopy, 2 and 4 
also by correct micro-analytical data, the molecular structure of 1 and 2 was solved by X-ray 
crystallography. The spectroscopic and analytical data are given in the Chapter 9.4.1. Suitable 
crystals for X-ray analysis were obtained for the benzylthiolato derivative 1 and for the 4-
nitrobenzylthiolato derivative 2 by vapor diffusion of diethylether into the dichloromethane solution 
of the complex. The molecular structures shown in Figure 20 can be described in terms of two p-
cymene ruthenium units held together by one μ-bridging thiolato unit and one μ-bridging chlorido 
unit. Selected bond lengths and angles are listed in Table 1. In accordance with the electron count of 
36, there is no metal-metal bond, the distance between the two ruthenium atoms being 3.6617(6) Å 
and 3.6555(4) Å, respectively. Both structures compare well with those of the dithiolato complex 
[(6-p-MeC6H4Pr
i
)2Ru2Cl2(-p-SCH2C6H4Bu
t
)2] [115] and of the trithiolato complex [(
6
-p-
MeC6H4Pr
i
)2Ru2(-SCH2C6H5)3]
+
 [105], where the ruthenium-ruthenium separations are 3.674(2) Å 
and 3.3489(8) Å, respectively. This is in contrast to the dinuclear pentamethylcyclopentadienyl 
ruthenium monothiolato complexes, in which there is a metal-metal bond: [(5-C5Me5)2Ru2Cl2(-
SPr
i
)(-PMe2)] [Ru-Ru 2.8839(5) Å] [123], and [(
5
-C5Me5)2Ru2(-SPr
i
){-2:2-C(CO2Bu
t
)=CH-
SPr
i
}][(Ru-Ru 2.747(1) Å] [124]. 
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Figure 20 - Molecular structures of 1 (left) and 2 (right) at 50% probability level ellipsoids hydrogen atoms were 
omitted for clarity. 
 
Table 1 - Selected bond lengths (Å) and angles (°) for complexes 1 and 2. 
 1 2 
Interatomic distances   
   
Ru1∙∙∙Ru2 3.6617(6) 3.6555(4) 
Ru1-Cl1 2.4000(14) 2.4144(8) 
Ru2-Cl2 2.4202(13) 2.4267(8) 
Ru1-Cl3 2.4549(13) 2.4342(8) 
Ru2-Cl3 2.4408(15) 2.4438(8) 
Ru1-S1 2.4167(14) 2.4173(8) 
Ru2-S1 2.4052(13) 2.4088(8) 
   
Angles   
   
Ru1-S1-Ru2 98.82(5) 98.48(3) 
Ru1-Cl3-Ru2 96.83(5) 97.07(3) 
S1-Ru1-Cl3 81.78(5) 81.90(3) 
S1-Ru2-Cl3 82.31(5) 81.87(3) 
Cl1-Ru1-Cl3 85.92(5) 85.63(3) 
Cl2-Ru2-Cl3 86.23(5) 86.03(3) 
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In order to prove the step-wise formation of trithiolato-bridged complexes as suggested in 
Scheme 3, we attempted the synthesis of a mixed dithiolato complex starting from a monothiolato 
complex. Thus, we reacted the monothiolato complex 2 with the 4-fluorobenzylthiol. However, the 
reaction yielded not only the expected mixed dithiolato product [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-S-p-
CH2C6H4NO2)(-S-p-CH2C6H4F)], but a complex mixture of products. By monitoring the reaction 
by 
19
F NMR spectroscopy (Figure 21), we observed  the formation of the mixed complex [(6-p-
MeC6H4Pr
i
)2Ru2Cl2(-S-p-CH2C6H4NO2)(-S-p-CH2C6H4F)] during the first minutes of the 
reaction, followed by the formation of the exchanged monothiolato complex [(6-p-
MeC6H4Pr
i
)2Ru2Cl2(-S-p-CH2C6H4F)(-Cl)] as well as of the homoleptic dithiolato complexes 
[(6-p-MeC6H4Pr
i
)2Ru2Cl2(-S-p-CH2C6H4F)2] and [(
6
-p-MeC6H4Pr
i
)2Ru2Cl2(-S-p-
CH2C6H4NO2)2], the latter one being NMR-silent in the 
19
F NMR spectra but being identified in the 
1
H NMR and ESI-MS spectra. A further product showing up at (19F) = -114.4 ppm is believed to 
be bis(4-fluorobenzyl) disulfide, arising from the oxidation of 4-fluorobenzylthiol. In a similar 
fashion, complex 1 reacts with 4-nitrobenzylthiol to give a mixture of the expected mixed dithiolato 
complex, the exchanged monothiolato complex and the two homoleptic dithiolato complexes. 
 
Scheme 3 - The reaction of p-cymene ruthenium dichloride dimer with thiols 
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These results confirm the existence of equilibria between the thiolato complexes and the thiols. 
The coordinated thiolato bridge can come off as free thiol to be replaced by a thiolato bridge 
derived from another thiol in the solution, which leads to a mixture of thiolato complexes. These 
equilibria are governed mostly by the reactivity of the thiols and to a lesser extent by the choice of 
the solvent and reaction conditions. 
 
 
Figure 21 - Time-dependent 
19
F NMR spectra of the reaction of 2 with 4-fluorobenzylthiol 
 
Since the derivatives 1 and 3 could not be isolated in a pure form because of these equilibria, the 
biological activities of the new monothiolato complexes were studied only with the derivatives 2 
and 4. Both complexes were found to be cytotoxic for human ovarian cancer cells (96 h of 
incubation), the IC50 values for the A2780 cell line being in the lower micromolar range (5.42  
0.55 M for 2 and 2.59  0.15 M for 4). The in vitro anticancer activity of the monothiolato 
complexes is comparable to that of the dithiolato complexes [115], but considerably lower than that 
of the trithiolato complexes, the IC50 values of which are in the nanomolar range [111-113]. Thus, 
the number of thiolato bridges seems to play a critical role for the cytotoxicity. We also studied the 
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catalytic activity of 2 and 4 for the oxidation of the tripeptide glutathione (GSH) to the oxidized 
form GSSG, since the catalytic oxidation of this endogenous antioxidant has been supposed to be at 
the origin of the biological activity of certain arene ruthenium complexes [125], and was shown to 
be at least partially responsible for the high cytotoxicity of the trithiolato complex [(6-p-MeC6H4-
Pr
i
)2Ru2(-S-p-C6H4Me)3]
+
 [111]. Surprisingly, only 2 was found to catalyze the oxidation of GSH 
in a D2O/(CD3)2CO (95 : 5) solution at 37°C in the presence of air, while 4 was completely inactive 
under these conditions. The catalytic reaction was monitored by 
1
H NMR spectroscopy, showing 
the disappearance of the signal at 3.0 ppm (-CH2 resonances of GSH) to be accompanied by the 
simultaneous appearance of the GSSG -CH2 resonances at 3.2 and 3.5 ppm. The catalytic turnover 
frequency at the time when half of the glutathione is converted (TOF50) for 2 was determined to be 
0.145 h
-1
, which means that the monothiolato complex 2 is catalytically much more active than the 
trithiolato complexes [111].  
Thus, the tendency in the TOF50 values is in contrast to that of the IC50 values, indicating that 
the catalytic GSH oxidation activity cannot be the main mode of action of the in vitro anticancer 
activity of dinuclear arene ruthenium complexes with thiolato bridges. This is also supported by the 
findings for complex 4, which is cytotoxic (comparable to cisplatin) but inactive for the catalytic 
oxidation of GSH.  
 
2.1.3  Conclusion 
In conclusion, we have synthesized and characterized four complexes of the type [(6-p-
MeC6H4Pr
i
)2Ru2Cl2(-Cl)(-SR)] containing one thiolato and one chlorido bridge. These mono-
thiolato complexes represent the missing link in the three-step synthesis of the well-known 
trithiolato complexes. The reaction of these monothiolato complexes with thiols to give the 
corresponding dithiolato complexes was shown to be reversible. The monothiolato complexes 2 and 
4 are cytotoxic for human ovarian cancer cells, but only complex 2 catalyzes the oxidation of 
glutathione.  
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2.2  Interactions of Mono-, Di- and Trithiolato Dinuclear Arene Ruthenium Complexes with 
Biological Ligands 
 
2.2.1  General 
The studies of the stability and the reactivity of some of the recently synthesized trithiolato 
complexes with various amino acids, peptides, nucleotides and DNA have revealed that the 
complexes are very stable in physiological conditions as well as under acidic and basic conditions 
and that they are particularly inert towards substitution. Only sulphur-containing biomolecules such 
as the amino acid cysteine (Cys) and the tripeptide glutathione (GSH) were found to interact with 
the complexes. Surprisingly, no adducts were identified, but Cys and GSH undergo a catalytic 
oxidation in the presence of trithiolato complexes, forming cystine and GSSG [111]. Such a mode 
of action has already been proposed for arene ruthenium azopyridine iodo complexes, which are 
surprisingly cytotoxic despite their inertness to ligand substitution: In a pioneering study, Sadler 
and co-workers demonstrated that these complexes act as catalysts for the oxidation of the tripeptide 
glutathione, supposed to be at the origin of their anticancer activity [125]. For our dinuclear 
trithiolato arene ruthenium complexes, no direct correlation between their cytotoxicity and catalytic 
activity for the oxidation of glutathione was found. Although a decrease in the glutathione levels 
with increasing concentration of the complex [(6-p-MeC6H4Pr
i
)2Ru2(-S-p-C6H4
t
Bu)3]Cl was 
observed both in vitro and in vivo (see Chapter 2.3), we assume other mechanisms to be mainly 
responsible for the high cytotoxicity of the trithiolato complexes. 
In an effort to rationalize the relationship between reactivity and the in vitro cytotoxicity of 
thiolato-bridged arene ruthenium complexes, we set out to investigate the hydrolysis of two 
monothiolato complexes 2 and 4 and two dithiolato complexes 5 and 6 (Figure 22) as well as their 
interactions with selected amino acids and a DNA 20-mer and to compare the results with those of 
trithiolato complexes. 
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Figure 22 - Structures of complexes 2, 4, 5 and 6, the symbols  in the formula of 4 representing CH groups of the 
carborane 
 
2.2.2  Results 
Synthesis and molecular structure of the dithiolato complex 6 
The new dithiolato complex 6 was synthesized by a slight variation of the reaction conditions 
published previously for other dithiolato complexes [115]. The p-cymene ruthenium dichloride 
dimer was dissolved in ethanol, the 4-methoxy-α-toluenthiol was added dropwise and the solution 
was stirred at room temperature for 3 hours. The product was precipitated with hexane, filtered and 
dried in vacuo. The resulting yellow crystalline powder was completely characterized. The X-ray 
quality crystals for 6 were obtained by the slow diffusion of diethylether into the solution of 6 in 
dichloromethane. The molecular structure shown in Figure 23 can be described in terms of two p-
cymene ruthenium units held together by two μ-bridging thiolato units. Selected bond lengths and 
angles are listed in Table 2. In accordance with the electron count of 36, there is no metal-metal 
bond, the distance between the two ruthenium atoms being 3.6555(9). The structure compares well 
with those of the previously published dithiolato complex [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-p-SCH2-
C6H4Bu
t
)2] [115] and of the trithiolato complex [(
6
-p-MeC6H4Pr
i
)2Ru2(-SCH2C6H5)3]
+
 [105], 
where the ruthenium-ruthenium distances are 3.674(2) Å and 3.3489(8) Å, respectively.  
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Figure 23 - Molecular structure of 6 at 50% probability level ellipsoids. Hydrogen atoms are omitted for clarity. 
 
Table 2 - Selected bond lengths (Å) and angles (°) for complex 4 (i = 1-x, 1-y. –z) 
 6 
Interatomic 
distances 
 
  
Ru1∙∙∙Ru1i 3.6555(9) 
Ru1-Cl1 2.4293(9) 
Ru1-S1 2.3931(8) 
Ru1-S1
i
 2.3783(8) 
S1-C1 1.845(3) 
  
Angles  
  
Ru1-S1-Ru1
i
 99.99(3) 
S1-Ru1-Cl1 90.49(3) 
S1-Ru1-S1
i
 80.01(3) 
S1-Ru1
i
-Cl1
i
 81.69(3) 
Ru1-S1-C1 109.67(10) 
Ru1
i
-S1
i
-C1
i
 111.26(11) 
 
 
Ru1 
Ru1
i
 
S1 
Cl1 
C1 
S1
i
 
Cl1
i
 
C1
i
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Stability of complexes 2, 4, 5 and 6 in aqueous solutions and in DMSO 
The stability of the monothiolato and dithiolato complexes in solution and in DMSO was 
studied by 1D 
1
H NMR and ESI-MS spectroscopy. Figure 24 shows 1D 
1
H-NMR spectra of 
complex 4 dissolved in a mixture acetone-d6/D2O (ratio 7 : 3) recorded at 37°C between 5 and 1440 
minutes together with the 1D 
1
H-NMR spectrum of complex 4 dissolved in acetone-d6. As is 
obvious from the spectra, additional resonances appeared already 5 minutes after dissolution; the 
hydrolysis reached a steady state after 1 hour and did not continue further. The two sets of two new 
doublets appearing at 5.44 ppm and 5.28 ppm and at 5.89 ppm and 5.80 ppm, respectively, prove 
the formation of at least two new species. Similar results were obtained for complex 2, which 
hydrolyzes significantly faster; the steady state is already achieved after 5 minutes, at the time of 
the first NMR measurement (Figure 24). ESI-MS spectra of the solutions of both 2 and 4 reveal the 
presence of three species corresponding to dinuclear complexes. In both spectra, the starting 
complex [(η6-p-MeC6H4Pr
i
)2Ru2Cl2(µ-Cl)(µ-SR)] at m/z = 709.1 and 717.12, respectively (Figure 
25), is still present, while new peaks (fragment m/z = 692.01 for 2 and m/z = 699.16 for 4, Figure 
25), corresponding to the hydrolyzed complex [(η6-p-MeC6H4Pr
i
)2Ru2Cl(OH)(µ-Cl)(µ-SR)] where 
one chlorido ligand has been replaced by a hydroxo ligand, are clearly observed. The third species 
observed by NMR presumably corresponds to the second hydrolyzed complex, [(η6-p-MeC6H4-
Pr
i
)2Ru2(OH)2(µ-Cl)(µ-SR)], but this product could not be confirmed, as it would show at the same 
m/z ratio as the first hydrolyzed complex. Therefore, we assume that these products of the 
hydrolysis to the second degree are present but we were not able to prove it by the employed 
methods. The last species in the ESI-MS spectra of 2 and 4 corresponds to the dithiolato complexes 
[(η6-p-MeC6H4Pr
i
)2Ru2Cl2(µ-SR)2], as indicated by the peaks at m/z = 842.2 and 857.3, respectively 
(Figure 25), in accordance with the previously reported thiol exchange in solution (Chapter 2.1). 
The stability of the two monothiolato complexes in DMSO is low. NMR and ESI-MS demonstrate 
that the complex 2 degrades into mononuclear fragments already after 5 minutes of incubation at 
37°C, complex 4 degrading more slowly, in accordance with their hydrolytic stability (Figure 26).  
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Figure 24 - Hydrolysis of 2 and 4 in acetone-d6/D2O mixtures followed by NMR 
24 h 
5 min 
4 in acetone-d6 
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4 
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Figure 25 - ESI-MS spectra of the hydrolysis of 2 and 4 in acetone-d6/D2O mixtures  
 
 
2 
4 
717.12 
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The dithiolato complexes proved to be more stable in aqueous solutions. Under neutral (no 
addition of buffer) and acidic (pH = 2) conditions, the complexes are stable, no changes in NMR 
spectra are observed after 24 hours at 37°C. On the other hand, at basic pH (pH = 10), additional 
peaks appeared in the 1D 
1
H NMR spectrum after 4 hours at 37°C for complex 5  and after24 hours 
for 6 (Figure 27). For both complexes 5 and 6, ESI-MS spectra show fragments at m/z = 763.12 and 
2 
2 
4 
Figure 26 - Stability of 2 and 4 in DMSO 
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795.11, respectively, corresponding to the hydrolyzed hydroxo complexes [(η6-p-MeC6H4-
Pr
i
)2Ru2Cl(OH)(µ-SR)2], which is confirmed by the new resonances appearing in the 
1
H NMR 
spectra. The hydrolysis to the second degree is expected to take place, but, similarly to 
monothiolato complexes 2 and 4 could not be proven. In accordance with the results for the two 
monothiolato complexes 2 and 4, the two dithiolato complexes 5 and 6 are also not very stable in 
DMSO. NMR and ESI-MS spectra demonstrate that the dithiolato complexes degrade into 
mononuclear ruthenium complexes already after 15 minutes of incubation at 37°C. The instability 
of both mono- and dithiolato complexes in DMSO strongly contrasts with the high stability of the 
trithiolato complexes, which are stable for at least 24 h. The Ru-Cl bond is therefore the reactive 
part of the mono- and dithiolato complexes, the Ru-S bond being highly stable, as is evidenced by 
the inertness of the trithiolato complexes [114]. 
 
 
24 h 
0 h 
5 
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Figure 27 - Hydrolysis of 5 and 6 in the aqueous solution at pH = 10 over 24 hours 
 
Reactivity of 2, 4, 5 and 6 with the DNA 20-mer 
In order to investigate the possible binding of the complexes 2, 4, 5 and 6 to DNA, we incubated 
the complexes at 37°C together with the single-stranded DNA 20-mer 
CGCGATCGCGGCGCTAGCGC. We assumed that once the complexes hydrolyzed, they would 
bind to the nucleophilic nitrogen of DNA nucleobases, in analogy with platinum complexes and 
some other ruthenium compounds [126-128]. However, even though the hydrolysis of the 
complexes 2 and 4 occurred in the same way as in aqueous solution, no adduct of either 
monothiolato or dithiolato complexes with DNA was observed by ESI mass spectroscopy in 
negative or positive mode. The inertness of both mono- and dithiolato complexes towards DNA is 
in line with the results obtained with trithiolato complexes. It appears therefore that DNA is not a 
target of these arene ruthenium thiolato-bridged complexes and that they exert their cytotoxicity 
through other mechanisms. 
 
 
24 h 
0 h 
6 
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Reactivity of 2, 4, 5 and 6 with aspartic acid, alanine and histidine 
Most of the metallodrugs currently used in antitumor therapy, such as carboplatin and cisplatin, 
are administered intravenously and can therefore encounter various reactive biomolecules in the 
bloodstream. Interactions with peptides and serum proteins can have a pronounced influence on the 
drug distribution, bioavailability and target or off-target effects [127-128]. To investigate some of 
these possible interactions, four different amino acids were chosen in order to account for the 
effects of pH and of various side chains. The neutral amino acid L-alanine, the acidic L-aspartic 
acid and the basic L-histidine were used to see the effect of the pH of amino acids. L-histidine was 
also chosen to see a possible binding between the imidazole side chain and ruthenium complexes, 
since it was already shown to strongly and rapidly interact with ruthenium compounds [129-132]. 
L-cysteine was used to evaluate the reactivity of the SH group towards the complexes. No buffers 
were used, to avoid the introduction of other ions into the solutions, which could influence the 
hydrolysis of the complexes. The pH values of the solutions, measured right after the mixing of the 
complex and the amino acid, are given in Table 3. 
 
Table 3 - pH values of aqueous solutions of complexes 2, 4, 5 and 6 and various amino acids 
 Ala Cys His Asp 
2 4.45 3.20 6.72 3.41 
4 4.28 3.48 5.99 3.60 
5 6.05 3.92 7.42 4.02 
6 6.86 4.45 7.70 4.08 
      
Alanine is not known to react with ruthenium complexes, although it was shown to slowly 
degrade a hexacationic arene ruthenium assembly possessing an oxalato linker to give mononuclear 
ruthenium-alanine adducts [132]. Upon addition of 3 eq of Ala, no adduct formation was observed 
for the four complexes 2, 4, 5 and 6. NMR and ESI-MS spectra showed the same hydrolysis 
products for 2 and 4 that were observed in aqueous solutions (Figure 25), the spectra of 5 and 6 did 
not show any change. The same result was observed with aspartic acid – the compounds 2 and 4 
underwent hydrolysis upon addition of 3 eq of Asp, while with 5 and 6 no adduct formation was 
observed and the compounds remained stable after 24 hours at 37°C.  
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Many ruthenium complexes are known to react with the basic imidazole ring of His. For 
instance, with arene ruthenium assemblies, the reactions with His were always complete and were 
finished within hours [131-132]. Surprisingly, it appears that none of the four complexes 
investigated in this study reacts with His, in line with the results for trithiolato complexes. In the 
mixture with histidine, 2 and 4 hydrolyzed in the same way as in aqueous solution (Figure 25). 
Complexes 5 and 6 also slowly hydrolyzed, forming the corresponding hydroxo complexes, 
evidenced by the peak at m/z = 763.12 for 5 and m/z = 795.11 for 6. After 24 hours of NMR 
monitoring, the reactions did not reach steady state. No adducts of histidine to the complexes were 
observed by NMR of by ESI-MS spectroscopy. We assume that the difference in the stability of 
complexes 5 and 6 in solution with histidine compared to their stability in aqueous solution is 
caused solely by the slight difference in the pH of the mixture (see Table 3).  
 
 
 
Figure 28 – Fragments of the three products detected by ESI-MS in the mixture of 2 with histidine after 24 hours 
 
Reactivity of 2, 4, 5 and 6 with cysteine 
Unlike Ala, Asp, and His, Cys reacts rapidly with the four complexes. In all four cases, the only 
product detected after 24 hours at 37°C was a trithiolato cationic complex, where the cysteinato unit 
occupies the position of the third (in the case of 5 and 6) or both second and third (in 2 and 4) 
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bridging thiolato ligands. This finding was surprising, since our previous attempts to synthesize 
cysteinato-containing trithiolato complexes by standard methods resulted in the degradation of the 
arene ruthenium unit and no trithiolato complexes could be isolated. Since the DOSY and ESI-MS 
data proved the formation of these cysteinato-containing complexes as the only species in the 
mixture after 24 hours (shown for 4 in Figure 29), we decided to modify the synthetic conditions 
and attempt the synthesis and isolation of cysteinato-containing trithiolato complexes by mimicking 
the conditions of our NMR experiments. Thus, the dithiolato precursor 7 was dissolved in a small 
amount of methanol and the excess of cysteine was added dropwise as a solution in distilled water. 
This mixture was allowed to stir at ambient temperature for two days, its color changing gradually 
from orange to yellow. The product proved to be highly unstable at higher temperature, not 
allowing even the evaporation at 40°C on the rotary evaporator. It also degraded rapidly in purely 
organic solutions. The product was therefore purified by size exclusion chromatography on 
Sephadex
®
 LH20 with MeOH/H2O 9 : 1 mixture, evaporated at room temperature and dried in 
vacuo. Spectroscopy methods and elemental analysis proved the structure of the cysteinato-
containing product (Scheme 4). Because of its low stability, it was not possible to obtain X-ray 
quality crystals. The synthesis of other cysteinato-containing complexes from dithiolato precursors 
5 and 6 was also attempted, but the products degraded rapidly and it was not possible to obtain 
analytically pure samples. 
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Figure 29 – Top: 2D 1H-DOSY NMR spectrum of the mixture 4/Cys (molar ratio 1:3) recorded at t = 24 h in a 
mixture D2O/acetone-d6 (7 : 3). Line 1: adduct with the presumed structure {(η
6
-p-MeC6H4Pr
i
)2Ru2[µ-
SCH2CH(NH2)COOH]2(µ-S-m-9-B10C2H11)]}
+
, line 2: free Cys, line 3: acetone. Bottom: ESI mass spectrum of the 
mixture 4/Cys dissolved in H2O recorded at t = 24 h. The adduct exhibits as a peak at m/z = 887.21.  
 
In view of the general lower stability of monothiolato complexes and the low stability of the 
synthesized complex 8, the isolation of cysteinato-containing trithiolato complexes corresponding 
to 2 and 4 was not attempted.  
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Scheme 4 – Synthesis of cysteinato-containing complex 8, isolated as tetrafluoroborate salt 
 
Many proteins, in particular serum proteins such as albumin and transferrin, were already shown 
to bind to metal complexes and influence their activity [128-129]. We assume that this is the main 
reasons for the lower cytotoxicity of mono- and dithiolato complexes as compared to the trithiolato 
ones [111-115]. The high stability of trithiolato arene ruthenium complexes allows them to 
accumulate inside the cells of a tumor (see Chapter 2.3), where they can reach their molecular target 
and exhibit their anticancer activity. The monothiolato and dithiolato complexes can, on the other 
hand, bind to proteins and other molecules containing the sulfhydryl group, which we assume 
impedes their accumulation in cancer cells in sufficient concentrations. 
 
2.2.3  Conclusion 
The stability of monothiolato and dithiolato complexes was studied in aqueous solutions and in 
DMSO. The results confirmed the hypothesis that the presence of chlorido ligands renders the 
complexes less stable. Monothiolato complexes were found to undergo hydrolysis, forming the 
corresponding hydroxo complexes. Dithiolato complexes are stable under acidic and neutral 
conditions, forming hydroxo complexes only at elevated pH. The hydrolysis to the second degree 
could not be observed by the employed analytical methods, but is presumed to proceed in the case 
of all four studied complexes. The complexes 2, 4, 5 and 6 do not interact with amino acids L-
alanine, L-aspartic acid or L-histidine. With L-cysteine, they form cationic trithiolato complexes, 
where the cysteinato unit forms the second and third thiolato bridge. One of the cysteinato-bridged 
complexes could be isolated and completely characterized. No interactions with a DNA fragment 
were observed. We propose that these results partially explain the difference between the 
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cytotoxicity of the previously studied trithiolato complexes and the more reactive, but an order of 
magnitude less cytotoxic mono- and dithiolato complexes. 
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2.3  In Vivo Study of [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-Bu
t
)3]Cl (diruthenium-1) 
Adapted from: P. Tomšík, D. Muthná, M. Řezáčová, S. Mičuda, J. Ćmielová, M. Hroch, R. 
Endlicher, Z. Červinková, E. Rudolf, S. Hanne, D. Stíbal, B. Therrien, G. Süss-Fink, [(p-
MeC6H4Pr
i
)2Ru2(SC6H4-p-Bu
t
)3]Cl (diruthenium-1), a dinuclear arene ruthenium compound with 
very high anticancer activity: An in vitro and in vivo study, Journal of Organometallic Chemistry, 
2015, 782, 42–51. 
 
2.3.1  General 
In vitro studies offer a rapid and largely accessible means to assess the anticancer potential of 
novel molecules. Their cytotoxicity on a wide range of cancer cell lines and their selectivity towards 
cancerous versus healthy cells can be established this way. However, as was clearly demonstrated 
by NAMI-A and RAPTA-C [52,82], it is not an approach without limitations. The cellular cultures 
used in in vitro studies are populations of single-phenotype cells extracted originally from a tumor 
of a patient. The tumors found in animal models or in human patients are, on the other hand, 
heterogeneous and contain a large variety of phenotypically different cells with possibly different 
responses towards the tested chemical agent [1]. It is therefore imperative to study the potential of 
anticancer drugs in vivo, to gain a more in-depth understanding of the behavior of the studied 
compound in an organism. 
Herein we report the in vitro and in vivo investigation of the tert-butyl derivative [(p-MeC6H4-
Pr
i
)2Ru2(SC6H4-p-Bu
t
)3]Cl (diruthenium-1, [9]Cl, Figure 30), which was selected from 21 com-
pounds of the three series [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-X)3]Cl (X = H, Me, Ph, Br, OH, NO2, 
OMe, CF3, F, Pr
i
, Bu
t
), [(p-MeC6H4Pr
i
)2Ru2(SC6H4-m-X)3]Cl (X = Me, OMe, OEt, CF3, NH2, Cl) 
and [(p-MeC6H4Pr
i
)2Ru2(SC6H4-o-X)3]Cl (X = Me, OMe, Pr
i
, CF3) as the most active one in vitro 
[111,113]. 
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Figure 30 - Structure of diruthenium-1 
 
2.3.2  Results 
The complex [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-Bu
t
)3]
+
 was prepared by a simple one-step synthetic 
process from the commercially available p-cymene ruthenium dichloride dimer and p-tert-
butylthiophenol in refluxing ethanol; it was obtained as the chloride salt in high yield by a slight 
variation of the published method (Chapter 9.4.5.) [111]. 
The diruthenium-1 shows anticancer activity in vitro and in vivo. The antiproliferative effect 
was evaluated towards the human ovarian cancer cell line A2780 and its cisplatin-resistant mutant 
A2780cisR using the MTT assay which measures the mitochondrial dehydrogenase activity as an 
indication of cell viability. The IC50 values for diruthenium-1 were determined to be 30 ± 10 nM for 
A2780 and 30 ± 10 nM for A2780cisR [111]. Thus, diruthenium-1 is with IC50 values in the lower 
nanomolar range for both cell lines, to the best of our knowledge, the ruthenium compound with the 
highest in vitro anticancer activity reported so far. 
The in vivo anticancer effect of diruthenium-1 was studied using a mouse model: Initially, the 
maximum tolerated dose (MTD) was assessed as the maximum dose of diruthenium-1, dissolved in 
water/propane-1,2-diol, that could be administered i.p. (by intraperitoneal injection) to healthy mice 
without causing toxic deaths or body weight loss of more than 15%. The MTD for healthy animals 
was estimated on this basis to be 2 mg/kg. For the in vivo anticancer study, a total of 98 female 
NMRI mice (average weight 33.5 g) were inoculated subcutaneously with a solid breast cancer Ehr-
lich tumor. The tumor-bearing mice, divided into 7 groups of 14 animals, were administered with 
the water/propane-1,2-diol solution of diruthenium-1, in doses of 0.2, 0.4, 0.6, 1.0, or 2.0 mg/kg i.p. 
on days 1 and 7, in volumes of 0.2 ml per 20 g body weight. A control group was treated with the 
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pure solvent and a positive control group received a standard cisplatin treatment (5.0 mg/kg cis-
platin i.p.). The mice were weighed on the first, fourth, sixth and seventh day. On the eighth day, 
half of the mice were sacrificed; the remaining animals were kept in order to observe their survival. 
In addition to the total body weight, the tumor weight was also determined.  
 
Figure 31 - Weight of the solid Ehrlich tumor (in grams) on day 8 of the sacrificed mice injected on days 1 and 7 
i.p. with pure solvent, diruthenium-1 or cisplatin. Values are the means ± SD (n = 7 in each group). C = tumor-bearing 
control treated with pure solvent; R: diruthenium-1, R0 = 0.2 mg/kg i.p.; R1 = 0.4 mg/kg i.p.; R2 = 0.6 mg/kg i.p.; R3 = 
1.0 mg/kg i.p.; R4 = 2.0 mg/kg i.p.; Pt = cisplatin 5.0 mg/kg i.v. Significantly different from the control: 
*
P < 0.05, 
**
P < 
0.01, 
***
P < 0.001. 
 
No macroscopic metastases were found in the organs. Figure 31 shows the weight of the tumors 
in mice treated with the pure solvent, with diruthenium-1 in various doses, and with cisplatin 
measured on day 8. It documents the inhibitory effect of diruthenium-1 at 0.4 and 0.6 mg/kg, 
although it is inferior compared to cisplatin in high dose (5.0 mg/kg). Tumor-bearing mice showed 
symptoms of acute intoxication (especially weight loss) already after the first injection of 1.0 or 2.0 
mg/kg of diruthenium-1, doses which were tolerated in healthy mice during the previous acute 
toxicity study. This is why only the dose groups from 0.2 to 0.6 were included in the survival study. 
The administration of diruthenium-1 0.6 mg/kg prolonged significantly the survival time of tumor-
bearing mice, when compared with untreated tumor-bearing control mice (P ˂ 0.01). It was also 
C    R0 R1 R2        R3     R4 Pt 
0
0.5
1
1.5
2
2.5
3
3.5
4
*  ** 
        * 
          *** 
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effective compared to cisplatin (P ˂ 0.05), which itself did not exert a significant effect on the 
survival (P = 0.068), see Figure 32. 
 
 
Figure 32 - Kaplan-Meier analysis of survival: The i.p. administration of diruthenium-1 0.6 mg/kg (R2) on days 1 
and 7 significantly prolonged the survival of tumor-bearing mice compared to the tumor-bearing control group treated 
with the pure solvent (C). The injection of cisplatin 5 mg/kg (Pt) had the second largest effect, although this was not 
statistically significant. R0 = 0.2 mg/kg, R1 = 0.4 mg/kg (n = 7 in each group). 
 
The tumor homogenates from mice treated with cisplatin showed significant decrease in the 
amount of PCNA (proliferating cell nuclear antigen), a marker of cell proliferation, contrary to 
those from the mice injected with diruthenium-1, in which we did not observe any changes in 
PCNA. Investigating the effect on the anticancer immune response mediated by T-lymphocytes, we 
did not detect a significant change in the expression of the CD3 antigen, an indicator of T-lympho-
cytes, after either diruthenium-1 or cisplatin therapy (Figure 33). 
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Figure 33 - Western blot analysis to detect the presence of the proliferation-related marker PCNA and CD3 
(indicator of T-lymphocytes) antigens in tumor homogenates from mice treated i.p. with pure solvent (C), [(p-MeC6H4-
Pr
i
)2Ru2(SC6H4-p-X)3]Cl, 0.4 mg/kg (R1) and 0.6 mg/kg (R2), or cisplatin 5.0 mg/kg (Pt). Apart from the inhibitory 
effect of cisplatin to PCNA, no significant changes in expression of these proteins were detected. Values are the means 
± SD (n = 7 in each group, exemplified by 3 samples for each group). Significantly different from the control: **P < 
0.01. 
 
In addition to the core results focused on the anticancer effect of diruthenium-1, we also 
performed a preliminary evaluation of its pharmacokinetics using four mice from the sacrificed R2 
group. ICP-MS measurements at m/z = 101 were done in plasma and selected tissues (tumor, brain, 
liver, and kidney) from the mice 48 hours after the second administration, when we anticipated 
(based on similar studies with other ruthenium- or platinum-based compounds [133-134]) the 
terminal excretory period with finished distribution (Table 4). High ruthenium concentrations were 
observed in liver and kidneys, but ruthenium also accumulated at high levels in the tumor. The 
levels in the tumor were well above the previously assessed IC50 values [111,113].
 
No ruthenium 
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was detected in the brain, indicating that diruthenium-1 does not cross the blood-brain barrier. Cal-
culations of tissue content showed that at least 31.6% of the administered dose still persisted in the 
organism, which corresponds to an elimination half-life of 30 hours.  
 
Table 4 - Biodistribution of diruthenium-1 into different organs after repeated administration of 2.0 mg/kg i.p. on 
days 1 and 7, studied by ICP-MS of 
101
Ru. The ruthenium concentration (conc.) is given in ng/g wet weight, the total 
uncertainty being approximately 10%. The weight of the organs is in grams. Number of animals n = 4. 
 1 2 3 4 
Organ Organ 
weight 
 
Conc. Organ 
weight 
 
Conc. Organ 
weight 
 
Conc. Organ 
weight 
 
Conc. 
 
Tumor 1.4
70 
 
320 1.3
83 
 
310 1.1
41 
 
150 1.4
75 
 
200 
Brain 0.4
87 
 
3.5 0.4
60 
 
2.3 0.4
72 
 
1.4 0.4
75 
 
1.3 
Liver 1.5
22 
 
270
0 
1.5
40 
 
290
0 
1.9
78 
 
900 1.5
19 
 
100
0 Kidney L 0.1
56 
 
570 0.1
62 
 
890 0.1
58 
 
760 0.1
75 
 
620 
Kidney R 0.1
73 
 
670 0.1
66 
 
760 0.1
86 
 
610 0.1
78 
 
580 
Plasma 0.5 
 
53 0.6 
 
55 0.5 
 
18 0.6 
 
25 
 
Figure 34a shows that diruthenium-1 at the concentration of 200 nM and higher significantly 
decreased the proliferation of MCF-7 cells. Interestingly, after treatment with low concentrations 
(50 and 100 nM), the proliferation of BT-549 cells was stimulated.  The quantity of LDH (lactate 
dehydrogenase) as a marker of cytotoxicity significantly increased after the treatment with 100 nM 
diruthenium-1 and its release occurred in a concentration dependent manner in both cell lines. 
A 
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Figure 34 – A: The influence of diruthenium-1 on cell proliferation (WST-1 assay) and its cytotoxic effect (LDH 
cytotoxicity detection assay) in MCF-7 and BT-549 cells. Values represent means of 3 independent experiments, P 
values < 0.05 are considered significant, * indicate values significantly different from control. B: The effect of 
diruthenium-1 on ATP levels in MCF-7 and BT-549 cells. Values represent means of 3 independent experiments, P 
values < 0.05 are considered significant, * indicate values significantly different from control. C: The influence of 
B 
C 
D 
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MCF-7 
p53 
BT-549 
p53_S15 
C    50    200   800        C     50   200   800  
(nM) 
diruthenium-1 on intracellular levels of reduced (GSH) and oxidized (GSSG) glutathione in MCF-7 cells. The levels of 
GSH and GSSG were related to the protein amount in the appropriate sample. Values represent means of 3 independent 
experiments, P values < 0.05 are considered significant, * indicate values significantly different from control. D: The 
effect of diruthenium-1 on levels of lactate in the cultivation medium of MCF-7 and BT-549 cells. The levels of lactate 
were divided by the concentration of protein in the appropriate sample. Values represent means of 3 independent 
experiments, P values < 0.05 are considered significant, * indicate values significantly different from control. 
 
Diruthenium-1 caused a decrease of ATP levels in the cells, as shown in Figure 34b. In MCF-7 
cells, a significant decrease of ATP was observed after the treatment with 800 nM of diruthenium-1, 
as the ATP level dropped to the half of the control in both time intervals. BT-549 cells appear to be 
more sensitive. After 72 hours of treatment with 200 nM of diruthenium-1, the level of ATP 
decreased to 41% of the control, and 800 nM caused a decline to 19%. MCF-7 cells incubated with 
diruthenium-1 showed a drop in the intracellular levels of both reduced (GSH) and oxidized 
(GSSG) glutathione, the latter being less impacted (Figure 34c). It may imply an interaction of 
diruthenium-1 with glutathione other than its oxidation. We observed the same GSH and GSSG 
decrease in BT-549 cells, but without statistical significance (data not shown). An increase in the 
concentration of lactate in the cultivation medium was observed after 72 hours of incubation (Figure 
34d). In MCF-7 cells it rose in a concentration dependent manner, whereas in BT-549 it peaked at 
200 nM of diruthenium-1. In BT-549 cells, we observed an increase in the expression of protein p53 
after 24 hours of treatment with 800 nM diruthenium-1. This increase was accompanied by the 
phosphorylation of p53 at serine 15 which was also present in MCF-7 cells. We further examined 
the expression of selected MAP (mitogen-activated protein) kinases. In an early interval of 
treatment, no changes were observed in the case of MCF-7 cells, whereas in BT-549 a decrease in 
phosphorylation occurred in a concentration dependent manner. In both cell lines, treatment with 50 
nM diruthenium-1 for 72 hours led to an enhanced phosphorylation of ERK (extracellular signal-
regulated kinases) and p38. This phosphorylation surprisingly declined with increasing 
concentration of diruthenium-1 (Figure 35). 
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The measurement of oxygen consumption in rat liver mitochondria (Figure 36) revealed a 
significant inhibition of both the complex I and II upon the addition of diruthenium-1. The 
respiration after addition of complex I substrates (glutamate + malate) was 47% after 5 minutes and 
only 32% after 10 minutes of incubation with diruthenium-1 when compared with the control. The 
respiration after addition of succinate, which is the substrate of complex II, was 59% of that of the 
control after 5 minutes of exposure to diruthenium-1 and 40% after 10 minutes. Significant 
recovery of the respiration of mitochondria incubated with diruthenium-1 was observed after the 
addition of cytochrome c, a marker of the status of the mitochondrial outer membrane. This increase 
was observed both for complex I and complex II, indicating a disintegration of the outer membrane 
by diruthenium-1.   
p_ERK 
p_p38 
MCF-7 
24 H                      72H 
C    50   200  800      C     50  200  800    C     50   200  800        C    50   200  800  
(nM) 
BT-549 
24 H                      72H 
Figure 35 - Changes in the expression of protein p53 and its phosphorylation at serine 15 after 24 hours treatment 
with diruthenium-1 at the indicated concentrations (top). Changes in the expression of ERK phosphorylated at 
T202/Y204 and p38 phosphorylated at T180/Y182 after 24 and 72 hours treatment with diruthenium-1 at the indicated 
concentrations (bottom). 
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Figure 36 - Respiration of rat liver mitochondria, with a special focus on complex I (A) and II (B). To the 2 ml of 
K-medium (30°C), mitochondria (mit) 0.2 mg protein/ml were added followed by 10 mM glutamate + 2.5 mM malate 
(G+M) for complex I or 10 mM succinate for complex II, further 1.5 mM ADP, 0.8 µM diruthenium-1 and 20 µM 
cytochrome c (CytC). In both A and B, diruthenium-1 decreased the oxygen consumption which was reversible by the 
addition of cytochrome c. 
A 
B 
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2.3.3  Conclusion 
For the study of the anticancer activity of diruthenium-1 in vivo, a solid Ehrlich tumor in immu-
nocompetent mice was employed as a model of mammary adenocarcinoma sensitive to cisplatin, 
which was used as a positive control drug. The study revealed that diruthenium-1 at doses of 0.4 
and 0.6 mg/kg administered twice within 8 days inhibits the tumor growth in tumor-bearing mice, 
although this effect was somewhat less pronounced than for cisplatin. On the other hand, it was only 
diruthenium-1 at the dose of 0.6 mg/kg that significantly prolonged the survival rate of tumor-
bearing mice. In terms of post-treatment survival, diruthenium-1 was in fact more effective than 
cisplatin, which can be considered a clinically valuable marker [135]. A possible explanation could 
be a mode of action that produces a longer lasting inhibition of the tumor regrowth rather than a 
significantly longer persistence of diruthenium-1 in the body.  
The elimination half-life predicted in our preliminary study correlates with the data formerly 
reported for other ruthenium-containing compounds in mice [136-137], and points toward a more 
rapid excretion than that detected for cisplatin [138-139]. Although we are aware of the limitations 
of such a prediction, overall pharmacokinetics similar to other heavy metal containing cytostatic 
agents can be anticipated, although a more detailed study is highly desirable. Due to the supposed 
elimination half-life, the influence of the first dose given 192 h before the sample collection seems 
to be negligible. Repeated administration was chosen in order to assess the concentrations of 
ruthenium in the tumor tissue during our in vivo study. Since the concentrations in tumor were more 
than one order of magnitude higher than the IC50 values [111,113], the inhibitory concentrations 
should be reached even if a considerable part of the compound were in an inactive state.  
The dose of cisplatin was chosen near the reported MTD [140], since the dose range of diruthe-
nium-1 was also adjacent to the MTD assessed in our study. However, at the doses of 1.0 and 2.0 
mg/kg, which had been at the upper range of tolerance in healthy mice, diruthenium-1 did not 
display any anticancer activity and instead caused severe acute toxicity to tumor-bearing mice. The 
use of the selected tumor model allows the observation of the effect on anticancer immune response 
[141-142]. The observed absence of changes in T-cell-infiltration into the tumor may refer to the 
mechanism of action of cisplatin, since alkylating agents were reported to impair the immune 
response [143]. The disproportion between the distinct tumor-inhibitory effect of diruthenium-1 and 
the absence of any changes in PCNA expression could also support the hypothesis of rapid cell 
death.  
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We studied cellular mechanisms of action of diruthenium-1 in human MCF-7 and BT-549 breast 
cancer cells. It exhibited antiproliferative and cytotoxic effects against both cell lines, the MCF-7 
cells seem to be more sensitive than BT-549. Both cell lines produced higher levels of lactate after 
diruthenium-1 treatment. The increase in lactate production was accompanied by a decrease in the 
level of ATP, which could indicate a switch to anaerobic glucose metabolism. In order to 
investigate this hypothesis, we measured the consumption of oxygen by the electron transfer chain 
in rat liver mitochondria. Diruthenium-1 was found to inhibit both the complex I and II of the 
electron transfer chain. In addition, it disrupts the outer mitochondrial membrane. Such 
mitochondrial dysfunction typically augments the formation of reactive oxygen species (ROS) 
[144]. This is why we expected an increased oxidation of GSH, in addition to the previously 
demonstrated catalytic GSH oxidation under cell-free conditions [111,113]. During the incubation 
of cells with diruthenium-1, the intracellular levels of GSH indeed decreased. However, since 
GSSG dropped rather than rose, we conclude that another type of interaction with glutathione 
prevails in living cells than the oxidation of GSH to GSSG. It might well be that diruthenium-1 
interacts with sulphur-containing peptides and proteins including the components of the electron 
transfer chain.  
Chen et al. [145] and Zhao et al. [146] described mitochondrial dysfunction and an increase in 
p53 in cells treated with other ruthenium complexes. The p53 protein, a key player in apoptosis, 
was also increased and activated by the phosphorylation at serine 15 in our study after the treatment 
with 800 nM diruthenium-1. The balance between MAPK members ERK1 and p38 is critical in 
terms of cell death or survival. In diruthenium-1 treated cells, we observed increased amount of 
phosphorylated ERK and p38 protein after 72 hours; interestingly it decreased with increasing 
concentration of diruthenium-1. Zhao et al. [146] associated the slight suppression of ERK after 
treatment with ruthenium polypyridyl complexes with an overproduction of ROS by dysfunctional 
electron transfer chain as a result of the regulation of Bcl-2 (B-cell lymphoma 2) family proteins.  
In conclusion, our results show that diruthenium-1, the most cytotoxic ruthenium compound 
reported so far, has indeed a potential as an anticancer drug, since it significantly prolongs the 
survival of tumor-bearing mice. However, further studies on pharmacokinetics, on the mode of 
action as well as on the assessment of its indication range are required.  
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Chapter 3:  Trithiolato Complexes with Fluorinated Side-Chains 
3.1  General 
Large numbers of synthetic fluorine-containing compounds have been used in a variety of fields, 
notably in the field of medicinal chemistry. Currently, up to 20% of all pharmaceuticals contain 
fluorine substituents, because of the unique properties that the incorporation of fluorine atom(s) or 
fluorinated group(s) can provide [147-148]. It is well known that fluorine’s electronegativity, size, 
lipophilicity, and electrostatic interactions can dramatically influence chemical and biological 
behavior of the resulting compounds [149]. The bioisosterism of fluorine-containing substituents 
with other chemical groups is therefore often exploited in the search for more active or more 
selective compounds in medicinal chemistry [150]. Thus, the C–F, C–OH, and C–OMe bonds can 
be sometimes interchanged without a major influence on the biological behavior of the compound 
[147], the C–CF3 fragment can be used as a substitute for the C=O group [151], the CF3 group is 
often used as a bioisoster of the CH3 group or as a variation of other halide groups; the fluorovinyl 
group (C=CHF) has been used as a replacement for the peptide bond [152]. 
The lack of selectivity of most of the currently used anticancer agents manifests by their severe 
side-effects. In the search for more selective means of cancer treatment, many new approaches have 
been devised such as phototherapy, treatment with magnetic nanoparticles or thermotherapy. 
During these therapies, a non-toxic agent (photosensitizer, magnetic nanoparticles or thermo-
responsive drug, respectively) is introduced into the tumor tissue, followed by the application of an 
external inducer such as light [153], magnetic field [154] or hyperthermia [155], which then 
activates the agent, thus increasing its cytotoxicity. Since these external inducers can be applied 
locally on the area containing the tumor tissue, the selectivity of such treatments is significantly 
increased and the side-effects are limited. In recent years, thermoresponsive properties of 
compounds with long fluorinated alkyl chains were investigated by the Dyson group (Figure 37) 
[156-157]. Fluorinated derivatives of the alkylating agent chlorambucil (Figure 37a) were shown to 
be non-toxic at 37°C but active against 8 different cancer cell lines under mild hyperthermia 
(41.5°C) [156]. Subsequently, the thermoresponsive properties of ruthenium complexes of the 
general formula [(6-p-MeC6H4Pr
i
)Ru(-NC5H4-m-C2H5COOC2H5(CF2)nCF3] (n = 5, 7, 9) were 
also studied [157]. The Ru(III) complexes with fluorinated alkyl chains on the pyridine ligand 
(Figure 37b) were shown to be up to two orders of magnitude more toxic to cancer cells under mild 
hyperthermia than under normal conditions (37°C), while being non-toxic to healthy HEK293 cells. 
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The fluorinated ligands were discussed as the source of the thermoresponsive properties, since they 
displayed marked difference in toxicity under normal conditions and under mild hyperthermia 
already on their own [157]. The benefits of thermotherapy with ruthenium-based drugs were later 
confirmed by in vivo studies, showing 90% decrease in tumor growth after the application of the 
ruthenium complex [(6-p-MeC6H4Pr
i
)Ru(-NC5H4-m-C2H5COOC2H5(CF2)9CF3] together with 
local hyperthermia [157].  
 
 
Figure 37 - Thermoresponsive chlorambucil derivatives (a) and ruthenium(III) complexes (b) 
 
The cytotoxicity of the arene ruthenium thiolato-bridged complexes was shown to depend on the 
lipophilicity of the complexes, the most active compound [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-Bu
t
)3]Cl 
being also one of the most lipophilic derivatives [111]. The lipophilicity of long fluorinated chains 
on the dinuclear ruthenium core could therefore have a positive effect on the anticancer activity of 
the resulting compounds. Thus, in order to investigate the effects of fluorinated alkyl chains on the 
solubility, cytotoxicity and thermoresponsivness of thiolato-bridged arene ruthenium complexes, we 
synthesized a new series of complexes of the general formula [(6-p-MeC6H4Pr
i
)2Ru2(-
SC2H4R)3]
+
, R = (CF2)7CF3 (11), (CF2)5CF3 (12), (CF2)3CF3 (13) and (CH2)5CH3 (14). Their 
structure, stability and anticancer activity under normal conditions and under mild hyperthermia are 
reported. 
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3.2  Results 
The dinuclear p-cymene complex [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-Cl)2] reacts with the thiols RSH 
[R = C2H4(CF2)7CF3, C2H4(CF2)5CF3, C2H4(CF2)5CF3 and C2H4(CH2)5CH3] to give cationic 
trithiolato arene ruthenium complexes 11 – 14 (Scheme 5). All four complexes were isolated in the 
form of their chloride salts as light orange crystalline powders and characterized by spectroscopic 
methods and correct elemental analyses. The analytical data are given in the experimental section.  
 
 
Scheme 5 - Synthesis of trithiolato complexes 11 – 14, isolated as chloride salts 
 
The stability of the compounds was tested at 37°C in DMSO-d6/D2O solution and followed by 
1D 
1
H NMR spectroscopy. As can be seen in Figure 38, no changes were observed in the NMR 
spectra after a week of incubation at 37°C. We therefore considered the compounds stable and 
proceeded with the biological studies of their anticancer activity and thermoresponsivness.  
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Figure 38 – Stability of complex 12 in DMSO-d6/D2O solution over 7 days 
 
Unfortunately, compounds [11]Cl and [12]Cl had a very low solubility in H2O mixtures, due to 
their long fluorous chains; it was therefore not possible to prepare solutions of sufficient 
concentrations for in vitro experiments even with 1% of DMSO as co-solvent. These compounds 
had to be abandoned and the biological studies were performed only with compounds [13]Cl and 
[14]Cl. 
 
Table 5 – Cytotoxicity of compounds [13]Cl and [14]Cl against cancer cell lines 
Compound A2780 (37°C) 
µM 
A2780 (41°C) 
µM 
A2780cisR 
µM 
HEK293 
µM 
[13]Cl 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.02 0.08 ± 0.05 
[14]Cl 0.10 ± 0.02 0.10 ± 0.02 0.08 ± 0.02 0.17 ± 0.03 
 
1 day 
7 days 
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To study the effects of hyperthermia on the trithiolato compounds, preliminary experiments 
were performed with A2780 ovarian cancer cells at 37°C and 41°C. Although the IC50 values of 
compounds [13]Cl and [14]Cl were in nanomolar range, no difference was observed when the 
experiments were performed at 41°C. These results suggest that the fluorous chains on compound 
[13]Cl have no significant effect on their thermoresponsivness, contrary to chlorambucil derivatives 
and Ru(III) complexes reported previously [156-158]. Therefore, the cytotoxicity for A2780cisR 
and HEK293 cell lines was studied only at 37°C and showed the compounds to be highly cytotoxic 
to both cell lines and slightly less cytotoxic (by the factor of two) to the healthy HEK293 cells 
(Table 5). The cytotoxicity of compounds [13]Cl and [14]Cl to A2780 and A2780cisR matches well 
with the observations for previously reported trithiolato complexes of the type [(p-
MeC6H4Pr
i
)2Ru2(SC6H4-p-X)3]
+
 (X = H, Me, Ph, Br, OH, NO2, OMe, CF3, F, Pr
i
 or Bu
t
), where the 
chloride salt of the most lipophilic complex [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-Bu
t
)3] (9) was found to 
be the most cytotoxic, with IC50 value of 0.03 µM for A2780 and A2780cisR. Compound [13]Cl is 
therefore as active as 9[Cl] for the cisplatin-sensitive cell line A2780 and only slightly less active 
for the cisplatin-resistant cell line A2780cisR, which makes is one of the most active ruthenium 
complexes discovered to date. The high activity of the complex is supposedly related to the high 
lipophilicity of the fluorous chains. 
 
3.3  Conclusion 
Four dinuclear arene ruthenium complexes 11 – 14 were synthesized and fully characterized. 
The long fluorous chains influenced the solubility of the complexes, not allowing to test compounds 
[11]Cl and [12]Cl in vitro. The compounds [13]Cl and [14]Cl were highly cytotoxic towards cancer 
cell lines, their IC50 values being similar to those of complex 9, most active thiolato-bridged 
complex synthesized so far. The lipophilicity of the compounds [13]Cl and [14]Cl is presumably 
the reason for this high cytotoxicity. No enhancement of the anticancer activity by hyperthermia 
was observed and the compounds did not exhibit any particular selectivity to cancer cells compared 
to healthy cells. 
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Chapter 4: Mixed Trithiolato Complexes 
To address the second objective of this thesis – the synthesis of conjugates of biologically 
relevant compounds with arene ruthenium thiolato-bridged complexes – new complexes that would 
allow the tethering of organic compounds had to be synthesized. Several examples of the so-called 
mixed trithiolato complexes were already known [112] and allowed us to use the hydroxo 
derivatives of the general formula [(6-p-MeC6H4Pr
i
)2Ru2(SCH2R)2(SC6H4-p-OH)]
+
 for 
esterification reactions (the results of which will be presented in Chapters 6 and 7). The conditions 
for the synthesis of mixed trithiolato complexes were also applied on the synthesis of new 
derivatives, intended as precursors for different coupling reactions. The reasoning behind the design 
of these complexes as well as the obstacles encountered during their synthesis and isolation are 
presented herein. 
 
4.1  Trithiolato Complexes with Halido Substituents 
During the investigation of the stepwise synthesis of trithiolato complexes (Chapter 2.1), various 
thiols were tested to find examples that form preferentially monothiolato products. During this 
screening, a correlation between the reactivity of the thiol of a general formula HSCH2-p-C6H4R 
and its pKa was observed, presented in the Table 5 (pKa values were obtained from the SciFinder
®
 
database). 
Table 6 – Relationship between the pKa of the thiol and product of the reaction 
R  pKa value Product 
NO2  8.74 ± 0.1 Monothiolato 
Cl  9.32 ± 0.1 Monothiolato and dithiolato 
Br  9.32 ± 0.1 Monothiolato and dithiolato 
I  9.53 ± 0.1 Monothiolato and dithiolato 
H  9.68 ± 0.1 Dithiolato 
Bu
t
  
 
9.83 ± 0.1 Dithiolato 
OMe  
 
9.93 ± 0.1 Dithiolato 
    
Thus, under the standard conditions (see Chapter 9.4.2), the three previously reported dithiolato 
complexes [115] were synthesized from the p-cymene dichloride dimer and benzenemethanethiol 
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(10), 2-phenylethanethiol (5, not presented in the table) and (4-tert-butylphenyl)methanethiol (7) 
and the fourth dithiolato complex was synthesized by the same method using (4-
methoxyphenyl)methanethiol (see Chapter 9.4.3, product 6); (4-nitrophenyl)methanethiol yielded 
the monothiolato complex 2 described in the Chapter 2.1.  
The formation of dithiolato complexes from the reaction with (4-chlorophenyl)methanethiol, (4-
bromophenyl)methanethiol and (4-fluorophenyl)methanethiol provided us with the possibility to 
increase the number of dithiolato precursors available for the syntheses of various conjugates. 
Therefore, by increasing the temperature, the reaction time and the ratio between the p-cymene 
dichloride dimer and the thiol, it was possible to synthesize the tree dithiolato complexes 15 – 17 
(Figure 39) without the presence of the contamination by the monothiolato product. The complexes 
were significantly less soluble than the four dithiolato complexes reported previously, precipitating 
from the ethanolic solution already during the reaction.  
 
Figure 39 – Structure of thiolato arene ruthenium complexes with halido substituents 
 
The three complexes were then reacted with HS-p-C6H4-OH in order to obtain the mixed 
trithiolato complexes (isolated as their chloride salts) and use them as starting products in the 
synthesis of chlorambucil conjugates (Chapter 7). When the Steglich esterification with the 
trithiolato complexes 19 and 20 was attempted, however, the resulting conjugates proved unstable 
(already the elemental analysis of complex 19 suggests its slight instability). The NMR spectra 
taken directly after the synthesis showed the expected products, but the results of elemental 
analyses showed that no nitrogen (and therefore no bound chlorambucil) was present. We assume 
that the slow degradation took place during the time between the synthesis and the elemental 
analysis. The reasons for this instability or the precise nature of the degradation products were not 
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studied. The esterification of product 18 with chlorambucil gave a stable conjugate, which was fully 
characterized and is discussed in the Chapter 7. 
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4.2 Trithiolato Complexes with Amino Groups 
The reaction of a carboxylic acid R-COOH with an amine R’-NH2 forms a peptide bond R-CO-
NH-R’. Since it is the basis of all peptides and proteins, peptide bond is probably one of the most 
abundant structural features in living organisms. As such, it is frequently used in the design of 
pharmaceutical agents, because of its relative stability in biological environments [159]. The 
synthesis of trithiolato complexes containing an NH2 group would allow us to attach various 
biologically active compounds to the ruthenium center. Examples of such compounds include 
amino acids or peptides (which could be attached by their C-terminus), biologically active 
carboxylic acids such as ethacrynic acid, ibuprofen or chlorambucil, or compounds with tumor 
targeting properties, such as folic acid or biotin. Besides the formation of the peptide bond, NH2 
derivatives of trithiolato complexes would also allow us to explore the possibility of other organic 
coupling reactions, for example the Buchwald-Hartwig amination (cross-coupling reaction between 
amines and aryl halides or pseudohalides), thus broadening the spectrum of compounds that can be 
attached to the dinuclear arene ruthenium core. 
 
 
Figure 40 - Synthesis of amino derivatives 24 – 26 isolated as chloride salts 
 
The syntheses of products 21 – 23 were carried out using the standard reaction conditions 
published previously [112,115], refluxing the ethanolic solution of the dithiolato precursor and 6 
equivalents of the 4-aminothiophenol for 16 hours. The resulting mixture was separated by column 
chromatography, yielding chloride salts of the products 21 – 23 as orange crystalline powders 
(Figure 40). Both NMR and ESI-MS spectra of the products contained an impurity that was 
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impossible to remove by any of the employed separation methods. The impurity appeared in the 
aromatic region of the NMR and also in the ESI-MS spectra (two doublets at 7.18 ppm and 6.57 
ppm and a peak at m/z = 942.0 for the product 21, see Figure 41).  
 
 
 
Figure 41 - Impurity in the product 21, NMR and ESI-MS spectra 
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This impurity could not be isolated or identified and its presence did not allow the correct 
elemental analyses of the products. Therefore, this approach for the synthesis of conjugates of 
trithiolato arene ruthenium complexes had to be abandoned. NMR and ESI-MS data for the chloride 
salts of the three products 21 – 23 are given in the section 9.4.8. 
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4.3  Trithiolato Complexes with Carboxylic Acid Groups 
Since the synthesis of NH2-containg derivatives of arene ruthenium thiolato-bridged complexes 
was unsuccessful, we decided to approach the problem from the opposite side – the complexes 
containing a carboxylic acid moiety would still allow us to attach NH2-containing molecules by the 
formation of peptide bond and would at the same time provide us with the possibility of tethering 
biologically interesting molecules containing OH groups, such as flavonols [160]. We therefore set 
out to synthesize the carboxylic acid derivatives of the mixed trithiolato complexes. 
 
Scheme 6 – Synthesis of trithiolato complexes with COOH functionality 
 
When the standard reaction conditions for the synthesis of the mixed trithiolato complexes were 
used (3 equivalents of thiol, ethanol, reflux, 16 hours), the two dithiolato precursors 5 and 9 yielded 
a mixture of the COOH containing complex and its respective ethyl ester (Scheme 6). Although the 
majority of the ester-containing complex could be separated by column chromatography, a trace 
contamination was always present in the desired COOH derivative (manifested by NMR resonances 
at 4.40 ppm and 1.42 ppm for the derivative 24 and 4.36 ppm and 1.39 ppm for 25) and no 
separation method that we tried afforded the pure product. Therefore, the correct elemental analysis 
of the products 24 and 25 was not obtained and it was not possible to use them in further reactions. 
The 1D 
1
H NMR and ESI-MS data of the two products are shown in the section 9.4.9. The attempts 
to run the reaction in other solvents that would not form esters (MeCN at reflux, ethyl acetate at 
reflux or CH2Cl2 in pressure Schlenk tube at 75°C) did not yield the desired product.  
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Figure 42 – Structure of the tris(mercaptobenzoic acid) derivative 26 
 
Interestingly, when the p-cymene dichloride dimer was reacted with 6 equivalents of 4-
mercaptobenzoic acid in ethanol, only the carboxylic acid derivative of the triply bridged arene 
ruthenium complex was obtained (Figure 42). This product ([26]Cl) was therefore isolated by 
column chromatography on silicagel using a mixture EtOH/CH2Cl2 1 : 1 with 0.1% of formic acid 
and was subsequently fully characterized. 
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Chapter 5: Propargyl Derivatives of Dinuclear Thiolato Ruthenium 
Complexes 
5.1  General 
In 2001, K. B. Sharpless et al. coined the term “Click chemistry”, describing reactions that are 
useful in synthetic chemistry to generate substances by joining small structural units together. These 
reactions, as defined by Sharpless et al., have to be: “… modular, wide in scope, give very high 
yields, generate only inoffensive byproducts that can be removed by nonchromatographic methods, 
and be stereospecific (but not necessarily enantioselective). The required process characteristics 
include simple reaction conditions (ideally, the process should be insensitive to oxygen and water), 
readily available starting materials and reagents, the use of no solvent or a solvent that is benign 
(such as water) or easily removed, and simple product isolation. Purification (if required) must be 
by nonchromatographic methods, such as crystallization or distillation, and the product must be 
stable under physiological conditions.” [161]. One such reaction that has gained a remarkable 
amount of interest and has been frequently used in various fields of chemistry is the Huisgen 1,3-
dipolar addition, named “Click reaction”. In this synthetic transformation, an organic azide reacts 
with an alkyne in water or water/organic mixture to form a triazole [162]. The reaction, catalyzed 
most frequently by Cu(I) species  (formed in situ by the reduction of CuSO4 by sodium ascorbate or 
ascorbic acid), gives selectively 1,4-disubstituted 1,2,3-triazoles (Scheme 7) [163]. Due to its 
robustness, tolerance to water and air and due to the commercial availability of a large number of 
organic alkynes and azides, this reaction has become the basis for the synthesis of a plethora of 
compounds and materials, including dendrimers [164], derivatized nanoparticles [165-166] or 
carbon nanotubes [167]. It is also worth noting that a variation of the Click reaction that utilizes 
metal azides was developed for the use in bioinorganic chemistry and was termed “iClick” (= 
inorganic Click reaction) [168].  
 
Scheme 7 - Copper-catalyzed Huisgen 1,3-cycloaddition (“Click reaction”) 
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The synthesis of dithiolato dinuclear ruthenium complexes in 2010 [115] provided us with the 
possibility to prepare the mixed trithiolato complexes, where the third bridging thiol contains a 
chemically modifiable substituent on the benzene ring, such as methyl, trifluoromethyl, hydroxyl, 
fluoride or bromide. Since azides of some biologically important substrates such as glucose, 
galactose or biotin are commercially available [169], we attempted the synthesis of alkyne-
containing arene ruthenium complexes from the hydroxo derivatives [(6-p-MeC6H4Pr
i
)2-
Ru2(SCH2R)2(SC6H4-p-OH)]
+
 (Scheme 8). The resulting complexes could then be used as a 
platform for the Click reaction with various azides. 
 
Scheme 8 - Synthesis of the precursor complexes 27 – 30 
 
5.2  Results 
The four complexes 27 – 30 (the new complex 30 was synthesized by analogy to the previously 
published complexes 27 – 29, see Chapter 9.4.3) were subjected to the Williamson reaction with 
propargyl bromide in the presence of K2SO4, yielding propargyl-containing complexes 31 – 34 
(Scheme 9). All the four complexes were isolated as tetrafluoroborate salts and completely 
characterized.  
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Scheme 9 - Synthesis of propargyl-containing complexes 31 – 34 
 
Due to the high number of synthetic steps needed to obtain the precursor compounds [27 – 
30][BF4] and due to low yields of the Williamson reaction, it was difficult to obtain sufficient 
amounts of products for further syntheses of conjugates and this approach was therefore not 
prioritized. However, a proof-of-concept experiment was conducted in order to see if the propargyl-
containing complexes can indeed react with azide functionality and form triazoles. Thus, the 
compound [33][BF4] was reacted with benzyl azide under the conditions of the Click reaction (0.4 
eq sodium ascorbate, 0.1 eq CuSO4, H2O, CH2Cl2, rt, 24 h). The resulting mixture was extracted 
with CH2Cl2 and directly subjected to NMR and ESI-MS analysis. The spectra clearly show the 
formation of the “clicked” product, demonstrated by the fragment at m/z = 1126.6 and by the new 
resonances in the NMR spectrum belonging to the aromatic protons of p-cymene and aliphatic 
protons of SCH2-p-C6H4-Bu
t
 (Figure 43). 
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Figure 43 - NMR and ESI-MS spectra of the triazole-containing product 
p-cymene  SCH2-p-C6H4Bu
t
  
Starting material 33[BF4]  
Product of the Click reaction  
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Therefore, the synthesized propargyl-containing products are available for the copper-catalyzed 
Huisgen 1,3-cycloadition, although the reaction seems to proceed significantly slower than in the 
case of purely organic substrates - reaction between benzyl azide and (2-propynyloxy)benzene 
under the same conditions gives 95% yield in 12 hours [170].  
 
5.3  Conclusion 
Four propargyl-containing trithiolato complexes were synthesized and their availability for the 
Huisgen 1,3-cycloaddition was demonstrated. The products form selectively the 1,4-substituted 
triazoles, the expected product of the copper-catalyzed Click reaction. Provided that the synthetic 
procedure to obtain products 30 – 34 can be optimized to give better yields, the products could be 
coupled with commercially available azides to prepare useful conjugates with glucose, galactose, 
biotin (a molecule frequently used in the syntheses of targeted agents [171-172]) or other 
biologically relevant molecules to which the azide moiety can be synthetically attached. 
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Chapter 6:  Ibuprofen Conjugates of Dinuclear Thiolato Ruthenium 
Complexes 
6.1  General 
Tumors have been called “wounds that do not heal” [173], referring to the critical role that 
inflammation plays in tumorigenesis [174]. It is now well established that inflammatory 
microenvironment is an essential component of all tumors [175] and that the induction of 
inflammation, for example by bacterial and viral infection, increases cancer risk [176]. Moreover, 
recent work has shown that tobacco smoke is a tumor promoter because of its ability to trigger 
chronic inflammation [177], in addition to its high carcinogen content. Those findings encouraged 
the research of the effects of anti-inflammatory drugs on cancer. Thus, non-steroid anti-
inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, naproxen or indomethacin were studied 
for their influence on cancer incidence, progression and mortality. The mode of action of NSAIDs 
is the inhibition of the enzyme cyclooxygenase (COX), which is the effect at the origin of the 
analgesic, antipyretic and antirheumatic effects of NSAIDs [9]. The inducible version of the COX 
(COX-2) was shown to be overexpressed in tumor tissue and involved in tumor initiation and 
progression [178-180]. Subsequently, several large-scale epidemiologic studies showed that 
individuals who take NSAIDs on a regular basis have 40-50% reduction in mortality from 
colorectal cancer [181]. Furthermore, a direct effect on the proliferation and cell cycle of colon 
cancer cells was evidenced by in vitro studies – a series of 18 NSAIDs exhibited IC50 values in the 
micromolar range for HT-29 and DLD-1 colon cancer cell lines, similar results were obtained for 
human breast cancer, lung cancer and melanoma cells [182]. Aspirin, indomethacin, naproxen and 
piroxicam increased the proportion of cancer cells in the G0/G1 phase, reduced the proportion in the 
S phase of the cell cycle and induced apoptosis [183]. In a different study, 7 examples of NSAIDs 
were found to inhibit the heat shock protein 70 (HSP70), a family of proteins that play an essential 
role for cell survival in stressful conditions and that is often overexpressed in cancer cells [184-
185]. This finding was used to explore the effect of ibuprofen, one of the studied agents, on the 
cisplatin anticancer activity. The cisplatin-dependent cellular events leading to lung cancer cell 
apoptosis were found to be accelerated by ibuprofen, an effect that was ascribed to the HSP70 
inhibition [186]. 
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The combination studies of two different anticancer drugs can encounter problems of disparate 
biodistribution of the two agents, not allowing to replicate the in vitro results in the following in 
vivo studies [187]. This problem could be addressed by attaching the two agents by a chemical 
bond, forming a drug conjugate with unified biodistribution and possibly with the biological effects 
of the two composing parts [188]. NSAIDs were already successfully coupled with platinum 
anticancer drugs, yielding complexes with interesting properties. Cheng et al. synthesized 
platinum(IV) complex with aspirin as one of the axial ligands that showed up to ten-fold increase in 
cytotoxicity compared to cisplatin [189]. Similarly, the binding of two molecules of ibuprofen or 
indomethacin as the two axial ligands of the oxidized cisplatin and oxaliplatin yielded anticancer 
compounds with up to two orders of magnitude higher cytotoxicity to colorectal carcinoma and at 
the same time with the ability to inhibit COX-1 and COX-2 and to overcome cisplatin resistance 
[188,190]. Recently, the group of Hartinger synthesized arene ruthenium compounds with non-
selective NSAID piroxicam and a preferential COX-2 inhibitor meloxicam as O,O-chelating ligands 
(Figure 44). These ruthenium-based compounds proved to be only slightly toxic to HCT116 colon 
carcinoma cells, the IC50 of the most active compound being 80 µM. Docking studies with the 
COX-2 enzyme showed low binding affinities of the complexes, suggesting that the coordination of 
the arene ruthenium unit changes the mode of action of the COX inhibitor [191]. 
 
Figure 44 - Structure of the two Ru(III) complexes with oxicams as O,O-chelating ligands, synthesized by 
Hartinger et al. [191] 
 
Herein we report the synthesis of a series of arene ruthenium dinuclear trithiolato conjugates 
with ibuprofen. The NSAID molecule is covalently bound to the ruthenium core by an ester bond, 
which we suppose might allow the ibuprofen moiety to preserve its anti-inflammatory effect and 
enhance the anticancer activity of the trithiolato ruthenium complex. 
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6.2  Results 
The complexes 27 – 30 were reacted with ibuprofen using the Steglich esterification conditions, 
yielding ibuprofen conjugates 35 – 38 (Scheme 10). The tetrafluoroborate salts of the four 
ibuprofen conjugates were isolated by column chromatography as orange crystalline powders and 
completely characterized. They are well soluble in chlorinated solvents, lower alcohols and polar 
solvents such as acetonitrile and THF. 
 
Scheme 10 - Synthesis of ibuprofen conjugates 35 – 38 
 
 
Figure 45 – Stability of complex 32 in DMSO-d6/D2O mixture over 14 days 
1 day 
14 days 
2 days 
3 days 
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The stability of the conjugates in aqueous solution was investigated by NMR spectroscopy and 
showed the complex 32 to be stable for more than 1 week in DMSO-d6/D2O mixture, as can be seen 
in Figure 45. The anticancer activity of the four compounds [31 – 34][BF4] was therefore studied in 
vitro on ovarian cell line A2780 and its cisplatin-resistant mutant A2780cisR as well as in the 
healthy cell line HEK293. The IC50 values of all four compounds were in the nanomolar range, 
matching well with those of the chloride salts of the mixed trithiolato complexes 27 – 30 that served 
as precursors for the ibuprofen conjugates [112]. Unfortunately, no selectivity towards cancer cells 
was observed and the conjugates were highly cytotoxic also towards HEK293 cell line (Table 7).  
 
Table 7 – In vitro cytotoxicity of compounds [35 – 38]Cl 
Compound IC50 (A2780) 
[µM] 
IC50 (A2780cisR) 
[µM] 
IC50 (HEK293) 
[µM] 
    [35][BF4] 0.21 ± 0.05 0.20 ± 0.04 0.21 ± 0.02 
[36][BF4] 0.37 ± 0.07 0.39 ± 0.07 0.34 ± 0.03 
[37][BF4] 0.29 ± 0.04 0.20 ± 0.06 0.22 ± 0.07 
[38][BF4] 0.54 ± 0.14 0.45 ± 0.10 0.49 ± 0.03 
     
These results suggest that the coupling of the ibuprofen moiety does not confer any selectivity 
towards ovarian cancer cells. The same effect as in the case of the complexes with meloxicam and 
piroxicam could be the reason – the coupling of ibuprofen with the ruthenium complex might 
influence the binding affinity of the NSAID to the COX enzyme. The conjugates cannot therefore 
benefit from the anti-inflammatory properties of ibuprofen and can exert their anticancer activity 
solely by the mode of action already described for the trithiolato complex 9 (Chapter 2.3). 
 
6.3  Conclusion 
The Steglich esterification of hydroxo derivatives of trithiolato arene ruthenium complexes 
afforded four conjugates with ibuprofen [31 – 34][BF4]. The complexes were fully characterized by 
analytical methods and found to be sufficiently stable for in vitro biological studies. The results 
show high anticancer activity of the four conjugates, the IC50 values being in sub-micromolar range. 
No selectivity towards ovarian cancer cells was observed. The conjugation of ibuprofen to the 
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ruthenium core does not provide the expected benefits of higher anticancer activity or selectivity, 
presumably because of the different binding affinity of the conjugates to the COX enzyme 
compared to the free ibuprofen. The choice of a different cancer model, for example the colorectal 
or the breast cancer that responded to the treatment of ibuprofen alone [182,186] might yield new 
insights into the anticancer activity of the ibuprofen conjugates. 
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Chapter 7:  Chlorambucil Conjugates of Dinuclear Thiolato 
Ruthenium Complexes 
7.1  General 
Both platinum and ruthenium anticancer complexes have been shown to benefit from coupling 
with organic molecules that can increase their solubility, facilitate their transport into cells or 
enhance their selectivity for cancer cells. For instance, the ruthenium complex [(6-p-
MeC6H4Pr
i
)Ru(pta)Cl2] was coupled with ethacrynic acid, a compound that inhibits the enzyme 
glutathione-S-transferase. The resulting complex was found to bind to glutathione-S-transferase, 
whereupon the metal moiety was enzymatically cleaved and released into the sensitized cancer cell 
[192]. A similar approach was patented by the Lippard group for platinum(IV) complexes coupled 
to vitamin E precursors. These complexes act as anticancer agents with increased selectivity for 
cancer cells, where both the platinum moiety and vitamin E precursor attack cancer cells via a 
separate mode of action [193]. In a similar manner, thiolato-bridged arene ruthenium complexes 
were recently coupled to oligopeptides, which largely increased their solubility in water, thus 
facilitating their application [194]. 
 
 
Figure 46 - N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil) 
 
In this chapter we report the synthesis and in vitro activity of four thiolato-bridged arene 
ruthenium complexes coupled to the alkylating agent chlorambucil (Figure 46). Chlorambucil [N,N-
bis(2-chloroethyl)-p-aminophenylbutyric acid] is a drug standardly employed in the treatment of 
chronic myeloid leukemia, myeloma and chronic lymphocytic leukemia [195]. Its anticancer 
properties are explained by its direct binding to DNA, specifically to N7 of guanines. Chlorambucil 
can form either monofunctional nucleotide adducts, or interact with DNA by both of its electro-
HO
O
N
Cl
Cl
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philic sites at once, forming either intrastrand or interstrand DNA cross-links [196]. Very recently, 
RAPTA-type  complexes were reported, in which the arene ligand was functionalized by chloram-
bucil moieties; some of these chlorambucil-functionalized RAPTA complexes show superior 
anticancer activity to cisplatin-resistant cancer cells as compared to chlorambucil, to the parent 
RAPTA complex, or to the mixture of both. These conjugates are supposed to act by two disparate 
modes of action, namely by protein ruthenation and by DNA alkylation [197]. 
Dinuclear arene ruthenium trithiolato complexes can be functionalized on one of the thiolato 
ligands, in particular since mixed complexes of the type [(6-arene)2Ru2(SR
al
)2(SR
ar
)]
+
 are easily 
accessible with aliphatic (al) and aromatic (ar) substituents on the thiolato bridges [112]. We there-
fore prepared the neutral precursors [(6-p-MeC6H4Pr
i
)2Ru2(SCH2R)2Cl2] (R = Ph: 10, R = CH2Ph: 
5, R = C6H4-p-Bu
t
: 7, R = C6H4-p-OMe: 6) from p-cymene ruthenium dichloride dimer and the 
corresponding thiol, and the mixed cationic complexes [(6-p-MeC6H4Pr
i
)2Ru2(SCH2R)2(SC6H4-p-
OH)]
+
 (Ph: 27, R = CH2Ph: 28, R = C6H4-p-Bu
t
: 29), by reaction with p-mercaptophenol according 
to published methods
 
[112,115]; the new derivative [(6-p-MeC6H4Pr
i
)2Ru2(SCH2C6H4-p-
OMe)2(SC6H4-p-OH)]
+
 (30) was synthesized by analogy. The mixed cationic complexes 27 – 30 
containing a phenolic group in one of the thiolato bridges can be used for the functionalization with 
chlorambucil. 
 
7.2  Results and Discussion 
The mixed trithiolato complexes [(6-p-MeC6H4Pr
i
)2Ru2(SCH2R)2(SC6H4-p-OH)]
+
 (27 – 30) 
react in dichloromethane with chlorambucil (cabOOH) under Steglich esterification conditions to 
give the chlorambucil conjugates [(6-p-MeC6H4Pr
i
)2Ru2(SCH2R)2(SC6H4-p-OOCcab)]
+
 R = Ph: 
39, R = CH2Ph: 40, R = C6H4-p-Bu
t
: 41, R = C6H4-p-OMe: 42), which can be isolated as tetrafluo-
roborate salts in the form of orange crystalline powders (Scheme 11). The compounds [39 – 
42][BF4] are well soluble in chlorinated solvents, alcohols and polar solvents such as acetonitrile, 
THF or DMSO. All complexes have been fully characterized by 
1
H and 
13
C NMR spectroscopy, 
mass spectroscopy and elemental analysis. The conjugation of product 18 (Chapter 4.1) yielded a 
stable complex [(6-p-MeC6H4Pr
i
)2Ru2(SCH2C6H4-p-Cl)2(SC6H4-p-OOCcab)]
+ 
(43), that had 
significantly lower solubility in organic solvents and in water than the other four conjugates and 
was therefore not included in the further studies. 
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Scheme 11 - Synthesis of chlorambucil conjugates 39 – 43 
 
The in vitro anticancer activity of the chlorambucil conjugates [39 – 42][BF4] was evaluated 
against the human ovarian cancer cell line A2780 and its cisplatin-resistant mutant A2780cisR, 
using the The CellTiter-Glo
®
 luminescent cell viability assay (CTG) that determines the number of 
viable cells in culture based on quantitation of the ATP present, an indicator of metabolically active 
cells. As far as the neutral dithiolato precursor complexes and the cationic trithiolato precursor are 
concerned, the IC50 values for the known derivatives 5, 6, 7 and 10
 
[115] and 27 – 30 [112] have 
been taken from our earlier publications (Tables 8 and 9). In general, the neutral dithiolato 
complexes are less cytotoxic than the cationic trithiolato complexes; the derivative 30 confirms this 
tendency. All cationic trithiolato complexes exhibit IC50 values in nanomolar range. 
 
Table 8 - IC50 values of the neutral dithiolato complexes 5, 6, 7 and 10 for human ovarian carcinoma cells. Values 
are given as the means ± the standard error of the mean. 
Complex IC50 A2780 
[nM] 
IC50 A2780cisR 
[nM] 
5 2940 ± 600 3600 ± 800 
6 200 ± 50 310 ± 80 
7 > 5000 > 5000 
10 235 ± 50 > 5000 
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Table 9 - IC50 values of the cationic trithiolato complexes [27 – 30][BF4] for human ovarian carcinoma cells. 
Values are given as the means ± the standard error of the mean. 
Compound IC50 A2780 
[nM] 
IC50 A2780cisR 
[nM] 
[27]Cl 47.8 ± 3.0 42.9 ± 1.0 
[28]Cl 74.4 ± 2.8 49.9 ± 1.9 
[29]Cl 163 ± 8.0 59.5 ± 1.3 
[30]Cl 320 ± 80 109 ± 30 
 
The cytotoxicity of chlorambucil conjugates [39 – 42][BF4] was studied using four cell lines: 
non-cancerous human embryonic kidney (HEK293) cells, immortalized endothelial cells (RF24), 
human ovarian carcinoma cell line (A2780) and cisplatin resistant human ovarian carcinoma cell 
line (A2780cisR). The results reveal the IC50 values for the two ovarian cancer cell lines to be in the 
nanomolar range (Table 10), though being higher than those of the corresponding trithiolato com-
plexes 27 – 30 that are not conjugated to chlorambucil (Table 9). This may be partially explained by 
the change in lipophilicity caused by the conjugation of chlorambucil. The lipophilicity (represented 
by Hammett constants σp and the lipophilicity parameter log P) has been shown to be a major factor 
influencing the anticancer activity of trithiolato arene ruthenium complexes [111].  
 
Table 10 - IC50 values of [39 – 42][BF4] against human carcinoma cell lines A2780 and A2780cisR determined 
using the CTG assay after 72 h. Values are given as the means ± the standard error of the mean. 
Compound IC50 A2780 
[nM] 
IC50 A2780cisR 
[nM] 
IC50 HEK293 
[nM] 
IC50 RF24   
[nM] 
[39][BF4] 75 ± 14 321 ± 44 335 ± 26 152 ± 15 
[40][BF4] 55 ± 6 353 ± 10 448 ± 40 325 ± 45 
[41][BF4] 183 ± 25 335 ± 50 451 ± 65 280 ± 36 
[42][BF4] 600 ± 72 591 ± 62 1580 ± 300 770 ± 100 
 
The cell viability experiments conducted in the four cell lines (Figure 47) show that 
chlorambucil conjugates [40][BF4] and [42][BF4] exhibit an interesting selectivity for the A2780 
cell line at the dose range 50 to 300 nM (compound [40][BF4]) or 50 to 100 nM (compound 
[42][BF4]), while being only slightly active in RF24, HEK293 or A2780cisR cells. The IC50 value 
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for the chlorambucil conjugate [40][BF4] is 55 ± 6 nM for A2780 cells, similar as for its precursor, 
compound [28]Cl (49.9 ± 1.9 nM), while for chlorambucil alone it is reported to be approximately 
22-fold higher (1200 nM [198]). The IC50 of [39][BF4] in A2780 cells is 75 ± 14 nM and only 2-
fold higher in endothelial RF24 cells. Complex [41][BF4], at low doses (up to 70 nM), seems to be 
the most selective towards A2780cisR cells, which is not observed in the higher dose range.  
  
Figure 47 - Dose-dependent cell viability after administration of compounds [39 – 42][BF4]. Values are presented 
as the means ± the standard error of the mean. 
 
In order to study the mechanism of action of the new chlorambucil conjugates, the compound 
[40][BF4] was incubated with the tripeptide glutathione and with the nucleobase 2-deoxyguanosine 
5’monophosphate. The catalytic oxidation of glutathione is reported to be at least partially 
responsible for the high in vitro cytotoxicity of trithiolato dinuclear arene ruthenium complexes 
[112]. On the other hand, the mode of action of chlorambucil is its covalent binding to DNA 
nucleobases, namely to the position 7 of guanine. Both of these targets were investigated in order to 
see if the chlorambucil conjugates retain the mode of action of its composing parts.  To our surprise, 
the compound [40][BF4] does not oxidize glutathione, although its precursor [28]Cl has a reported 
[41][BF4] 
[39][BF4] [40][BF4] 
[42][BF4] 
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turnover frequency of 7.02 h
-1 
for the catalytic glutathione oxidation [112].  After 24 hours of 
incubation at 37°C, the NMR spectrum shows only the peaks of glutathione, no formation of the 
disulfide was detected. The interaction of [40][BF4] with 2-deoxyguanosine 5’-monophosphate 
(dGMP) was studied at two different pH values - at pH = 3.5 without the addition of any buffer or 
base, and after the addition of 0.1 M NaOH, which raised the pH to 8. According to studies of 
chlorambucil binding to DNA, the alkylation of guanines proceeds much faster at elevated pH 
[199]. However, in our case the ESI-MS spectra showed no adducts of 2-deoxyguanosine 5’-
monophosphate and [40][BF4] even at pH 8. At pH = 3.5, the only detected products aside from the 
original complex were the two hydrolysis products of the chlorambucil conjugate, as shown in 
Figure 48.  
 
 
Figure 48 - Hydrolysis products of the complex 40 after 24 hours incubation at 37°C with 4 equivalents of 2-
deoxyguanosine 5’monophosphate. Insert: Simulated (top) and measured (bottom) MS spectra. 
 
These results demonstrate that the conjugation of the thiolato-bridged arene ruthenium complex 
to chlorambucil hampers the chlorambucil moiety to interact with nucleobases. Conversely, the 
conjugation also blocks the catalytic activity of the dinuclear trithiolato unit. We therefore assume 
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that these conjugates can deploy their anticancer properties in the cancer cells only after hydrolysis 
of the ester bond brought about by the esterases in the cells. 
Compound [40][BF4] was used to evaluate the effect of the conjugates on tumor growth and that 
on the survival of tumor-bearing mice of an immunocompetent strain. The doses were selected 
according to the dose-finding study which had revealed a maximum tolerated dose (MTD) of 20 
mg/kg. Figure 49 shows the weight of tumors in mice treated with saline, [40][BF4], chlorambucil 
or cisplatin measured on day 11, and significantly documents differences in the effect of the used 
drugs. [40][BF4] at the dose of 15 mg/kg had a significant inhibitory effect on tumor growth (P = 
0.0474). The positive control, cisplatin, was the most potent. Chlorambucil itself was also effective 
(P > 0.05); interestingly, a multiple comparison revealed that its effect did not significantly differ 
from the one of [40][BF4] (P > 0.05).   
 
Figure 49 - Weight of the solid Ehrlich tumor (in grams) on day 11 of mice injected on days 1, 4 and 8 i.p. with 
[40][BF4] in doses of 10, 15, or 20 mg/kg, or chlorambucil 5 mg/kg, or cisplatin 5 mg/kg. Values are the means ± SEM 
(n = 7 in each group). Values that are significantly different from the controls are labeled by * (
*
P < 0.05, 
***
P < 0.001). 
 
As for the effect on survival, the mean overall survival of tumor-bearing mice without therapy 
was 21.6 days. [40][BF4] at both 10 mg/kg and 15 mg/kg showed a tendency to prolong the survival 
albeit the effect was not significant (P = 0.458 and 0.693, respectively). The group receiving 
[40][BF4] 20 mg/kg could not be evaluated because of their bad general condition. Unlike the 
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healthy mice in the MTD finding study, the tumor bearing mice treated with 20 mg/kg of [40][BF4] 
displayed severe symptoms of intoxication and had to be euthanized. Only chlorambucil prolonged 
the mean survival time significantly when compared with untreated tumor-bearing control mice (P 
= 0.0401). Chlorambucil was also more effective when compared with its conjugate [40][BF4] at 
both doses evaluated (P ˂ 0.01). The effect of cisplatin could not be considered significant (P = 
0.0869). The Kaplan-Meier analysis of survival can be seen in Figure 50. 
 
 
Figure 50 - Kaplan-Meier analysis of survival. Only the administration of chlorambucil 5 mg/kg significantly 
prolonged the survival of tumor-bearing mice when compared with tumor-bearing controls treated with saline i.p. 
(CTRL). Neither 10 mg nor 15 mg of [40][BF4]/kg BW (body weight), nor 5 mg of cisplatin/kg BW had any 
statistically significant effect. The compounds were administered i.p. on days 1, 4 and 8 after tumor inoculation. 
 
The conjugate [40][BF4] at any dose did not have a significant therapeutic effect in comparison 
to chlorambucil alone. When the dose of 20 mg/kg, which is stoichiometrically almost equivalent to 
5 mg/kg chlorambucil, was applied, [40][BF4] turned out to be more systemically toxic and less 
potent than chlorambucil itself. It is quite possible that, even if the conjugate was completely 
hydrolyzed into the putatively more active components, the summation of their toxicity might 
hinder the body´s own defence mechanisms such as the anticancer immune surveillance. Studies in 
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more cancer models are needed to determine whether or not the conjugation in question increases 
the anticancer potential of the components.  
 
7.3  Conclusions 
Four chlorambucil conjugates of trithiolato arene ruthenium complexes were synthesized, fully 
characterized and studied for their anticancer properties. In vitro studies showed the complexes to 
be highly cytotoxic, their IC50 values being comparable to those of the trithiolato precursors. The 
difference in the cytotoxicity towards the cisplatin-resistant cell line A2780cisR shows the clear 
influence of the chlorambucil moiety. The cisplatin-resistant cancer cells are known to be cross-
resistant to chlorambucil, [200] presumably due to the similar modes of action of the two agents. 
The difference in the spectrum of anticancer activity of the chlorambucil conjugates compared to 
their trithiolato precursors suggests that chlorambucil is cleaved after uptake into cells with both 
parts of the conjugate subsequently exhibiting the cytotoxic effects by their respective modes of 
action. 
In a breast cancer model in immunocompetent mice, [40][BF4] at the dose of 15 mg/kg shows an 
interesting effect on the inhibition of tumor growth. However, it did not show a statistically 
significant effect on the survival of tumor bearing mice, possibly due to the high systemic toxicity 
of 40[BF4]. It will be necessary to carry out experiments with other cancer models to assess the 
therapeutic potential of the chlorambucil conjugates. Since the high toxicity of the tested compound 
turned out to be a problem, it is possible that the conjugates that exhibited lower cytotoxicity in 
vitro might have more advantageous properties in vivo compared to the tested compound [40][BF4]. 
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Chapter 8:  General Conclusion and Perspectives 
The work presented in this thesis focused on three main aspects of the research of the dinuclear 
thiolato-bridged arene ruthenium complexes:  
1) The step-wise synthesis of the trithiolato complexes and the investigation of the properties of 
the three obtained types of products. 
2) The in vitro and in vivo investigation of the mode of action of the trithiolato complexes. 
3) The effect of the coupling of trithiolato complexes with biologically active molecules on the 
anticancer properties of the resulting conjugates. 
 
The investigation of the reaction of p-cymene ruthenium dichloride dimer with thiols resulted in 
the isolation of three types of thiolato-bridged complexes: monothiolato, dithiolato and trithiolato 
complexes. The reactivity of the thiol was found to have major influence on the product of the 
reaction, followed by the reaction conditions. The influence of the pKa of the thiol on the formation 
of mono- or dithiolato complex was clearly demonstrated for a subset of thiols.  
 
Figure 51 – General structures of monothiolato, dithiolato and trithiolato complexes 
 
Differences in the anticancer activity of the three isolated species (Figure 51) prompted us to 
study their stability and their reactivity with biological ligands. The monothiolato complexes were 
found to be the least stable, hydrolyzing rapidly in aqueous solutions and reacting with amino acid 
cysteine to give dicysteinato-bridged cationic complexes. The dithiolato complexes are more stable 
towards hydrolysis, but react with cysteine in the same manner as monothiolato complexes, yielding 
monocysteinato-bridged cationic complexes. Interestingly, none of the studied complexes interact 
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with amino acids alanine, aspartic acid or histidine or with a DNA fragment. The trithiolato 
complexes are highly inert, not reacting with any of the tested amino acids and not interacting with 
DNA; however, in solution with the amino acid cysteine or the tripeptide glutathione, the trithiolato 
complexes catalyze the oxidation of these two compounds into the corresponding disulfides. The 
stability of the monothiolato, dithiolato and trithiolato complexes correlate well with their 
anticancer activity – the stable trithiolato complexes are highly cytotoxic towards ovarian cancer 
cell lines A2780 and A2780cisR, having IC50 values in nanomolar range. The more reactive 
monothiolato and dithiolato complexes are by an order of magnitude less cytotoxic, having IC50 
values in micromolar range. We assume that this difference in cytotoxicity stems from the reactions 
of dithiolato and monothiolato complexes with extracellular and intracellular substrates, not 
allowing them to reach their target in sufficient concentrations. Trithiolato complexes can, on the 
other hand, reach their intracellular targets with high specificity, not interacting with other 
biological substrates. 
  
Figure 52 – Structure of diruthenium-1 and diruthenium-2 
 
To identify the mode of action of the trithiolato complexes, a detailed in vitro and in vivo study 
was performed with the most active compound of the trithiolato series, [9]Cl (diruthenium-1). The 
study showed its influence on the levels of ATP and lactate, suggesting an effect on the aerobic 
metabolism of cells. This observation was confirmed by the measurement of the mitochondrial 
respiration, which showed the inhibition of both complex I and complex II of the electron transfer 
chain by diruthenium-1, revealing some of the molecular bases of its mode of action. The in vivo 
study showed a marked effect of diruthenium-1 on the survival of mice bearing a solid Ehrlich 
tumor. To understand the influence of chemical modifications of the trithiolato complexes on their 
biological properties, another compound of the series, [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-OH)3]Cl, 
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termed diruthenium-2 (Figure 52), is currently undergoing in vitro and in vivo studies, the results of 
which will be published shortly.  
 
Figure 53 – General structures of the three series of conjugates 
 
The synthesis of conjugates of trithiolato arene ruthenium complexes with biologically active 
molecules yielded three series of complexes (Figure 53). The propargyl-containing complexes were 
synthesized by the Williamson reaction of propargyl bromide with the hydroxo derivatives of mixed 
trithiolato complexes. This type of complexes was found to be available for the copper-catalyzed 
Huisgen 1,3-cycloaddition (Click reaction), which would allow the tethering of targeting molecules 
such as biotin, galactose or folic acid onto the ruthenium core. The second series, the series of 
conjugates with ibuprofen, was designed with the intention to influence the inflammatory 
microenvironment of tumors, providing the complexes with selectivity towards cancer cells. This 
theory was not confirmed; the resulting conjugates show no particular selectivity, presumably due 
to the chemical changes to the ibuprofen moiety that prevent its interaction with the 
cyclooxygenases. The third series of conjugates was synthesized by the esterification of the mixed 
trithiolato complexes with nitrogen mustard chlorambucil. The two disparate modes of action of the 
ruthenium complex and the alkylating agent chlorambucil were thought to provide higher anticancer 
activity to the resulting conjugates as well as the ability to overcome possible resistance of cancer 
cells. The conjugates were found to be highly cytotoxic to four different cancer cell lines, although 
their IC50 values are in the same range as those of the precursor trithiolato complexes. The 
tetrafluoroborate salts of conjugates 39 and 40 show an interesting selectivity to A2780 cells 
compared to the three other cell lines. The chlorambucil moiety clearly influences the spectrum of 
anticancer activity, which is apparent from the lower activity of the conjugates towards the 
cisplatin-resistant A2780cisR cells. The in vivo studies of the compound [40][BF4]  showed its high 
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systemic toxicity, the probable cause being the summation of the toxicities of the ruthenium 
complex and the chlorambucil – the ester bond of the conjugate is assumed to hydrolyze in cells and 
to liberate the two composing parts of the conjugate. 
 
Figure 54 – Synthesis of “aromatic” dithiolato complexes 
 
The presented results indicate possible directions of the future research of the subject of 
dinuclear thiolato-bridged arene ruthenium complexes. The preliminary results of the synthesis of 
new neutral “aromatic” dithiolato complexes of the type [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-R)2Cl2] 
(Figure 54) indicate the possibility to synthesize trithiolato complexes with highly variable chemical 
properties. The synthesis of the corresponding trithiolato complexes [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-
R)2(SC6H4-p-R’)]
+
 would offer three binding positions for the attachment of biologically relevant 
molecules. The large variety of derivatives that could be synthesized by this approach would allow 
the use of a number of organic coupling reactions that are frequently employed in synthetic organic 
chemistry. Throughout the course of this thesis, only three organic coupling reactions were used to 
synthesize conjugates of arene ruthenium complexes – the Williamson reaction for the propargyl 
derivatives, followed by the Click reaction that was used as a proof of concept for the availability of 
the resulting complexes for this approach; the ibuprofen and chlorambucil conjugates were 
synthesized using the Steglich esterification reaction. The success of these reactions with arene 
ruthenium complexes suggests that with careful choice of the thiolato ligand, a vast number of 
coupling reactions routinely used in synthetic organic chemistry could be used in the synthesis of 
new arene ruthenium thiolato-bridged conjugates. For example, Sonogashira coupling of the 
propargyl derivatives could be employed to attach aryl or vinyl halides onto the ruthenium core. 
Kumada coupling reaction could be used to synthesize conjugates with bromide-containing mixed 
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trithiolato complexes. Other reactions, such as Heck or Suzuki coupling, could also increase the 
possibilities to vary the properties of the trithiolato arene ruthenium conjugates.  
 
In conclusion, this thesis increased the understanding of the chemistry and biological properties 
of thiolato-bridged arene ruthenium complexes. It also proved the versatility of the dinuclear 
thiolato-bridged arene ruthenium platform as well as the influence that the chemical variations of 
the thiolato ligands can have on the biological properties of the resulting complexes. The results 
show that the dinuclear trithiolato arene ruthenium unit can be exploited to design novel anticancer 
agents with advantageous chemical and biological behavior and with variable mechanism of action, 
combining the benefits of both the organic part and the ruthenium core. 
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Chapter 9:  Experimental 
9.1  General 
Solvents of analytical grade purchased from Acros Organics, Honeywell or VWR International 
S.A.S were used for syntheses and not degassed or distilled prior to use, unless stated otherwise. All 
organic starting materials were purchased from Acros Organics, Sigma-Aldrich, Fluka, Alfa Aesar 
or TCI-Europe and used as received. The silicagel used for column chromatography (32-64, 60 Å) 
was purchased from Brunschwig. The starting material [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-Cl)2] was 
prepared according to published methods [201]. All other reagents were bought from commercial 
sources and were used without further purification. 
 
9.1.1  X-Ray Structure Analyses 
Single-Crystal X-Ray Structure Analysis of 1 and 2: Crystals of 1 and 2 were mounted on a 
Stoe Image Plate Diffraction system equipped with a  circle goniometer, using Mo-K graphite 
monochromated radiation ( = 0.71073 Å) with  range 0-200º. The structures were solved by 
direct methods using the program SHELXS-97, while the refinement and all further calculations 
were carried out using SHELXL-97 [202]. The H-atoms were included in calculated positions and 
treated as riding atoms using the SHELXL default parameters. The non-H atoms were refined 
anisotropically, using weighted full-matrix least-square on F
2
. Crystallographic details are 
summarized in Table 11. Figure 20 was drawn with ORTEP [203]. CCDC 1016530 (1) and 
1016531 (2) contain the supplementary crystallographic data for these compounds. This data can be 
obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
 
 
 
 
Experimental 
  
104 
Table 11 - Crystallographic data and structure refinement parameters for 1 and 2. 
 1 2 
Chemical formula C27H35Cl3Ru2S C27H34Cl3NO2Ru2S 
Formula weight 700.10 745.10 
Crystal system  Monoclinic Monoclinic 
Space group P 21/n (no. 14) P 21/c (no. 14) 
Crystal color and shape  Orange block Orange block 
Crystal size 0.22 x 0.18 x 0.18 0.21 x 0.20 x 0.16 
a (Å) 10.7440(5) 12.6397(5) 
b (Å) 13.0281(6) 14.5768(5) 
c (Å) 19.8652(9) 15.5388(6) 
β (°) 102.819(4) 98.077(3) 
V (Å3) 2711.3(2) 2834.57(18) 
Z 4 4 
T (K) 173(2) 173(2) 
Dc (g·cm
-3
) 1.715 1.746 
μ (mm-1) 1.502 1.448 
Scan range (°) 1.88 <  < 29.26 1.63 <  < 29.21 
Unique reflections 7331 7661 
Observed refls [I>2σ(I)] 4703 5927 
Rint 0.1318 0.0826 
Final R indices [I>2σ(I)]* 0.0577, wR2 0.1009 0.0443, wR2 0.0614 
R indices (all data) 0.1087, wR2 0.1146 0.0696, wR2 0.0656 
Goodness-of-fit 0.975 1.079 
Max, Min Δρ/e (Å-3) 0.984, -1.358 0.668, -0.719 
* Structures were refined on F0
2
: wR2 = [Ʃ[w (F0
2
 - Fc
2
)
2] / Ʃw (F0
2
)
2
]
1/2
, where w
-1
 = [Ʃ(F0
2
) + 
(aP)
2
 + bP] and P = [max(F0
2
, 0) + 2Fc
2
]/3 
 
Single-Crystal X-Ray Structure Analysis of 6: 
Crystal of complex 6 · 2 CHCl3 was mounted on a Stoe Image Plate Diffraction system 
equipped with a  circle goniometer, using Mo-K graphite monochromated radiation ( = 0.71073 
Å) with  range 0 – 180º. The structure was solved by direct methods using the program SHELXS–
97 [204]. Refinement and all further calculations were carried out using SHELXL–97 [205]. The H-
atoms were included in calculated positions and treated as riding atoms using the SHELXL default 
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parameters. The non-H atoms were refined anisotropically, using weighted full-matrix least-square 
on F
2
. Crystallographic details are summarized in Table 12. 
 
Table 12 - Crystallographic and structure refinement parameters for complex 6 · 2 CHCl3. 
 6 · 2 CHCl3 
Chemical formula C38H48Cl8O2Ru2S2 
Formula weight 1086.62 
Crystal system  Triclinic 
Space group P -1 (no. 2) 
Crystal color and shape  Orange block 
Crystal size 0.24 x 0.21 x 0.19 
a (Å) 10.034(2) 
b (Å) 10.070(2) 
c (Å) 12.124(2) 
α (°) 112.75(3) 
β (°) 95.58(3) 
γ (°) 98.51(3) 
V (Å3) 1101.2(4) 
Z 1 
T (K) 173(2) 
Dc (g·cm
-3
) 1.639 
μ (mm-1) 1.299 
Scan range (°) 1.85 <  < 29.31 
Unique reflections 5787 
Observed refls [I>2σ(I)] 4504 
Rint 0.0575 
Final R indices [I>2σ(I)]* 0.0386, wR2 0.0868 
R indices (all data) 0.0530, wR2 0.0917 
Goodness-of-fit 0.965 
Max, Min Δρ/e (Å-3) 0.941, - 1.470 
Structures were refined on F0
2
: wR2 = [[w (F0
2
 - Fc
2
)
2
] / w (F0
2
)
2
]
1/2
, where w
-1
 = [(F0
2
) + (aP)
2
 + bP] and P = 
[max(F0
2
, 0) + 2Fc
2
]/3 
 
Experimental 
  
106 
9.1.2  NMR Experiments 
The 
1
H, 
13
C, COSY, HSQC and HMBC NMR spectra were recorded on a Bruker Avance II 400 
spectrometer using the residual protonated solvent as internal standard.  
For the stability and reactivity study of mono- and dithiolato complexes (Chapter 2.2), the 
spectra were recorded using a Bruker Avance II 500-MHz NMR spectrometer equipped with an 
inverse triple channel (
1
H, 
13
C, 
31
P) z-gradient 1.7 mm microprobehead. One-dimensional 
1
H NMR 
data were measured with 16 – 64 transients into 32 k data points over the width of 12 ppm using a 
classic presaturation to eliminate the water resonance. A relaxation delay of 4 s was applied 
between the transients. Two-dimensional 
1
H – 1H NMR correlation spectroscopy data were 
acquired over a frequency width of 12 ppm in both F2 and F1 into 2 k complex data points in F2 
(acquisition time 213 or 170 ms) using 128 t1 increments. The water resonance was suppressed by 
means of a presaturation routine. Two-dimensional 
1
H diffusion-ordered spectroscopy (DOSY) 
NMR data were acquired with a standard longitudinal encode – decode pulsed-field-gradient 
stimulated echo sequence containing bipolar gradients [206-207]. For all experiments, the airflow 
was increased to 670 l/min, and the NMR tube was not spun. Experimental parameters were Δ = 
100 ms (diffusion delay), τ = 1 ms (gradient recovery delay) and T = 5 ms (eddy current recovery 
delay). For each data set, 4 k complex points were collected, and the gradient dimension was 
sampled by means of 32 experiments in which the gradient strength was linearly increased from 1.0 
to 50.8 G/cm. The gradient duration δ/2 was adjusted to observe a near-complete signal loss at 50.8 
G/cm. A 2-s recycle delay was used between scans for the data shown. For each data set, the 
spectral axis was processed with an exponential function (3 – 5 Hz line broadening), and a Fourier 
transform was applied to obtain 8 k real points. The DOSY reconstruction was realized with 8 k 
complex points in the detection dimension and with 256 points in the diffusion dimension. 32 scans 
were used for each sample. All NMR data were processed using TopSpin (versions 2.1 or 3.0, 
Bruker, Switzerland).  
Catalytic Glutathione Oxidation: Each compound (approximately 0.1 mg) was incubated with 
10 equivalents of glutathione in a D2O/(CD3)2CO (95 : 5) solution (0.5 mL), the same solution 
without the complex being inactive for glutathione oxidation. The resulting mixture was 
subsequently analyzed by 
1
H-NMR at 37°C every hour for a total of 24 hours on a Bruker Avance 
II 400MHz spectrometer equipped with an inverse dual channel (
1
H, X) z-gradient probehead 
(BBI). 1D 
1
H-NMR data were acquired with 16 to 64 transients into 32K data points over a width of 
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12 ppm using a classical presaturation to eliminate the residual water resonance. All NMR data 
were processed using Topspin (version 3.0, Bruker Switzerland). Turnover numbers (TON) were 
calculated from the integrals (I) relative to the corresponding resonances of glutathione in its 
reduced (GSH) and oxidized forms (GSSG), according to the following equation: 
       
              
*
[   ] 
[       ]
 . Turnover frequencies for the GSH conversion (TOF) were obtained by 
fitting the TONs as a function of time using the exponential function        . 
Stability of complexes 11 – 13 and 35 – 38 
The stability of complexes 11 – 13 and 35 – 38 in aqueous solutions was studied by dissolving 1 
mg of the complexes in the D2O/DMSO-d6 1 : 1 mixture and incubating the solutions at 37°C. 1D 
1
H-NMR spectra were recorded every 24 hours. 
 
9.1.3  Other Analytical Instruments 
Electrospray mass spectra in the Chapter 2.2 were recorded with an LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a nanoelectrospray ion 
source. The samples were analysed in the positive or negative ion mode with a voltage of +700 V 
applied to the glass emitter (New Objective, Woburn, MA, USA). The tube lens was at +150 V and 
the transfer capillary was held at 200°C. Spectra were acquired in Fourier transform mass 
spectrometry mode over an m/z range from 100 to 2,000 with a resolution of 100,000 at m/z = 400. 
Calibration of the instrument was performed with ProteoMass LTQ/FT-Hybrid electrospray 
ionization (ESI) positive mode calibration mix (Supelco Analytical, Bellefonte, PA, USA). The 
Xcalibur software package (version 2.0.7, Thermo Fisher Scientific) was used for instrument 
control and data processing. All the other ESI-MS spectra were recorded on a Bruker APEX II 9.4-
tesla FT-ICR-MS equipped with an Apollo II electrospray ion source: sample condition 10-50 
μmol/l in methanol or in methanol/dichloromethane mixture at 30ºC, end plate voltage being 3500 
V and capillary voltage - 4000 V. 
Infrared spectra were recorded as KBr pellets on a Perkin-Elmer FTIR 1720-X spectrometer. 
Elemental analyses were done by Mikroelementar-analytisches Laboratorium de ETH Zürich or by 
the Schürch group at the University of Bern.  
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9.2  Studies of Interactions with Biological Ligands  
All reactions were monitored by 1D 
1
H NMR spectroscopy. Two-dimensional homonuclear 
1
H–
1H and DOSY experiments were performed after 24 hours of incubation at 37°C. All experiments 
were carried out in aqueous solutions without the addition of any buffers. The pD values of 
solutions were obtained by use of a glass electrode and by addition of 0.4 to the pH meter reading 
[208-209]. Oxygen was not excluded from the solutions. 
Stability of 2, 4, 5 and 6 in aqueous solution 
The stability of complexes 2, 4, 5 and 6 in aqueous solutions was studied by dissolving 1 mg of 
the complexes in the mixture of an appropriate deuterated solvent and water (D2O/acetone-d6 6 : 4 
for 2, D2O/acetone-d6 7 : 3 for 4 and D2O/MeCN-d3 7 : 3 for 5 and 6,). The pH of the solutions was 
varied by the addition of NaOD or DCl. The solutions were subsequently transferred to 1.7 mm 
NMR tubes and 1D 
1
H-NMR experiments were recorded at 37°C after 5, 15, 45, 75, 105, 135, 195, 
255 and 1440 minutes. Between the measurements, the NMR tubes were stored in an incubator at 
37°C.  
Stability of 2, 4, 5 and 6 in DMSO 
The stability in DMSO was studied by dissolving the complexes 2, 4, 5 and 6 in DMSO-d6 and 
recording 1D 
1
H-NMR experiments according to the protocol for investigating the stability in 
aqueous solutions described above. 
Interactions of 2, 4, 5 and 6 with amino acids 
1 mg of the respective complex was dissolved in the appropriate aqueous solution (vide supra). 
When the hydrolysis reactions had reached a steady state, 3 equivalents of amino acid (Ala, Asp, 
Cys or His) were added. The solutions were then transferred into NMR tubes and 1D 
1
H-NMR 
experiments were measured after 5, 15, 45, 75, 105, 135, 195, 255 and 1440 minutes at 37°C. 
Between the measurements, the tubes were stored in the incubator at 37°C. ESI-MS, 2D 1H – 1H 
COSY and 2D 
1
H-DOSY spectra were recorded after the last 1D 
1
H-NMR experiment. 
Interactions of 2, 4, 5 and 6 with the DNA 20-mer 
Interaction of complexes with the DNA 20-mer was studied by dissolving the complexes in 
appropriate aqueous solution (vide supra), adding 1 mg of DNA fragment (Mw = 6119.2) and 
incubating the mixture at 37°C. ESI-MS measurements were performed after 2 h and 24 h of 
incubation.  
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9.3  Biological Studies 
9.3.1  In Vitro Cytotoxicity Studies 
The in vitro cytotoxicity studies for monothiolato compounds 2 and 4 were carried out by the 
Furrer group at the University of Bern. All the other in vitro studies (except for the in-depth study 
of diruthenium-1) were carried out in the group of Paul J. Dyson at the EPFL. 
Complexes 2 and 4 
Human A2780 ovarian carcinoma cells were obtained from the European Centre of Cell 
Cultures (ECACC, Salisbury, UK) and maintained in culture as described by the provider. The cells 
were routinely grown in RPMI-1640 medium which contained fetal calf serum (FCS) (10%), 2 mM 
Gln, and 1% antibiotics (penicillin/streptomycin) at 37°C and CO2 (5%). The cytotoxicity was 
determined using the cell counting kit 8 (Dojindo). Therefore, the cells were seeded in 96-well 
plates as monolayers with 100 μL of cell solution (approximately 10’000 cells) per well. The 
compounds were dissolved in DMSO, then added to the culture medium and serially diluted with 
water to the appropriate concentration, to give a final DMSO concentration of 1%. 100 μL of drug 
solution were added to each well and the plates were incubated for 96 h. After incubation the 
culture medium was removed completely and subsequently, 10 μL kit solution and 100 μL fresh 
medium were added to the cells. The plates were incubated for a further 90 minutes. The optical 
density, directly proportional to the number of surviving cells, was quantified at 450 nm using a 
multiwell plate reader and the fraction of surviving cells was calculated from the absorbance of 
untreated control cells. The evaluation is based on means from four independent experiments, each 
comprising four micro-cultures per concentration level. 
Complexes 6, 30 and 39 – 42 
Human A2780 and A2780cisR ovarian carcinoma cells were obtained from the European Centre 
of Cell Cultures (ECACC, UK). Non-cancerous human embryonic kidney HEK293 cells were 
provided by the Institute of Pathology, CHUV, Lausanne, Switzerland. Immortalized human 
endothelial cells RF24 were kindly provided by the Angiogenesis Laboratory of VU Medical 
Center, Amsterdam, Netherlands. A2780 and A2780cisR cells were routinely grown in RPMI 1640 
medium supplemented with GlutaMAX (Gibco), 10% fetal calf serum and 1% antibiotics 
(Penicillin/Streptomycin, Sigma), while HEK293 cells were grown in DMEM medium, both 
containing heat-inactivated fetal calf serum (FCS, Sigma, USA) (10%) and 1% antibiotics at 37°C 
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and CO2 (5%). RF24 cells were maintained in RPMI 1640/DMEM (1 : 1) supplemented as above. 
10x10
4
 cells/well were seeded in 96-well cell culture plates as described previously [210]. Briefly, 
24 h after seeding, culture medium with or without compounds was added and cells were grown for 
an additional 72 hours. Cell viability was assessed using the CellTiter-Glo
®
. Luminescent Cell 
Viability Assay (Promega, Madison, WI) according to the manufacturer’s instructions. Evaluation is 
based on means from two independent experiments, each comprising three microcultures per 
concentration level. 0.1% DMSO in 0.9% NaCl was used as the control. 
Complexes 11 – 14 and 35 – 38 
Human A2780 and A2780cisR ovarian carcinoma cells were obtained from the European Centre 
of Cell Cultures (ECACC, Salisbury, UK). Nontumorigenic HEK293 cells were obtained from 
ATCC (Sigma, Switzerland). A2780 and A2780cisR cells were routinely grown in RPMI 1640 
medium with GlutaMAX containing 5% fetal bovine serum (FBS) and 1 % antibiotics (penicillin 
and streptomycin) at 37°C and 5% CO2. HEK293 cells were grown in DMEM medium containing 
5% fetal bovine serum (FBS) and 1% antibiotics (penicillin and streptomycin) at 37°C and 5% CO2. 
In order to keep the A2780cisR cells resistant to cisplatin the cells were monthly treated with 2 µM 
cisplatin for one passage. Cytotoxicity was determined using the MTT assay [MTT = 3(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide)]. Briefly, the cells were seeded in 96-
well plates (10’000 cells per well) and grown for 24 h in complete medium. For each testing, 
compounds were freshly prepared as DMSO stock solution, then dissolved in the culture medium 
and immediately serially diluted to the appropriate concentration, to give a final DMSO 
concentration of 0.5% v/v. Drug solution (100 µL) was added to each well and the plates were 
incubated at 37°C for 72 h or 2 h at 41.5°C followed by a 68 h incubation at 37°C. Following drug 
exposure, 20 µL of MTT (5 mg/mL solution in PBS) were added to the cells and incubated for 4 h, 
then the culture medium was aspirated and the violet formazan crystals were dissolved in DMSO 
(100 µL). The optical density of each well (96-well plates) was quantified at 590 nm using a 
multiwell plate reader (Molecular Devices, UK), and the percentage of surviving cells was 
calculated from the ratio of absorbance of treated to untreated cells. The IC50 values for the 
inhibition of cell growth were determined by fitting the plot of the logarithmic percentage of 
surviving cells against the logarithm of the drug concentration using a linear regression function. 
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9.3.2  Diruthenium-1 
Due to the poor solubility of diruthenium-1 in water, a co-solvent in an amount close to the 
upper limit of acceptance (0.77 ml of propane-1,2-diol/kg of body weight) had to be added to saline, 
which is the reason why the i.p. route of administration was chosen rather than the i.v. way. 
Animals and Tumor Model  
Female outbred mice (NMRI) obtained from Masaryk University (Brno, Czech Republic) were 
used for this study. Animal care was conform to EU recommendations and in accordance with the 
European convention for the protection of vertebrate animals used for experimental and other 
scientific purposes; it was approved by the Ethical Commission of the Medical Faculty in Hradec 
Králové (Nr. MSMT-56249/2012-310). For the MTD assessment, two or three healthy mice per 
group were observed for weight loss over 14 days after injection of the solution. For the in vivo 
activity study, 98 NMRI female mice weighting in the average 33.5 g (SD = 3.42) were fed a 
standard diet and water ad libitum. A solid Ehrlich tumor was purchased from the Research Institute 
for Pharmacy and Biochemistry (VUFB) in Prague, and then maintained in NMRI mice by 
periodical transplantations. The homogenized tumor tissue was inoculated subcutaneously into all 
mice on day 0, using 0.2 ml of 1/1 (v/v) homogenate freshly prepared in isotonic glucose solution. 
The tumor-bearing mice were then divided into 7 groups of 14 animals as follows: a control group 
treated with the pure solvent, 5 groups of animals treated with diruthenium-1 in doses of 0.2, 0.4, 
0.6, 1.0, or 2.0 mg/kg i.p. and a positive control receiving 5 mg/kg cisplatin i.p. (cisplatin 50 ml/25 
mg, EBEWE Pharma, Austria) [211]. The solutions were administered on days 1 and 7 in volumes 
of 0.2 ml per 20 g body weight.  
Statistical Analysis  
One-Way Analysis of Variance with post-hoc Dunnetts’s multiple comparison test was used to 
detect differences in tumor weight. Kaplan-Meier curves and logrank tests were used to compare 
survival times in groups. Here, the level of significance was α = 0.05. MS Excel 2003 and NCSS 
software were used for the calculations and statistical evaluations. 
Inductively Coupled Plasma-Mass Spectrometry of Ruthenium 
Tissue samples were cut with the aid of a ceramic knife. Approx. 20 mg of sample were 
weighed into pre-cleaned glass vials. Then 0.3 mL ultrapure double sub-boiled HNO3 conc. and 0.1 
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mL ultrapure H2O2 (VWR) was added. After 5 min reaction time 0.05 mL ultrapure sub-boiled HCl 
conc. was added,  the  vessels  were  closed and  digested  employing  closed  vessel  microwave  
digestion (Microwave 3000, Anton Paar)  with  Rotor  64MG5  (64  positions)  applying the  dige-
stion program as follows: 750 W/15 min (5 min ramp), 600 W/15 min, 0 W/15 min. Tmax of the IR 
sensor was set to 140°C. After digestion the clear samples were quantitatively transferred into a pre-
cleaned polyethylene tube and filled to approximately 5 g using ultrapure sub-boiled water. The 
solutions were stored at 4°C until measurement. Ruthenium analysis was carried out at m/z = 101 on 
an Element 2 sector field ICP-MS (Thermo Electron, Bremen, Germany) combined with a PFA-ST 
microflow nebulizer and a cyclonic spray chamber operated at 4°C (Elemental Scientific, ESI, 
Omaha, NE, USA). Quantification was performed with external calibration (internal standardization 
with indium) in a working range of 0.06 – 23.30 µg L-1. The procedural limit of detection of Ru was 
0.2 ng/g wet weight. 
Cell Isolation and Cultivation 
MCF-7 and BT-549 (ATCC,  USA) breast carcinoma cells were cultured in 5% CO2 atmosphere 
under 37°C in Dulbecco´s modified Eagle´s medium (Sigma, St Louis, MO, USA) supplemented 
with 10% FCS (PAA, Dartmouth, MA, USA), 1% glutamine (Gibco, Paisley, UK), 
penicillin/streptomycin (Gibco), only for MCF-7 1% non-essential amino acids (Sigma) and only 
for BT-549 0.01% insulin (Sigma). Cells were dissociated and reseeded using trypsin-EDTA 
(Gibco). In all experiments early passages (< 10 passages) of the cells were used and each of the 
passage reached approximately 70% confluence. 
Treatment of Cells 
Stock solution of diruthenium-1 was prepared by dissolving 1 mg of the substance in 1 ml of 
DMSO (Sigma) and diluted by distilled water to reach the concentration of 50 µM. For the 
experiments, the stock solution was diluted by cultivation medium to final concentrations from 50 
nM to 800 nM. 
WST-1 Cssay and LDH Cytotoxicity Assay 
For both the assays, MCF-7 and BT-549 cells were seeded in 96-well plates at a concentration 
of 1x10
3
 cells/well in 200 µl of culture medium. Cells were allowed to settle overnight at 37 °C in 
5% CO2. Cultures were exposed to diruthenium-1 in concentrations 50, 100, 200, 400 and 800 
nmol/l for 72 hours. Then, WST-1 (Roche, Switzerland) was used according to manufactures 
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instruction. Absorbance was measured with Tecan SpectraFluor Plus Spectrometer (Tecan Austria 
GmbH, Grodig, Austria) and corresponds to metabolic transformation of WST-1 in mitochondria of 
viable cells. Data are expressed as ratio of each sample absorbance againts control (100%). To 
measure LDH release, LDH cytotoxicity detection kit (Roche, Switzerland) according to 
manufactures instruction was used. LDH release corresponds to absorbance detected by Tecan 
SpectraFluor Plus Spectrometer (Tecan). Data represent the ratio of free LDH in medium and total 
LDH (free in medium plus intracellular released after cell lysis) of appropriate samples.   
Lactate 
The concentration of lactate in cultivation medium was measured on Modular PP (Roche 
Diagnostics, Mannheim, Germany) by the kit Lactate Cobas® (Roche Diagnostics GmbH, 
Germany) according to the manufacturer’s instructions. 
Determination of ATP Levels 
ATP content in breast carcinoma cells MCF-7 and BT-549 was measured by ATP colorimetric 
assay kit by Bio Vision (Baria, Prague, Czech Republic). Briefly, treated and control cells were 
harvested at 24 h and 72 h and lysed on ice. Afterwards, 100 µl of ATP lysing buffer was added and 
lysates were deproteinized using Deproteinization Sample Preparation Kit. Then, 25 µl of sample 
were added to a 96-well plate, adjusted to 50 µl volume/well with ATP Assay Buffer. After addition 
of ATP standard and reaction mix (total volume 50 µl/well), plates were incubated at room 
temperature for 30 min, protected from light. Absorbance was measured at (OD 570 nm) in a 
microplate reader TECAN SpectraFluor Plus (TECAN Austria GmbH, Grödig, Austria). ATP 
content was calculated from a standard curve derived from known concentrations of ATP and was 
expressed as a percentage of control. 
Electrophoresis and Western Blotting 
Samples for protein analysis were obtained either from cancer tissue using an Ultra-turrax T10 
Basic Disperser (IKA-Werke GmbH & Co.KG, Germany) and RIPA buffer (Sigma-Aldrich) or 
from cells, that were treated with increasing concentration of diruthenium-1 for 72 hours and then 
whole cell lysates were prepared. The protein concentration was determined with BCA Protein 
Assay Kit (Pierce). Proteins were separated by SDS-PAGE, transferred to a PVDF membrane 
(Millipore), washed, and incubated with primary antibody (anti-PCNA, β-actin, anti-CD3 - Sigma-
Aldrich; p53 - Exbio; p53_S15 - Calbiochem-Merck; ERK, p_ERK, p_p38 - Cell Signaling 
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Technology) at 4°C overnight. Then, the membrane was incubated with polyclonal anti-mouse or 
anti-rabbit secondary antibody (DakoCytomation, CZE). For the signal detection a 
chemiluminescent detection kit (Roche, CZE) was used. Densitometry was performed using a 
ScanMaker i900 (UMAX) and the QuantityOne imaging software (BioRad).  
Quantification of Glutathione 
For the measurement of individual GSSG and GSH glutathione forms in the cell homogenate, a 
selective HPLC method was used [212]. It is based on the derivatization of GSH with o-
phthalaldehyde yielding a fluorescent product. For the selective measurement of GSSG, GSH in the 
samples were blocked by N-ethylmaleimide prior to o-phthalaldehyde derivatization. 
Measurement of Oxygen Consumption 
The experiment was performed on adult Wistar male rats with body weight of 220 g. Liver 
mitochondria were isolated by differential centrifugation [213]. Oxygen consumption by 
mitochondria was measured at 30°C using High Resolution Oxygraph2K (Oroboros, Austria). 
Mitochondria were incubated in K medium (80 mM KCl, 10 mM Tris-HCl, 5 mM K-phosphate, 3 
mM MgCl2, 1 mM EDTA, pH = 7.2), with substrates for complex I or complex II. Cytochrome c 
was added to evaluate the state of the outer mitochondrial membrane. The respirations were 
inhibited by 0.8 µM diruthenium-1 for the period of 10 minutes. 
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9.4  Syntheses and Characterizations 
9.4.1  Monothiolato Complexes 1 – 4 
Synthesis of 1: [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-Cl)2] (100 mg, 0.163 mmol) was dissolved in 50 
mL of ethanol. The mixture was cooled down to - 25°C and benzylthiol (0.25 mmol, 29 µL) was 
added dropwise. The mixture was stirred for two hours at - 25°C and then concentrated to 5 mL. 
The product was precipitated by addition of diethylether, separated by filtration and dried in vacuo. 
The product was a mixture of 1 and [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-SCH2C6H5)2] [115], estimated to 
approximately 3 : 1 on the basis of the NMR spectra. 
Data for 1: Yield: 108 mg (95%). C27H35Cl3Ru2S (699.96): ESI-MS (MeOH/CH2Cl2): 665.6 
[M]
+
. 
1
H NMR (400 MHz, CDCl3): δ = 7.61 (d, 
3
J = 7 Hz, 2 H, SCH2C6H5), 7.30 (m, 3 H, 
SCH2C6H5), 4.93 [m, 8 H, p-CH3C6H4CH(CH3)2], 4.41 (d, 
3
J = 11 Hz, 1 H, SCH2C6H4), 3.71 (d, 
3
J 
= 11 Hz, 1 H, SCH2C6H4), 2.15 [m, 2H, p-CH3C6H4CH(CH3)2], 1.85 [s, 6 H, p-
CH3C6H4CH(CH3)2], 1.20 [d, 
3
J = 7 Hz, 12 H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, 
CDCl3): δ = 130.4, 128.0, 86.7, 83.0, 37.9, 37.6, 30.5, 22.4, 19.3 ppm. 
Synthesis and Isolation of 2: 100 mg of [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-Cl)2] (0.163 mmol) were 
dissolved in 10 mL of dichloromethane and 29.0 mg of 4-nitrobenzylthiol (0.163 mmol) were added 
as a solution in 5 mL of CH2Cl2. The mixture was stirred at room temperature for 4 hours. 
Afterwards the solvent was evaporated under reduced pressure and the product was precipitated, 
filtered, washed with hexane and dried in vacuo.  
Data for 2: Yield: 107 mg (93%). C27H34Cl3NO2Ru2S · 0.25 CH2Cl2 (765.93): calcd. C 42.71, 
H 4.54, N 1.83; found C 42.94, H 4.52, N 1.93. ESI-MS (MeOH/CH2Cl2): m/z = 709.9 [M]
+
. 
1
H 
NMR (400 MHz, CDCl3): δ = 8.18 (d, 
3
J = 8 Hz, 2 H SCH2C6H4NO2), 7.81 (d, 
3
J = 8 Hz, 2 H, 
SCH2C6H4NO2), 5.16 [m, 8 H, p-CH3C6H4CH(CH3)2], 4.67 (d, 
3
J = 11 Hz, 1 H, SCH2C6H4NO2), 
3.67 (d, 
3
J = 11 Hz, 1 H, SCH2C6H4NO2), 2.84 [m, 2 H, p-CH3C6H4CH(CH3)2], 2.17 [s, 6 H, p-
CH3C6H4CH(CH3)2], 1.23 [m, 12 H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 
131.2, 123.1, 85.5, 83.2, 36.3, 30.3, 22.2, 19.0 ppm. 
Synthesis of 3: 100 mg of [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-Cl)2] (0.163 mmol) were dissolved in 
40 mL of ethanol and the 1-adamantylthiol (57.7 mg, 0.326 mmol) was added dropwise as a 
solution in 10 mL of EtOH. The mixture was stirred at room temperature for 3 days. The solvent 
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was evaporated and the product was isolated by preparative TLC on silica (CH2Cl2/EtOH 7 : 1), 
extracted from the orange main band with EtOH and dried in vacuo. The product was a mixture of 3 
and [(p-MeC6H4
i
Pr)2Ru2Cl4] (approximately 8 : 1 based on the NMR data). 
Data for 3: Yield: 64 mg (53%). C30H43Cl3Ru2S (744.02): ESI-MS (MeOH/CH2Cl2): m/z = 
709.30 [M]
+
. 
1
H NMR (400 MHz, CDCl3): δ = 5.78 [d, 
3
J = 6 Hz, 4 H, CH3C6H4CH(CH3)2], 5.66, 
[d, 
3
J = 6 Hz, 4 H, CH3C6H4CH(CH3)2], 2.59 [sept, 
3
J = 7 Hz, 2 H, CH3C6H4CH(CH3)2], 2.18 (m, 
15 H, SC10H15), 1.81 [s, 6 H, CH3C6H4CH(CH3)2], 1.25 [m, 12 H, CH3C6H4CH(CH3)2] ppm, 
13
C 
NMR (100 MHz, CDCl3): δ = 98.3, 49.6, 46.7, 36.2, 30.9, 30.2, 22.38, 18.27 ppm. 
Synthesis and Isolation of 4: [(6-p-MeC6H4Pr
i
)2Ru2Cl2(-Cl)2] (100 mg, 0.163 mmol) was 
dissolved in 20 mL of ethanol and m-carborane-9-thiol (86.3 mg, 0.489 mmol) was added dropwise 
as a solution in 5 mL of EtOH. The mixture was stirred for 5 days at 40°C, then the solvent was 
evaporated and the product isolated by preparative TLC on silica (CH2Cl2/EtOH 7 : 1), extracted 
from the main red band with EtOH and dried in vacuo. 
Data for 4: Yield: 79 mg (64%). C22H38B10Cl3Ru2S · HCl (789.05): calcd. C 33.50, H 5.11; 
found C 33.93, H 5.38. ESI-MS (MeOH/CH2Cl2): m/z = 717.9 [M]
+
. 
1
H NMR (400 MHz, CDCl3): δ 
= 5.62 [d, 
3
J = 5 Hz, 4 H, CH3C6H4CH(CH3)2], 5.42 [d, 
3
J = 5 Hz, 4 H, CH3C6H4CH(CH3)2], 3.75 – 
1.65 (m, 11 H, C2H11B10), 2.63 [sept, 
3
J = 7Hz, 2H, CH3C6H4CH(CH3)2], 2.14 [s, 6 H, 
CH3C6H4CH(CH3)2], 1.22 [d, 
3
J = 7 Hz, 12 H, CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, 
CDCl3): δ 81.7, 55.9, 29.8, 22.4, 19.2 ppm. 
 
9.4.2  Dithiolato Complexes 5, 7 and 10 
The attempts to synthesize complexes 5, 7, and 10 using the previously reported synthesis [115] 
led to the discovery of monothiolato complexes and to the findings presented in the Chapter 2.1. 
Therefore, a new procedure had to be developed for the synthesis of dithiolato complexes that were 
needed for the synthesis of conjugates.  
The products 5 and 7 were prepared by the following procedure: 0.16 mmol of [(p-
MeC6H4Pr
i
)2Ru2Cl4] were dissolved in EtOH (10 mL). When the compound had completely 
dissolved, the corresponding thiol RSH (2 equivalents, 0.32 mmol) was added dropwise as the 
solution in 5 mL of ethanol. The reaction was stirred at rt for 3 h, the volume was then reduced to 5 
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mL and diethyl ether (30 mL) was added to precipitate the products. The filtration and washing of 
the solid 2 times with 20 mL of diethylether afforded the products as orange crystalline powders. 
The products were dried under vacuum and analyzed by NMR and ESI-MS. The spectra were 
identical to those reported for the dithiolato products [(p-MeC6H4Pr
i
)2Ru2(µ-SC2H4Ph)Cl2] and [(p-
MeC6H4Pr
i
)2Ru2(µ-S-p-CH2C6H4Bu
t
)Cl2] [115]. 
The product 10 was prepared by the following procedure: 0.16 mmol of [(p-MeC6H4Pr
i
)2Ru2Cl4] 
were dissolved in CH2Cl2 (10 mL). When the compound had completely dissolved, the benzyl thiol 
(0.32 mmol) was added dropwise as the solution in 5 mL of ethanol. The reaction was stirred at rt 
for 3 h, the volume was then reduced to 5 mL and hexane (30 mL) was added to precipitate the 
product. The filtration and washing of the solid 2 times with 20 mL of hexane afforded the product 
as orange crystalline powder, which was dried under vacuum and analyzed by NMR and ESI-MS. 
The spectra were identical to those reported for the dithiolato product [(p-MeC6H4Pr
i
)2Ru2(µ-
SCH2Ph)Cl2] [115]. 
 
9.4.3  Dithiolato Complex 6 and the Corresponding Trithiolato Complex 30 
Synthesis and data for 6: In a 100 mL reaction flask, 100 mg (0.163 mmol) of [(6-p-Me-
C6H4
i
Pr)2Ru2Cl4] was dissolved in 45 mL of EtOH. 50.3 µL (0.343 mmol) 4-methoxy-α-toluenthiol, 
dissolved in 5 mL of EtOH were added dropwise by a glass pipet. The solution was heated to 50°C 
overnight. Afterwards the solvent was reduced to 2 mL in vacuo, and the product was precipitated 
by adding hexane. The solid was filtered, washed with hexane and dried in vacuo to give the 
product as a light orange powder. Yield: 124.2 mg (89%), ESI-MS: (MeOH + CH2Cl2): m/z = 822.8 
[M]
+
. C36H46Cl2O2Ru2S2: calcd. C, 50.99; H, 5.47; found C, 50.76; H, 5.46.  
1
H NMR (400 MHz, 
CDCl3): δ = 7.49 (d, 
3
J = 8 Hz, 2H, SCH2C6H4-p-OCH3), 6.85 (d, 
3
J = 8 Hz, 2H, SCH2C6H4-p-
OCH3), 5.15 – 4.89 [m, 8H, p-CH3C6H4CH(CH3)2], 4.15 (d, 
3
J = 11 Hz, 2H, SCH2C6H4-p-OCH3), 
3.83 (s, 6H, SCH2C6H4-p-OCH3), 3.26 (d, 
3
J = 11 Hz, 2H, SCH2C6H4-p-OCH3), 2.86 [sept, 
3
J = 8 
Hz, 2H, p-CH3C6H4CH(CH3)2], 1.89 [s, 6H, p-CH3C6H4CH(CH3)2], 1.2 [s, 12H, p-CH3C6H4CH-
(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 133.03, 131.71, 113.05, 86.49, 78.75, 55.36, 35.93, 
29.73, 23.69, 21.29, 18.81 ppm. 
Synthesis and data for 30[Cl]: Complex 6 (100 mg, 0.118 mmol) was dissolved in EtOH (50 
mL). Then 46 mg (0.354 mmol) of 4-hydroxythiophenol, dissolved in 10 mL of EtOH, were added 
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to this solution dropwise by a pipet, and the solution was refluxed overnight. The solution was 
concentrated to dryness, the residue dissolved in CH2Cl2 (1 mL) and subjected to column 
chromatography on silica gel (solvent system CH2Cl2/EtOH 7 : 1). The reddish band was collected 
and evaporated to dryness to give the product as an orange powder. Yield: 110.6 mg (89%), ESI-
MS: (MeOH + CH2Cl2): m/z = 903.1 [M]
+
. C42H51ClO3Ru2S3: calcd. C, 53.80; H 5.48; found C, 
53.42; H, 5.34. 
1
H NMR (400 MHz, CDCl3): δ = 10.30 (s, 1H, SC6H4-p-OH), 7.48 (d, 2H, 
3
J = 8 
Hz, SC6H4-p-OH), 7.42 (t, 
3
J = 7 Hz, 4H, SCH2C6H4-p-OCH3), 7.22 (d, 2H, 
3
J = 8 Hz, SC6H4-p-
OH), 6.98 (t, 
3
J = 9 Hz, 4H, SCH2C6H4-p-OCH3), 5.03 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 
4.91 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 4.71 [t, 
3
J = 6 Hz, 4H, p-CH3C6H4CH(CH3)2], 3.88 
(d, 6H, 
3
J = 6 Hz, SCH2C6H4-p-OCH3), 3.53 (s, 2H, SCH2C6H4-p-OCH3), 3.34 (s, 2H, SCH2C6H4-
p-OCH3), 2.02 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.69 [s, 6H, p-CH3C6H4CH(CH3)2], 
1.03 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2], 0.97 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 159.44, 159.32, 157.81, 133.88, 131.69, 130.6, 130.40, 115.38, 
114.00, 113.85, 106.95, 99.97, 83.72, 83.59, 82.28, 55.99, 55.46, 39.51, 39.27, 30.87, 23.15, 22.42, 
17.99 ppm. 
 
9.4.4  Cysteinato-Bridged Trithiolato Complex 8 
Synthesis and data for [8][BF4]: The dithiolato complex [(η
6
-p-MeC6H4Pr
i
)2Ru2Cl2(µ-SC6H4-
p-Bu
t
)2] (5) (0.056 mmol) was dissolved in 25 mL of methanol. To this solution, cysteine (10 eq, 
0.560 mmol) was added dropwise as a solution in 15 mL of distilled water. The mixture was stirred 
at room temperature for two days. 10 equivalents of NaBF4 were then added and the suspension was 
stirred overnight. The solution was filtered and methanol was evaporated at room temperature; the 
light orange solid that precipitated during the evaporation was washed thoroughly with water and 
redissolved in MeOH/H2O 9 : 1 mixture. The product was isolated by size exclusion 
chromatography on Sephadex® LH20 from the yellow band. The solvents were evaporated in 
vacuo, yielding a yellow powder. Yield: 52.4 mg (95%), ESI-MS (MeOH): m/z = 950.0 [M]
+
, 
C45H64BF4NO2Ru2S3·H2O, calcd. C, 51.27; H, 6.31; N, 1.33, found C, 51.33; H, 6.15; N, 1.39; 
1
H 
NMR (400 MHz, CDCl3): δ = 7.56 – 7.41 [m, 8H, SCH2C6H4-p-C(CH3)3], 5.57 [broad, 1H, p-
CH3C6H4CH(CH3)2], 5.49 [broad, 1H, p-CH3C6H4CH(CH3)2], 5.46 [d, 
3
J = 5 Hz, 1H, p-CH3C6H4-
CH(CH3)2], 5.32 [d, 
3
J = 5 Hz, 1H, p-CH3C6H4CH(CH3)2], 5.22 [broad, 1H, p-CH3C6H4CH(CH3)2], 
5.17 [broad, 1H, p-CH3C6H4CH(CH3)2], 5.02 [broad, 1H, p-CH3C6H4CH(CH3)2], 4.95 [broad, 1H, 
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p-CH3C6H4CH(CH3)2], 3.77 [m, 1H, SCH2CH(NH2)COOH], 3.73 – 3.42 [m, 4H, SCH2C6H5-p-
C(CH3)3], 3.01 [d,  
3
J = 12 Hz, 1H, SCH2CH(NH2)COOH], 2.75 [m, 1H, SCH2CH(NH2)COOH], 
2.23 [m, p-CH3C6H4CH(CH3)2], 2.03 [m, 6H, p-CH3C6H4CH(CH3)2], 1.37 (s, 18H, SCH2C6H5-p-
C(CH3)3] 1.14 – 1.00 [m, 12H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 
170.55, 151.29, 129.01, 125.31, 107.18, 84.36, 83.66, 83.42, 83.22, 82.84, 82.48, 56.73, 48.63, 
41.66, 40.42, 38.97, 34.20, 31.39, 22.94, 17.49 ppm. 
 
9.4.5  Diruthenium-1 ([9]Cl) 
The compound [(p-MeC6H4Pr
i
)2Ru2(SC6H4-p-Bu
t
)3]Cl (diruthenium-1) was synthesized by a 
slight variation of the published method [111] and isolated as HCl adduct [(p-MeC6H4Pr
i
)2Ru2-
(SC6H4-p-Bu
t
)3]Cl  0.8 HCl; the purity was verified by NMR spectroscopy and by correct carbon 
and hydrogen elemental analysis prior to use for the biological study. Microanalyses were carried 
out by the Mikroelementaranalytisches Laboratorium, ETH Zürich (Switzerland). 
Synthesis and Data of Diruthenium-1: 100 mg (0.16 mmol) of [(6-p-MeC6H4Pr
i
)RuCl2]2 were 
dissolved in 50 mL of ethanol puriss. The solution was heated to 60°C; as soon as the starting 
material was completely dissolved, a solution of 174 L (1.01 mmol) p-ButC6H4SH in 5 mL ethanol 
puriss. was added dropwise to the hot solution. The resulting mixture was refluxed for 18 h. After 
cooling to 20°C, the solvent was removed under reduced pressure. The red oil obtained was purified 
by column chromatography on silica gel using a mixture of dichloromethane and ethanol (7 : 1) as 
the eluent. The product was isolated from the main fraction as air-stable red crystalline solid and 
dried in vacuo. Yield: 150 mg (89%) C50H67Ru2S3Cl  0.8 HCl (1031.00): calcd. C 58.25, H 6.63; 
found C 58.27, H 6.63. ESI-MS (MeOH): m/z = 967.4 [M]
+
. 
1
H NMR (400 MHz, CDCl3): δ = 7.78 
(d, 
3
J = 8.0 Hz, 6H, SC6H4C(CH3)3), 7.38 (d, 
3
J = 8 Hz, 6H, SC6H4C(CH3)3), 5.41 (d, 
3
J = 6 Hz, 2H, 
MeC6H4Pr
i
), 5.20 (d, 
3
J = 6 Hz, 2H, MeC6H4Pr
i
), 5.12 (d, 
3
J = 6 Hz, 2H, MeC6H4Pr
i
), 5.06 (d, 
3
J = 
6 Hz, 2H, MeC6H4Pr
i
), 1.84 (sept, 
3
J = 7 Hz, 2H, CH(CH3)2), 1.65 (s, 6H, CH3), 1.35 (s, 27H, 
SC6H4C(CH3)3), 0.86 (d, 
3
J = 7 Hz, 6H, CH(CH3)2), 0.69 (d, 
3
J = 7 Hz, 6H, CH(CH3)2) ppm, 
13
C 
NMR (100 MHz, CDCl3): δ = 151.9, 134.5, 132.3, 126.2, 106.5, 100.7, 85.1, 84.6, 84.1, 84.0, 58.6, 
34.9, 31.3, 30.4, 22.5, 22.0, 17.8 ppm. 
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9.4.6  Complexes with Fluorinated Side-Chains 11 – 13 
Synthesis of 11 – 13: 0.153 mmol (93.8 mg) of the ruthenium p-cymene dichloride dimer were 
introduced in a Schlenk tube and dissolved in 20 mL of distilled methanol. 0.919 mmol of the 
corresponding thiol were dissolved in 10 mL of distilled MeOH and introduced dropwise into the 
Schlenk tube. The reaction mixture was refluxed under inert atmosphere for 40 hours (for 
compounds 11 and 13) or for 5 days (for compound 12). Afterwards the solvent was evaporated in 
vacuo and the mixture was separated by column chromatography on silicagel (solvent system 
CH2Cl2/EtOH 7 : 1). The red band was collected, solvents evaporated in vacuo and the product was 
recrystallized from CH2Cl2/pentane mixture. Resulting orange crystals were collected and dried 
under reduced pressure. 
Data for [11]Cl: Yield: 267.9 mg (90%). C50H40ClF51Ru2S3 (1943.56): calcd. C, 30.90; H, 2.07; 
found C, 30.62; H, 1.94. ESI-MS: (MeOH + CH2Cl2): m/z = 1908.1 [M]
+
, 
1
H NMR (400 MHz, 
CDCl3): δ = 5.72 – 5.48 [broad, 8H, p-CH3C6H4CH(CH3)2], 2.84 – 2.47 [broad, 12H, S-C2H4C8F17, 
2H, p-CH3C6H4CH(CH3)2], 2.22 [s, 6H, p-CH3C6H4CH(CH3)2], 1.27 [m, 12H, p-CH3C6H4CH-
(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 108.03, 101.92, 84.02, 83.72, 83.52, 33.55, 31.72, 
29.13, 23.52, 22.37, 18.31 ppm. 
Data for [12]Cl: Yield: 75.3 mg (34%). C38H40ClF27Ru2S3 (1343.46): calcd. C, 33.37; H, 2.98; 
found C, 33.47; H, 2.85. ESI-MS: (MeOH + CH2Cl2): m/z = 1308.7 [M]
+
, 
1
H NMR (400 MHz, 
CDCl3): δ = 5.72 – 5.48 [broad, 8H, p-CH3C6H4CH(CH3)2], 2.84 – 2.47 [broad, 12H, S-C2H4C8F17, 
2H, p-CH3C6H4CH(CH3)2], 2.22 [s, 6H, p-CH3C6H4CH(CH3)2], 1.27 [m, 12H, p-CH3C6H4CH-
(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 108.03, 101.92, 84.02, 83.72, 83.52, 33.55, 31.72, 
29.13, 23.52, 22.37, 18.31 ppm. 
Data for [13]Cl: Yield: 236.6 mg (94%). C44H40ClF39Ru2S3 (1643.51): calcd. C, 31.70; H, 2.45; 
found C, 31.73; H, 2.16. ESI-MS: (MeOH + CH2Cl2): m/z = 1608.98 [M]
+
, 
1
H NMR (400 MHz, 
CDCl3): δ = 5.72 – 5.48 [broad, 8H, p-CH3C6H4CH(CH3)2], 2.84 – 2.47 [broad, 12H, S-C2H4C8F17, 
2H, p-CH3C6H4CH(CH3)2], 2.22 [s, 6H, p-CH3C6H4CH(CH3)2], 1.27 [m, 12H, p-CH3C6H4CH-
(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 108.03, 101.92, 84.02, 83.72, 83.52, 33.55, 31.72, 
29.13, 23.52, 22.37, 18.31 ppm. 
Synthesis and data for [14]Cl: 0.153 mmol (93.8 mg) of the ruthenium p-cymene dichloride 
dimer were introduced in a Schlenk tube and dissolved in 20 mL of distilled methanol. 1.632 mmol 
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of the 1-octanethiol were dissolved in 10 mL of distilled MeOH and introduced dropwise into the 
reaction mixture. The mixture was refluxed under inert atmosphere for 7 days. Afterwards, 1.5 
grams of activated charcoal were added, the suspension was stirred for 1 hour and it was then 
filtered. The solvent was evaporated in vacuo and the mixture was separated by column 
chromatography on silicagel (solvent system CH2Cl2/EtOH 9 : 1). The red band was collected, 
solvent evaporated in vacuo and the product washed thoroughly with diethylether and pentane. 
Resulting orange powder was dried under reduced pressure. Yield: 40.4 mg (28%). C44H79ClRu2S3 · 
0.75 CH2Cl2 · 0.5 C5H12 (1041.66): calcd. C, 54.48; H, 8.37 found C, 54.58; H, 8.65 ESI-MS: 
(MeOH + CH2Cl2): m/z = 906.20 [M]
+
, 
1
H NMR (400 MHz, CDCl3): δ = 5.46 [t, 
3
J = 6 Hz, 4H, p-
CH3C6H4CH(CH3)2], 5.32 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 5.24 [d, 5 Hz, 2H, p-
CH3C6H4CH(CH3)2], 2.55 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 2.34 [m, 6H, S-C8H17], 2.17 
[s, 6H, p-CH3C6H4CH(CH3)2], 1.79 – 1.62 [m, 6H, S-C8H17], 1.54 – 1.42 [m, 6H, S-C8H17], 1.40 – 
1.26 [m, 24H, S-C8H17], 1.29 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2], 1.23 [d, 
3
J = 7 Hz, 6H, p-
CH3C6H4CH(CH3)2], 0.95 – 0.86 [m, 9H, S-C8H17] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 106.41, 
101.27, 83.60, 83.14, 82.98, 82.87, 77.30, 76.98, 76.66, 38.96, 32.78, 31.73, 31.52, 29.34, 29.14, 
23.89, 22.58, 22.36, 18.14, 14.02.ppm. 
 
9.4.7  Complexes with Halido Substituents 15 – 20 
General procedure for the synthesis of 15 – 17: 0.16 mmol of [(p-MeC6H4Pr
i
)2Ru2Cl4] were 
dissolved in EtOH (10 mL). When the compound had completely dissolved, the corresponding thiol 
RSH (0.32 mmol) was added dropwise as the solution in 5 mL of ethanol. The reaction was stirred 
at 50°C overnight, the volume of the mixture was then reduced to 5 mL and diethyl ether (30 mL) 
was added to fully precipitate the products. The filtration and washing of the solid 2 times with 20 
mL of diethylether afforded the products as orange crystalline powders. The products were dried 
under vacuum and analyzed. 
Data for 15: Yield: 132.9 mg (95%), ESI-MS (MeOH): m/z = 822.80 [M]
+
, 
C34H40Cl4Ru2S2·0.25 Et2O: calcd. C, 48.03; H, 4.89; found C, 48.03; H, 4.74, 
1
H NMR (400 MHz, 
CDCl3): δ =  7.51 (m, 4H, SCH2C6H4-p-Cl), 7.29 (m, 4H, SCH2C6H4-p-Cl), 5.02 – 4.76 [m, 8H, p-
CH3C6H4CH(CH3)2], 4.20 (d, 
3
J = 11 Hz, SCH2C6H4-p-Cl), 3.24 (d, 
3
J = 11 Hz, SCH2C6H4-p-Cl), 
2.84 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.90 [s, 6H, p-CH3C6H4CH(CH3)2], 1.20 [m, 12H, 
p-CH3C6H4CH(CH3)2] ppm. 
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Data for 16: Yield: 146.7 mg (95%), ESI-MS (MeOH): m/z = 910.70 [M]
+
, C34H40Br2Cl2Ru2S2: 
calcd. C, 43.52; H, 4.41; found C, 43.59; H, 4.14, 
1
H NMR (400 MHz, CDCl3): δ = 7.45 (m, 8H, 
SCH2C6H4-p-Br), 5.02 – 4.78 [m, 8H, p-CH3C6H4CH(CH3)2], 4.19 (d, 
3
J = 11 Hz, SCH2C6H4-p-Br), 
3.22 (d, 
3
J = 11 Hz, SCH2C6H4-p-Br), 2.85 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.90 [s, 6H, 
p-CH3C6H4CH(CH3)2], 1.21 [m, 12H, p-CH3C6H4CH(CH3)2] ppm. 
Data for 17: Yield: 122.4 mg (91%), ESI-MS (MeOH): m/z = 788.70 [M]
+
, 
C34H40Cl2F2Ru2S2·0.25 CH2Cl2: calcd. C, 48.68; H, 4.83; found C, 48.81; H, 4.87, 
1
H NMR (400 
MHz, CDCl3): δ = 7.55 (m, 4H, SCH2C6H4-p-F), 7.01 (m, 8H, SCH2C6H4-p-F), 5.02 – 4.77 [m, 8H, 
p-CH3C6H4CH(CH3)2], 4.20 (d, 
3
J = 11 Hz, SCH2C6H4-p-F), 3.26 (d, 
3
J = 11 Hz, SCH2C6H4-p-F), 
2.85 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.90 [s, 6H, p-CH3C6H4CH(CH3)2], 1.20 [m, 12H, 
p-CH3C6H4CH(CH3)2] ppm. 
General procedure for the synthesis of 18 – 20: Complexes 15 – 17 (100 mg) were dissolved 
in EtOH (50 mL). Then 3 equivalents of 4-hydroxythiophenol, dissolved in 10 mL of EtOH, were 
added to this solution dropwise by a pipet, and the solution was refluxed overnight. The solution 
was concentrated to dryness, the residue dissolved in CH2Cl2 (1 mL) and subjected to column 
chromatography on silica gel (solvent system CH2Cl2/EtOH 7 : 1). The reddish band was collected 
and evaporated to dryness to give the products as orange powders. 
Data for [18]Cl: Yield: 88.3 mg (83%), ESI-MS (MeOH): m/z = 910.80 [M
+
], 
C40H45Cl3ORu2S3·0.25 CH2Cl2: calcd. C, 49.96; H, 4.74; found C, 49.75; H, 4.82, 
1
H NMR (400 
MHz, CDCl3): δ = 10.42 (s, 1H, SC6H4-p-OH), 7.53 – 7.39 (m, 2H, SC6H4-p-OH, 8H, SCH2C6H4-p-
Cl), 7.22 (d, 2H,
 3
J = 8 Hz, SC6H4-p-OH), 5.08 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 4.97 [d, 
2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 4.71 [d, 
3
J = 6 Hz, 4H, p-CH3C6H4CH(CH3)2], 3.58 (s, 2H, 
SCH2C6H4-p-Cl), 3.41 (s, 2H, SCH2C6H4-p-Cl), 2.01 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 
1.70 [s, 6H, p-CH3C6H4CH(CH3)2], 1.04 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2], 0.98 [d, 
3
J = 7 
Hz, 6H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 159.88, 138.33, 138.21, 
133.86, 133.76, 133.38, 130.74, 130.48, 128.89, 128.77, 123.72, 117.12, 107.63, 99.85, 84.20, 
83.75, 83.20, 81.97, 30.96, 23.11, 22.65, 17.94 ppm. 
Data for [19]Cl: Yield: 108.2 mg (99%), ESI-MS (MeOH): m/z = 878.90 [M
+
], 
C40H45ClF2ORu2S3·0.75CH2Cl2: calcd. C, 50.08; H, 4.80; found C, 50.16; H, 4.66, 
1
H NMR (400 
MHz, CDCl3): δ = 10.39 (s, 1H, SC6H4-p-OH), 7.54 – 7.44 (m, 2H, SC6H4-p-OH, 4H, SCH2C6H4-p-
F), 7.28 (m, 2H, SC6H4-p-OH), 7.16 (q, 4H,
 3
J = 9 Hz, SCH2C6H4-p-F), 5.06 [d, 2H, 
3
J = 4 Hz, p-
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CH3C6H4CH(CH3)2], 4.94 [d, 2H, 
3
J = 4 Hz, p-CH3C6H4CH(CH3)2], 4.74 [d, 
3
J = 4 Hz, 4H, p-
CH3C6H4CH(CH3)2], 3.57 (s, 2H, SCH2C6H4-p-F), 3.40 (s, 2H, SCH2C6H4-p-F), 2.02 [sept, 
3
J = 7 
Hz, 2H, p-CH3C6H4CH(CH3)2], 1.60 [s, 6H, p-CH3C6H4CH(CH3)2], 1.04 [d, 
3
J = 7 Hz, 6H, p-
CH3C6H4CH(CH3)2], 0.98 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, 
CDCl3): δ = 160.11, 133.26, 130.90, 130.72, 130.64, 123.42, 117.26, 115.61, 107.58, 99.90, 84.12, 
83.65, 83.23, 34.07, 31.00, 23.17, 22.63, 22.29, 17.95, 14.02 ppm. 
Data for [20]Cl: Yield: 79.9 mg (72%), ESI-MS (MeOH): m/z = 1000.70 [M
+
], 
C40H45Br2ClORu2S3: calcd. C, 46.40; H, 4.38; found C, 43.21; H, 4.24 – possible degradation. 
1
H 
NMR (400 MHz, CDCl3): δ = 10.48 (s, 1H, SC6H4-p-OH), 7.64 – 7.55 (m, 4H, SCH2C6H4-p-Br), 
7.50 – 7.39 (m, 2H, SC6H4-p-OH, 4H, SCH2C6H4-p-Br), 7.26 (m, 2H,SC6H4-p-OH), 5.07 [d, 2H, 
3
J 
= 6 Hz, p-CH3C6H4CH(CH3)2], 4.96 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 4.77 [d, 
3
J = 6 Hz, 
4H, p-CH3C6H4CH(CH3)2], 3.56 (s, 2H, SCH2C6H4-p-Br), 3.39 (s, 2H, SCH2C6H4-p-Br), 2.00 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.63 [s, 6H, p-CH3C6H4CH(CH3)2], 1.04 [d, 
3
J = 7 Hz, 6H, 
p-CH3C6H4CH(CH3)2], 0.98 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, 
CDCl3): δ = 159.77, 138.88, 133.39, 131.83, 131.70, 131.13, 130.85, 123.88, 121.76, 121.66, 
117.03, 107.62, 99.82, 84.21, 83.78, 83.19, 81.98, 39.43, 39.08, 30.91, 23.09, 22.65, 17.95 ppm. 
 
9.4.8 Amido Group-Containing Trithiolato Derivatives 21 – 23 
General synthesis for products 21 – 23: 100 mg of the ruthenium dithiolato precursor were 
introduced in a Schlenk tube and dissolved in 40 mL of ethanol. 3 equivalents of the 4-
aminothiophenol were dissolved in 10 mL of EtOH and introduced dropwise into the Schlenk tube. 
The reaction mixture was refluxed for 16 hours. Afterwards the solvent was evaporated in vacuo 
and the mixture was separated by column chromatography on silicagel (solvent system 
CH2Cl2/EtOH 5 : 1). The orange band was collected, solvent evaporated in vacuo and the product 
was dried under reduced pressure. 
Data for [21]Cl: Yield: 91 mg (92%), ESI-MS: (MeOH): m/z = 869.6 [M]
+
. 
1
H NMR (400 
MHz, CDCl3): δ = 7.45 – 7.36 (m, 2H, p-SC6H4NH2, 4H, SC2H4C6H5), 7.31 (m, 6H, SC2H4C6H5), 
6.63 (d, 
3
J = 8 Hz, 2H, p-SC6H4NH2), 5.18 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 5.16 [d, 
3
J = 6 
Hz, 2H, p-CH3C6H4CH(CH3)2], 5.11 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 5.04 [d, 
3
J = 6 Hz, 
2H, p-CH3C6H4CH(CH3)2], 3.06 (m, 4H, SC2H4C6H5), 2.81 (t, 
3
J = 7 Hz, 2H, SC2H4C6H5), 2.62 (t, 
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3
J = 7 Hz, 2H, SC2H4C6H5), 2.17 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.81 [s, 6H, p-
CH3C6H4CH(CH3)2], 1.11 – 1.04 [m, 12H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, 
CDCl3): δ = 204.3, 148.47, 139.71, 139.69, 133.41, 128.73, 128.71, 128.61, 128.55, 126.83, 123.28, 
115.24, 107.07, 99.91, 84.31, 83.87, 83.26, 82.78, 57.89, 40.36, 39.81, 38.72, 38.63, 30.85, 23.09, 
22.55, 18.28, 17.75 ppm. 
Data for [22]Cl: Yield: 98.2 mg (89%), ESI-MS: (MeOH): m/z = 953.2 [M]
+
. 
1
H NMR (400 
MHz, CDCl3): δ = 7.50 – 7.38 (m, 2H, p-SC6H4NH2, 8H, p-SCH2C6H4-Bu
t
), 7.67 (d, 
3
J = 8 Hz, 2H, 
p-SC6H4NH2), 5.03 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.92 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 4.76 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.61 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 3.56 (s, 2H, p-SCH2C6H4-Bu
t
), 3.39 (s, 2H, p-SCH2C6H4-Bu
t
), 2.00 [sept, 
3
J = 
7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.72 [s, 6H, p-CH3C6H4CH(CH3)2], 0.99 [d, 
3
J = 6 Hz, 6H, p-
CH3C6H4CH(CH3)2], 0.94 [d, 
3
J = 6 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm. 
Data for [23]Cl: Yield: 80.8 mg (83%), ESI-MS: (MeOH): m/z = 842.11 [M]
+
, 
1
H NMR (400 
MHz, CDCl3): δ = 7.57 – 7.34 (m, 2H, p-SC6H4NH2, 8H, SCH2C6H5), 6.66 (d, 
3
J = 8 Hz, 2H, p-
SC6H4NH2), 5.06 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.93 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 4.73 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.67 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 3.56 (s, 2H, SCH2C6H5), 3.42 (s, 2H, SCH2C6H5), 2.00 [sept, 
3
J = 7 Hz, 2H, 
p-CH3C6H4CH(CH3)2], 1.72 [s, 6H, p-CH3C6H4CH(CH3)2], 1.01 [d, 
3
J = 6 Hz, 6H, p-
CH3C6H4CH(CH3)2], 0.95 [d, 
3
J = 6 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm. 
 
9.4.9  Carboxylic Acid-Containing Trithiolato Derivatives 24 – 26 
General synthesis for products 24 and 25: 400 mg of the ruthenium dithiolato precursor were 
introduced in a Schlenk tube and dissolved in 100 mL of ethanol. 3 equivalents of the 4-
mercaptobenzoic acid were dissolved in 20 mL of EtOH and introduced dropwise into the Schlenk 
tube. The reaction mixture was refluxed for 16 hours. Afterwards the solvent was evaporated in 
vacuo and the mixture was separated by column chromatography on silicagel (solvent system 
CH2Cl2/EtOH 5 : 1). The second orange band was collected, solvent evaporated in vacuo and the 
product was dried under reduced pressure. 
Data for [24]Cl: Yield: 64.6 mg (14%), ESI-MS: (MeOH): m/z = 898.11 [M]
+
. 
1
H NMR (400 
MHz, CDCl3): δ = 8.17 (d, 
3
J = 8 Hz, 2H, p-SC6H4COOH), 7.61 (d, 
3
J = 8 Hz, 2H, p-
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SC6H4COOH), 7.41 (m, 4H, SC2H5C6H5), 7.32 (m, 6H, SC2H4C6H5), 5.18 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 5.12 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 5.09 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 5.03 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 3.06 (m, 4H, SC2H4C6H5), 
2.83 (t, 
3
J = 7 Hz, 2H, SC2H4C6H5), 2.64 (t, 
3
J = 7 Hz, 2H, SC2H4C6H5), 2.15 [m, 2H, p-
CH3C6H4CH(CH3)2], 1.80 [s, 6H, p-CH3C6H4CH(CH3)2], 1.07 [d, 
3
J = 6 Hz, 6H, p-
CH3C6H4CH(CH3)2], 1.07 [d, 
3
J = 6 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm. 
Data for [25]Cl: Yield: 49.8 mg (11%), ESI-MS: (MeOH): m/z = 871.08 [M]
+
. 
1
H NMR (400 
MHz, CDCl3): δ = 8.21 (d, 
3
J = 8 Hz, 2H, p-SC6H4COOH), 7.79 (d, 
3
J = 8 Hz, 2H, p-
SC6H4COOH), 7.50 (m, 4H, SCH2C6H5), 7.46 – 7.29 (m, 6H, SCH2C6H5), 5.12 [d, 
3
J = 5 Hz, 2H, 
p-CH3C6H4CH(CH3)2], 5.00 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.84 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 4.71 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 3.62  (s, 2H, SCH2C6H5), 3.44 
(s, 2H, SCH2C6H5), 1.96 [sept, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.67 [s, 6H, p-
CH3C6H4CH(CH3)2], 0.96 [d, 
3
J = 6 Hz, 6H, p-CH3C6H4CH(CH3)2], 0.89 [d, 
3
J = 6 Hz, 6H, p-
CH3C6H4CH(CH3)2] ppm. 
Synthesis and data for product [26]Cl: 0.327 mmol of the ruthenium p-cymene dichloride 
dimer were introduced in a Schlenk tube and dissolved in 130 mL of distilled ethanol. 1.96 mmol of 
the 4-mercaptobenzoic acid were dissolved in 20 mL of distilled EtOH and introduced dropwise 
into the Schlenk tube. The reaction mixture was refluxed for 16 hours. Afterwards the solvent was 
evaporated in vacuo and the mixture was separated by column chromatography on silicagel (solvent 
system CH2Cl2/EtOH 1 : 1 with 0.1% of HCOOH). The red band was collected, solvent evaporated 
in vacuo and the product was recrystallized from MeOH/Et2O mixture. Resulting orange crystals 
were collected by filtration and dried under reduced pressure. Yield: 300 mg (95%), ESI-MS: 
(MeOH): m/z = 930.9 [M]
+
. C41H43ClO6Ru2S3 ·  0.75H2O (979.07): calcd. C, 50.30; H, 4.58; found 
C, 50.25; H, 4.66.  
1
H NMR (400 MHz, CDCl3): δ = 8.01 (d, 
3
J = 8 Hz, 6H, p-SC6H4COOH), 7.94 
(d, 
3
J = 8 Hz, 6H, p-SC6H4COOH), 5.83 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 5.60 [d, 
3
J = 5 
Hz, 2H, p-CH3C6H4CH(CH3)2], 5.43 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 5.39 [d, 
3
J = 5 Hz, 
2H, p-CH3C6H4CH(CH3)2], 1.91 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.55 [s, 6H, p-
CH3C6H4CH(CH3)2], 0.80 [d, 
3
J = 6 Hz, 6H, p-CH3C6H4CH(CH3)2], 0.67 [d, 
3
J = 5 Hz, 6H, p-
CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 167.38, 144.12, 133.22, 130.20, 
130.04, 107.40, 100.60, 85.79, 85.02, 84.25, 30.75, 22.64, 21.64, 17.54 ppm. 
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9.4.1 Propargyl Derivatives 31 – 34 
General procedure for the synthesis of 31 – 34: 0.052 mmol of the starting trithiolato complex 
was dissolved in DMF. The solution of propargyl bromide (30 equivalents) was added to this 
solution, followed by 30 equivalents of potassium carbonate. The suspension was stirred at room 
temperature for 3 days, after which the solvent was evaporated, the mixture redissolved in 
dichloromethane, filtered and the product was separated by the column chromatography on silica 
gel (solvent system dichloromethane/acetone 7 : 1). The product eluted in the second orange band. 
After the evaporation of the solvent, the resulting orange powder was washed with pentane and 
dried in vacuo. 
Data for [31][BF4]: Yield: 28.7 mg (57%), ESI-MS (MeOH): m/z = 879.90 [M]
+
. IR: 2110.5 
cm
-1
 C≡C stretch, C43H49BF4ORu2S3: calcd. C, 53.41; H, 5.11; found C, 53.36, H, 5.12. 
1
H NMR 
(400 MHz, CDCl3): δ = 7.74 (d, 2H, 
3
J = 8 Hz, SC6H4-p-OCH2CCH), 7.54 (t, 
3
J = 8 Hz, 4H, 
SCH2C6H5), 7.35 – 7.05 (m, 6H, SCH2C6H5), 6.96 (d, 2H, 
3
J = 8 Hz, SC6H4-p-OCH2CCH), 5.16 [d, 
2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 5.03 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 4.87 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 4.74 [m, 2H, p-CH3C6H4CH(CH3)2, 2H, SC6H4-p-OCH2CCH], 
3.66 (s, 2H, SCH2C6H5), 3.50 (s, 2H, SCH2C6H5), 2.56 (t, 1H, 
3
J = 2 Hz, SC6H4-p-OCH2CCH), 
1.93 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.75 [s, 6H, p-CH3C6H4CH(CH3)2], 0.98 [d, 
3
J = 7 
Hz, 6H, p-CH3C6H4CH(CH3)2], 0.92 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 
MHz, CDCl3): δ = 157.86, 139.82, 139.76, 133.90, 129.52, 129.36, 128.74, 128.56, 128.13, 128.01, 
115.47, 107.05, 100.02, 83.89, 83.80, 83.71, 82.34, 78.02, 77.28, 77.17, 76.97, 76.65, 75.86, 56.04, 
40.15, 39.87, 30.84, 23.16, 22.47, 18.05 ppm. 
Data for [32][BF4]: Yield: 21.2 mg (41%), ESI-MS (MeOH): m/z = 908.60 [M]
+
. IR: 2118.7 
cm
-1
 C≡C stretch, C45H53BF4ORu2S3: calcd. C, 54.32; H, 5.37; found C, 54.54; H, 5.37, 
1
H NMR 
(400 MHz, CDCl3): δ = 7.65 (d, 2H, 
3
J = 8 Hz, SC6H4-p-OCH2CCH), 7.43 – 7.27 (m, 6H, 
SC2H4C6H5), 6.92 (d, 2H, 
3
J = 8 Hz, SC6H4-p-OCH2CCH), 5.23 – 5.17 [m, 4H, p-CH3C6H4CH-
(CH3)2], 5.15 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 5.09 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH-
(CH3)2], 4.74 [d, 2H, 
3
J = 2 Hz, SC6H4-p-OCH2CCH], 3.12 – 3.02 (m, 4H, SC2H4C6H5), 2.86 (t, 2H,
 
3
J = 7 Hz, SC2H4C6H5), 2.63 (t, 2H,
 3
J = 7 Hz, SC2H4C6H5), 2.56 (t, 1H, 
3
J = 2 Hz, SC6H4-p-
OCH2CCH), 2.10 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.81 [s, 6H, p-CH3C6H4CH(CH3)2], 
1.05 [t, 
3
J = 7 Hz, 12H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 157.85, 
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139.86, 133.83, 129.83, 128.81, 126.80, 115.36, 106.97, 100.22, 84.25, 83.85, 83.73, 83.09, 55.97, 
40.96, 39.99, 38.66, 38.59, 30.87, 23.15, 22.44, 17.76 ppm. 
Data for [33][BF4]: Yield: 40.4 mg (72%), ESI-MS (MeOH): m/z = 993.0 [M]
+
. IR: 2119 cm
-1
 
C≡C stretch, C51H65BF4ORu2S3 · 0.1 C5H12: calcd. C, 56.94; H, 6.14; found C, 57.15; H, 5.94. 
1
H 
NMR (400 MHz, CDCl3): δ = 7.72 (d, 2H, 
3
J = 8 Hz, SC6H4-p-OCH2CCH), 7.52 – 7.40 [m, 8H, 
SCH2C6H4-p-C(CH3)3], 6.95 (d, 2H, 
3
J = 8 Hz, SC6H4-p-OCH2CCH), 5.09 [d, 2H, 
3
J = 6 Hz, p-
CH3C6H4CH(CH3)2], 4.96 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 4.86 [d, 2H, 
3
J = 6 Hz, p-
CH3C6H4CH(CH3)2], 4.74 [d, 2H, 
3
J = 2 Hz, SC6H4-p-OCH2CCH], 4.59 [d, 2H, 
3
J = 6 Hz, p-
CH3C6H4CH(CH3)2], 3.60 (s, 2H, SCH2C6H4-p- C(CH3)3), 3.40 (s, 2H, SCH2C6H4-p- C(CH3)3), 
2.56 (t, 1H, 
3
J = 2 Hz, SC6H4-p-OCH2CCH), 1.89 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.74 
[s, 6H, p-CH3C6H4CH(CH3)2], 1.35 [d, 18H, 
3
J = 12 Hz, SCH2C6H4-p-C(CH3)3], 0.94 [d, 
3
J = 7 Hz, 
6H, p-CH3C6H4CH(CH3)2], 0.90 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 
MHz, CDCl3): δ = 157.83, 151.64, 136.70, 133.87, 129.44, 129.25, 129.07, 125.49, 125.30, 115.44, 
106.85, 100.34, 84.00, 83.61, 83.55, 82.37, 56.05, 34.74, 34.70, 31.38, 30.77, 23.05, 22.60, 18.13  
ppm. 
Data for [34][BF4]: Yield: 32.1 mg (60%), ESI-MS (MeOH): m/z = 940.9 [M]
+
. IR: 2117.7 cm
-
1
 C≡C stretch, C45H53BF4O3Ru2S3: calcd. C, 52.63; H, 5.20; found C, 52.58; H, 5.41. 
1
H NMR (400 
MHz, CDCl3): δ = 7.72 (d, 2H, 
3
J = 8 Hz, SC6H4-p-OCH2CCH), 7.44 (t, 4H, SCH2C6H4-p-OCH3), 
7.00 (d, 2H, 
3
J = 8 Hz, SC6H4-p-OCH2CCH), 6.95 (t, 4H, SCH2C6H4-p-OCH3), 5.11 [d, 2H, 
3
J = 6 
Hz, p-CH3C6H4CH(CH3)2], 4.99 [d, 2H, 
3
J = 6 Hz, p-CH3C6H4CH(CH3)2], 4.84 [d, 2H, 
3
J = 6 Hz, 
p-CH3C6H4CH(CH3)2], 4.74 [m, 4H, p-CH3C6H4CH(CH3)2, 2H, SC6H4-p-OCH2CCH], 3.87 (d, 6H, 
3
J = 10 Hz, SCH2C6H4-p-OCH3), 3.57 (s, 2H, SCH2C6H4-p-OCH3), 3.38 (s, 2H, SCH2C6H4-p-
OCH3), 2.56 (t, 1H, 
3
J = 2 Hz, SC6H4-p-OCH2CCH), 1.93 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH-
(CH3)2], 1.74 [s, 6H, p-CH3C6H4CH(CH3)2], 0.99 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2], 0.93 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 159.45, 159.33, 
157.81, 133.88, 131.69, 130.60, 130.40, 115.38, 114.01, 113.85, 106.97, 99.96, 83.71, 83.60, 82.28, 
55.99, 55.51, 55.45, 39.51, 39.23, 30.86, 23.15, 22.42, 17.99 ppm. 
 
9.4.1  Ibuprofen Conjugates 35 – 38 
General procedure for the synthesis of complexes 35 – 38: All the ibuprofen conjugates were 
synthesized using standard Schlenk techniques. The dinuclear trithiolato complex (0.314 mmol), 
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(±)-ibuprofen (2.0 eq.) and DMAP (1.0 eq.) were dissolved in distilled CH2Cl2 (4 mL). A solution 
of DCC (2.0 eq.) in the distilled CH2Cl2 (3 mL) was added dropwise and the reaction was stirred at 
room temperature for 16 hours. The solvent was removed under reduced pressure and the mixture 
was redissolved in cold acetonitrile. The white precipitate was filtered off by a syringe filter (PTFE, 
0.22 µm) and the filtrate was evaporated and chromatographed on silica (solvent system 
CH2Cl2/Acetone 7 : 1). The main orange band was collected, the solvent evaporated to dryness and 
the solid was washed several times with pentane and dried in vacuo. 
Data for [35][BF4]: Yield: 27.7 mg (79%), ESI-MS (MeOH/CH2Cl2): m/z = 1031.5 [M]
+
. 
C53H63BF4O2Ru2S3: calcd. C, 56.98; H, 5.68, found C, 57.12; H, 5.72. 
1
H NMR (400 MHz, CDCl3): 
δ =  7.78 (d, 3J = 8 Hz, 2H, SC6H4-p-O), 7.57 – 7.35 [m, 10H, SCH2C6H5], 7.31 [d, 
3
J = 8 Hz, 2H, 
OCC(CH3)C6H4CH2CH(CH3)2], 7.18 [d, 
3
J = 8 Hz, 2H, OCC(CH3)C6H4CH2CH(CH3)2], 6.97 (d, 
3
J 
= 8 Hz, 2H, SC6H4-p-O), 5.12 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.98 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 4.82 [t, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.70 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 3.96 [q, 
3
J = 7 Hz, 1H, OCCH(CH3)C6H4CH2CH(CH3)2], 3.65 [s, 2H, 
SCH2C6H5], 3.45 [s, 2H, SCH2C6H5], 2.49 [d, 
3
J = 7 Hz, 2H, OCCH(CH3)C6H4CH2CH(CH3)2], 
1.90 [m, 2H, p-CH3C6H4CH(CH3)2; 1H, OCCH(CH3)C6H4CH2CH(CH3)2], 1.73 [s, 6H, p-CH3C6H4-
CH(CH3)2], 1.62 [d, 
3
J = 7 Hz, 3H, OCCH(CH3)C6H4CH2CH(CH3)2], 0.98 [d, 
3
J = 7 Hz, 6H,  
OCCH(CH3)C6H4CH2CH(CH3)2], 0.92 [m, 12H, p-CH3C6H4CH(CH3)2] ppm. 
13
C NMR (100 MHz, 
CDCl3): δ = 204.31, 173.01, 151.14, 140.91, 139.72, 136.99, 133.53, 129.55, 129.33, 128.75, 
128.58, 128.12, 128.02, 127.15, 122.15, 107.24, 100.13, 83.81, 82.40, 45.19, 40.09, 30.88, 30.15, 
25.36, 23.12, 22.44, 22.37, 18.51, 17.97, 15.23 ppm. 
Data for [36][BF4]: Yield: 25.8 mg (72%), ESI-MS (MeOH/CH2Cl2): m/z = 1058.8 [M]
+
. 
C55H67BF4O2Ru2S3: calcd. C, 57.68; H, 5.90, found C, 57.43; H, 5.92. 
1
H NMR (400 MHz, CDCl3): 
δ =  7.69 (d, 3J = 8 Hz, 2H, SC6H4-p-O), 7.43 – 7.28 [m, 10H, SC2H4C6H5; 2H, 
OCCH(CH3)C6H4CH2CH(CH3)2], 7.18 [d, 
3
J = 8 Hz, 2H, OCC(CH3)C6H4CH2CH(CH3)2], 6.94 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 5.20 [m, 2H, p-CH3C6H4CH(CH3)2], 5.18 – 5.10 [m, 4H, p-CH3C6H4-
CH(CH3)2], 5.07 [m, 2H, p-CH3C6H4CH(CH3)2], 3.96 [q, 
3
J = 7 Hz, 1H, 
OCCH(CH3)C6H4CH2CH(CH3)2], 3.13 – 3.00 (m, 4H, SC2H4C6H5), 2.87 (t, 
3
J = 7 Hz, 2H, 
SC2H4C6H5), 2.64 (t, 
3
J = 7 Hz, 2H, SC2H4C6H5), 2.49 [d, 
3
J = 7 Hz, 2H,  
OCCH(CH3)C6H4CH2CH(CH3)2], 2.07 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.89 [sept, 
3
J = 
7 Hz, 1H, OCCH(CH3)C6H4CH2CH(CH3)2], 1.81 [s, 6H, p-CH3C6H4CH(CH3)2], 1.62 [d, 
3
J = 7 Hz, 
3H, OCCH(CH3)C6H4CH2CH(CH3)2], 1.04 [t, 
3
J = 7 Hz, 12H, p-CH3C6H4CH(CH3)2], 0.93 [d, 
3
J = 
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7 Hz, 6H, OCCH(CH3)C6H4CH2CH(CH3)2] ppm. 
13
C NMR (100 MHz, CDCl3): δ = 204.30, 173.01, 
151.08, 140.39, 139.87, 136.96, 135.49, 133.48, 129.55, 128.86, 128.79, 128.75, 128.72, 127.15, 
126.80, 122.01, 107.12, 100.28, 84.27, 84.01, 83.83, 83.14, 58.43, 45.19, 45.01, 41.17, 40.19, 
38.63, 38.54, 30.88, 30.16, 23.15, 22.41, 22.37, 18.49, 17.77 ppm. 
Data for [37][BF4]: Yield: 24.7 mg (64%), ESI-MS (MeOH/CH2Cl2): m/z = 1143.7 [M]
+
. 
C61H79BF4O2Ru2S3: calcd. C, 59.59; H, 6.48, found C, 59.77; H, 6.73. 
1
H NMR (400 MHz, CDCl3): 
δ =  7.77 (d, 3J = 8 Hz, 2H, SC6H4-p-O), 7.44 [m, 8H, SCH2C6H4-p-C(CH3)3], 7.31 [d, 
3
J = 8 Hz, 
2H, OCC(CH3)C6H4CH2CH(CH3)2], 7.17 [d, 
3
J = 8 Hz, 2H, OCC(CH3)C6H4CH2CH(CH3)2], 6.97 
(d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 5.09 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.97 [d, 
3
J = 6 Hz, 
2H, p-CH3C6H4CH(CH3)2], 4.86 [m, 2H, p-CH3C6H4CH(CH3)2], 4.61 [d, 
3
J = 6 Hz, 2H, p-
CH3C6H4CH(CH3)2], 3.96 [q, 
3
J = 7 Hz, 1H, OCCH(CH3)C6H4CH2CH(CH3)2], 3.60 [s, 2H, 
SCH2C6H4-p-C(CH3)3], 3.40 [s, 2H, SCH2C6H4-p-C(CH3)3], 2.49 [d, 
3
J = 7 Hz, 2H,  
OCCH(CH3)C6H4CH2CH(CH3)2], 1.89 [m, 2H, p-CH3C6H4CH(CH3)2; 1H, 
OCCH(CH3)C6H4CH2CH(CH3)2], 1.73 [s, 6H, p-CH3C6H4CH(CH3)2], 1.62 [d, 
3
J = 7 Hz, 3H, 
OCCH(CH3)C6H4CH2CH(CH3)2], 0.99 – 0.82 [m, 12H, p-CH3C6H4CH(CH3)2; 6H, 
OCCH(CH3)C6H4CH2CH(CH3)2] ppm. 
13
C NMR (100 MHz, CDCl3): δ = 204.30, 173.02, 151.62, 
151.49, 151.11, 140.91, 136.99, 136.65, 135.00, 133.47, 129.55, 129.25, 129.03, 127.15, 125.50, 
125.32, 122.12, 107.06, 100.43, 83.97, 83.89, 83.63, 83.60, 82.40, 45.18, 45.01, 39.85, 39.40, 
34.73, 34.68, 33.46, 31.38, 30.79, 30.15, 25.44, 24.78, 22.97, 22.57, 22.37, 18.50, 18.02 ppm. 
Data for [38][BF4]: Yield: 26.9 mg (73%), ESI-MS (MeOH/CH2Cl2): m/z = 1091.5 [M]
+
. 
C55H67BF4O4Ru2S3 · 0.75C5H12: calcd. C, 57.31; H, 6.22, found C, 57.43; H, 6.17. 
1
H NMR (400 
MHz, CDCl3): δ =  7.76 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 7.43 [m, 4H, SCH2C6H4-p-OCH3], 7.31 [d, 
3
J = 8 Hz, 2H, OCC(CH3)C6H4CH2CH(CH3)2], 7.17 [d, 
3
J = 8 Hz, 2H, 
OCC(CH3)C6H4CH2CH(CH3)2], 7.00 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 6.95 [m, 4H, SCH2C6H4-p-
OCH3], 5.17 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.99 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH-
(CH3)2], 4.83 [m, 2H, p-CH3C6H4CH(CH3)2], 4.75 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 3.95 
[q, 
3
J = 7 Hz, 1H, OCCH(CH3)C6H4CH2CH(CH3)2], 3.86 [d, 6H, 
3
J = 10 Hz, SCH2C6H4-p-OCH3], 
3.56 [s, 2H, SCH2C6H4-p-OCH3], 3.37 [s, 2H, SCH2C6H4-p-OCH3], 2.49 [d, 
3
J = 7 Hz, 2H, 
OCCH(CH3)C6H4CH2CH(CH3)2], 1.89 [m, 2H, p-CH3C6H4CH(CH3)2; 1H, 
OCCH(CH3)C6H4CH2CH(CH3)2], 1.73 [s, 6H, p-CH3C6H4CH(CH3)2], 1.62 [d, 
3
J = 7 Hz, 3H, 
OCCH(CH3)C6H4CH2CH(CH3)2], 0.98 [d, 
3
J = 7 Hz, 6H,  OCCH(CH3)C6H4CH2CH(CH3)2], 0.92 
[m, 12H, p-CH3C6H4CH(CH3)2] ppm. 
13
C NMR (100 MHz, CDCl3): δ = 204.31, 173.00, 159.34, 
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151.10, 140.91, 136.99, 133.49, 131.59, 130.62, 130.38, 129.55, 127.15, 122.09, 114.04, 113.87, 
107.23, 107.19, 99.97, 99.92, 83.75, 82.33, 55.51, 45.19, 45.01, 39.56, 33.27, 30.89, 30.15, 23.11, 
22.43, 22.40, 18.51, 17.97 ppm. 
 
9.4.2  Chlorambucil Conjugates 39 – 43 
General Procedure for the Synthesis of 39 – 43: In a Schlenk tube, 30 mg of [(6-p-
MeC6H4
i
Pr)2Ru2(SCH2R)2(SC6H4-p-OH)]Cl  (R = Ph 0.032 mmol, R = CH2Ph 0.032 mmol, R = 
C6H4-p-
t
Bu 0.029 mmol, R = C6H4-p-OMe 0.030 mmol) were dissolved in distilled 
dichloromethane (10 mL), 10 equivalents of NaBF4 were added, and the mixture was stirred at 
room temperature for 12 hours. Then the solution was filtered through a syringe filter (0.22 µm), 
passed through a small plug of silica gel (solvent system CH2Cl2/acetone 7 : 1) and transferred into 
another Schlenk tube containing a solution of chlorambucil (2.0 equivalents) and 4-(dimethyl-
amino)pyridine (1.0 equivalent) in CH2Cl2 (5 mL). A solution of dicyclohexylcarbodiimide (2.0 
molar equivalents) in the CH2Cl2 (5 mL) was added dropwise to this mixture. The reaction was 
stirred at room temperature under nitrogen atmosphere for 16 hours. The solvent was then removed 
under reduced pressure, the residue dissolved in cold acetonitrile, filtered through a syringe filter, 
evaporated to dryness and chromatographed on silica gel (solvent system CH2Cl2/acetone 7 : 1). 
The first orange band was collected and evaporated to give the products as orange powders. Product 
43 required a thorough washing with pentane to remove all the remaining impurities. 
Data for [39][BF4]: Yield: 29.7 mg (84%), ESI-MS (MeOH/ CH2Cl2): m/z = 1128.4 [M]
+
. 
C54H64BCl2F4NO2Ru2S3·0.75CH2Cl2: calcd. C 51.42; H 5.16; N 1.10; found C 51.64; H 5.18; N 
1.15. 
1
H NMR (400 MHz, CDCl3): δ = 7.82 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 7.59 – 7.35 (m, 10H, 
SCH2C6H5), 7.15 [d, 
3
J = 8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2 ], 7.05 (d, 2H, 
3
J = 8 Hz, p-
SC6H4O), 6.76 [d, 
3
J = 8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 5.15 [d, 
3
J = 5 Hz, 2H, , p-
CH3C6H4CH(CH3)2], 4.99 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.86 [d, 
3
J = 5 Hz, 2H, p-
CH3C6H4CH(CH3)2], 4.71 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 3.75 [m, 4H, OCC3H6-p-
C6H4N(C2H4Cl)2], 3.66 [m, 4H, OCC3H6-p-C6H4N(C2H4Cl)2,  2H, SCH2C6H5], 3.46 (s, 2H, 
SCH2C6H5), 2.68 [t, 
3
J = 7 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 2.59 [t, 
3
J = 7 Hz, 2H, OCC3H6-
p-C6H4N(C2H4Cl)2], 2.05 [quint, 
3
J = 7 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 1.92 [sept, 
3
J = 7 Hz, 
2H, p-CH3C6H4CH(CH3)2], 1.76 [s, 6H, p-CH3C6H4CH(CH3)2], 0.99 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4-
CH(CH3)2], 0.92 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2]  ppm, 
13
C NMR (100 MHz, CDCl3): δ = 
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150.96, 139.73, 133.59, 129.93, 129.53, 129.35, 128.77, 128.61, 128.15, 122.30, 107.06, 100.27, 
84.11, 83.62, 82.46, 40.09, 39.91, 30.88, 23.20, 22.36, 18.00 ppm. 
Data for [40][BF4]: Yield: 31.5 mg (81%), ESI-MS (MeOH/CH2Cl2): m/z = 1158.0 [M]
+
. 
C56H68BCl2F4NO2Ru2S3: calcd. C 54.10; H 5.51; N 1.13; found C 53.71; H 5.53; N 1.23. 
1
H NMR 
(400 MHz, CDCl3): δ = 7.73 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 7.45 – 7.27 (m, 10H, SC2H4C6H5), 
7.13 [d, 
3
J = 8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2 ], 7.01 (d, 2H, 
3
J = 8 Hz, SC6H4-p-O), 6.68 [d, 
3
J = 8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 5.23 [d, 
3
J = 5 Hz, 2H, , p-CH3C6H4CH(CH3)2], 5.19 
[d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 5.15 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 5.10 [d, 
3
J 
= 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 3.72 [m, 4H, OCC3H6-p-C6H4N(C2H4Cl)2], 3.65 [m, 4H, 
OCC3H6-p-C6H4N(C2H4Cl)2,  2H, SCH2C6H5], 3.08 (m, 4H, SC2H4C6H5), 2.88 (m, 2H, 
SC2H4C6H5), 2.66, [m, 4H, OCC3H6-p-C6H4N(C2H4Cl)2], 2.59 (t, 
3
J = 8 Hz, 2H, SC2H4C6H5), 2.06 
[m, 2H, OCC3H6-p-C6H4N(C2H4Cl)2, 2H, p-CH3C6H4CH(CH3)2], 1.83 [s, 6H, p-CH3C6H4CH-
(CH3)2], 1.05 [t, 
3
J = 7 Hz, 12H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 
171.72, 150.92, 139.85, 133.53, 129.75, 128.85, 128.77, 128.72, 126.82, 122.15, 112.49, 107.03, 
100.37, 84.18, 83.95, 83.19, 41.17, 40.41, 40.19, 38.67, 38.55, 33.87, 33.54, 30.88, 26.51, 23.21, 
22.38, 17.80 ppm. 
Data for [41][BF4]:. Yield: 28.0 mg (79%), ESI-MS (MeOH/CH2Cl2): m/z = 1240.6 [M]
+
. 
C62H80BCl2F4NO2Ru2S3: calcd. C 56.10; H 6.07; N 1.06; found C 56.19; H 6.17; N 1.05. 
1
H NMR 
(400 MHz, CDCl3): δ =  7.80 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 7.45 [m, 8H, SCH2C6H4-p-C(CH3)3], 
7.14 [d, 
3
J = 8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2 ], 7.04 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 6.73 [d, 
3
J = 8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 5.11 [d, 
3
J = 6 Hz, 2H, , p-CH3C6H4CH(CH3)2], 4.97 
[d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.89 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.60 [d, 
3
J 
= 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 3.74 [m, 4H, OCC3H6-p-C6H4N(C2H4Cl)2], 3.66 [m, 4H, 
OCC3H6-p-C6H4N(C2H4Cl)2], 3.61 [s, 2H, SCH2C6H4-p-C(CH3)3], 3.41 [s, 2H, SCH2C6H4-p-
C(CH3)3], 2.67 [t, 
3
J = 7 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 2.58 [t, 
3
J = 7 Hz, 2H, OCC3H6-p-
C6H4N(C2H4Cl)2], 2.05 [quint,
 3
J = 7 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 1.89 [sept,
 3
J = 7 Hz, 
2H, p-CH3C6H4CH(CH3)2], 1.76 [s, 6H, p-CH3C6H4CH(CH3)2], 1.37 [s, 9H, SCH2C6H4-p-
C(CH3)3], 1.33 [s, 9H, SCH2C6H4-p-C(CH3)3], 0.94 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2], 0.89 
[d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2] ppm, 
13
C NMR (100 MHz, CDCl3): δ = 171.66, 151.57, 
150.87, 136.68, 133.53, 129.88, 129.06, 125.51, 125.34, 122.25, 106.89, 100.54, 84.17, 83.47, 
82.46, 39.94, 39.38, 34.74, 33.88, 33.45, 31.34, 30.79, 26.36, 23.05, 22.52, 18.07 ppm. 
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Data for [42][BF4]: Yield: 21.7 mg (53%). C56H68BCl2F4NO4Ru2S3: calcd. C 52.75; H 5.37; N 
1.10; found C 52.61; H 5.40; N 1.11. ESI-MS (MeOH/CH2Cl2): m/z = 1189.6 [M]
+
. 
1
H NMR (400 
MHz, CDCl3): δ = 7.80 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 7.44 (m, 4H, SCH2C6H4-p-OCH3), 7.12 [d, 
3
J = 8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2 ], 7.02 (m, 2H, SC6H4-p-O, 2H, SCH2C6H4-p-OCH3), 
6.95 (d, 
3
J = 8 Hz, 2H, SCH2C6H4-p-OCH3), 6.67 [d, 
3
J = 8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 
5.14 [d, 
3
J = 5 Hz, 2H, , p-CH3C6H4CH(CH3)2], 5.00 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.87 
[d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.77 [d, 
3
J = 5 Hz, 2H, p-CH3C6H4CH(CH3)2], 3.86 (d, 
3
J 
= 11 Hz, 6H, SCH2C6H4-p-OCH3), 3.72 [m, 4H, OCC3H6-p-C6H4N(C2H4Cl)2], 3.65 [m, 4H, 
OCC3H6-p-C6H4N(C2H4Cl)2], 3.59 (s, 2H, SCH2C6H4-p-OCH3), 3.39 (s, 2H, SCH2C6H4-p-OCH3), 
2.67 [t, 
3
J = 7 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 2.58 [t, 
3
J = 7 Hz, 2H, OCC3H6-p-
C6H4N(C2H4Cl)2], 2.05 [m, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 1.92 [m, 2H, p-CH3C6H4CH(CH3)2], 
1.76 [s, 6H, p-CH3C6H4CH(CH3)2], 0.99 [d, 
3
J = 6 Hz, 6H, p-CH3C6H4CH(CH3)2], 0.93 [d, 
3
J = 6 
Hz, 6H, p-CH3C6H4CH(CH3)2]  ppm, 
13
C NMR (100 MHz, CDCl3): δ = 204.305, 171.29, 159.36, 
150.9, 144.45, 134.95, 133.56, 131.64, 130.61, 130.40, 130.18, 123.70, 122.19, 114.05, 113.88, 
112.24, 109.93, 107.10, 100.09, 83.87, 83.65, 82.40, 55.50, 55.44, 53.59, 40.55, 33.86, 33.55, 
30.87, 26.53, 23.16, 22.34, 17.97 ppm. 
Data for [43][BF4]: Yield: 26.8 mg (70%). C54H62BCl4F4NO2Ru2S3·0.5C5H12: calcd. C 51.41; 
H 5.19; N 1.06; found C 51.51; H 5.06; N 1.36. ESI-MS (MeOH/CH2Cl2): m/z = 1197.8 [M]
+
. 
1
H 
NMR (400 MHz, CDCl3): δ = 7.81 (d, 
3
J = 8 Hz, 2H, SC6H4-p-O), 7.52 (m, 4H, S-p-CH2C6H4-Cl), 
7.45 (d, 
3
J = 8 Hz, 2H, , S-p-CH2C6H4-Cl), 7.39 (d, 
3
J = 8 Hz, 2H, , S-p-CH2C6H4-Cl), 7.12 [d, 
3
J = 
8 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2 ], 7.04 (d, 2H, 
3
J = 8 Hz, p-SC6H4O), 6.66 [d, 
3
J = 8 Hz, 2H, 
OCC3H6-p-C6H4N(C2H4Cl)2], 5.19 [d, 
3
J = 6 Hz, 2H, , p-CH3C6H4CH(CH3)2], 5.06 [d, 
3
J = 6 Hz, 
2H, p-CH3C6H4CH(CH3)2], 4.94 [d, 
3
J = 6 Hz, 2H, p-CH3C6H4CH(CH3)2], 4.82 [d, 
3
J = 6 Hz, 2H, 
p-CH3C6H4CH(CH3)2], 3.72 [m, 4H, OCC3H6-p-C6H4N(C2H4Cl)2], 3.65 [m, 4H, OCC3H6-p-
C6H4N(C2H4Cl)2,  2H, S-p-CH2C6H4-Cl], 3.46 (s, 2H, SCH2C6H5), 2.66 [t, 
3
J = 7 Hz, 2H, OCC3H6-
p-C6H4N(C2H4Cl)2], 2.57 [t, 
3
J = 7 Hz, 2H, OCC3H6-p-C6H4N(C2H4Cl)2], 2.04 [quint, 
3
J = 7 Hz, 
2H, OCC3H6-p-C6H4N(C2H4Cl)2], 1.90 [sept, 
3
J = 7 Hz, 2H, p-CH3C6H4CH(CH3)2], 1.76 [s, 6H, p-
CH3C6H4CH(CH3)2], 0.99 [d, 
3
J = 7 Hz, 6H, p-CH3C6H4CH(CH3)2], 0.92 [d, 
3
J = 7 Hz, 6H, p-
CH3C6H4CH(CH3)2]  ppm, 
13
C NMR (100 MHz, CDCl3): δ = 144.43, 138.39, 133.63, 130.70, 
129.71, 128.87, 122.32, 112.17, 107.26, 100.30, 84.03, 83.74, 82.41, 53.56, 40.52, 33.85, 30.85, 
23.19, 22.33, 17.97 ppm. 
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Abbreviations 
A      adenosine 
acac     acetylacetone 
al      aliphatic substituent 
Ala      L-Alanine 
ar      aromatic substituent 
ATP     adenosine triphosphate 
Asp     L-Aspartic acid 
Bcl-2     B-cell lymphoma 2 
bip      bipyridine 
Bu
t
      tert-butyl group 
BW     body weight 
bz      benzene 
C      cytidine 
Cys     L-Cysteine 
COX     cyclooxygenase 
dha      dihydroanthracene 
dmso     dimethyl sulfoxide 
DNA     deoxyribonucleic acid 
DOSY     Diffusion-ordered spectroscopy 
dpp     2,3-bis(2-pyridyl)pyrazine 
en      ethylenediammine 
EPR      electron paramagnetic resonance spectroscopy 
ERK     extracellular signal-regulated kinases 
ESI-MS     electrospray ionization mass spectroscopy 
G      guanosine 
GSH     reduced form of glutathione 
GSSG     oxidized form of glutathione 
His      L-Histidine 
hmb      hexamethylbenzene 
HSP70     heat shock protein 70 
I      integral (in Chapter 9) 
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IC50     inhibitory concentration of 50% of cells 
ICP-MS     inductively coupled plasma mass spectroscopy 
im      imidazole 
ind      indazole 
inda      indane 
i.p.      intraperitoneal administration 
i.v.      intravenous administration 
LDH     lactate dehydrogenase 
MAP     mitogen-activated protein 
MTD     maximal tolerated dose 
MTT  3(4,5dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide) 
MS      mass spectroscopy 
NCI     National Cancer Institute 
NMR     nuclear magnetic resonance spectroscopy 
NSAID     non-steroid anti-inflammatory drug 
p.o.      per oral administration 
p-cym      para-cymene 
PCNA     proliferating cell nuclear antigen 
Pr
i 
     isopropyl group 
pta      1,3,5-triaza-7-phosphatricyclo-[3.3.1.1
3,7
]decane 
rt      room temperature 
SD      standard deviation 
SEM     standard error of the mean 
T      thymidine 
tha       tetrahydroanthracene 
THF     tetrahydrofuran 
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The goal of the presented thesis was to investigate the properties of dinuclear arene ruthenium 
thiolato-bridged complexes and to establish their potential as anticancer drugs. In the first part of 
the thesis, several monothiolato, dithiolato and trithiolato complexes were synthesized and 
evaluated for their stability and reactivity with biological substrates. The results were correlated 
with the in vitro anticancer activity of the three types of complexes and showed the most stable 
trithiolato complexes to be the most active against ovarian cancer cell lines. Subsequently, the most 
active trithiolato derivative, diruthenium-1, was thoroughly investigated in vitro and in vivo to 
establish the mode of action of this complex, showing its promising ability to influence the tumor 
growth and to prolong the survival of tumor-bearing mice.  
In the second part of this thesis, three series of conjugates of the mixed trithiolato complexes 
were synthesized to demonstrate the potential of the coupling of dinuclear arene ruthenium 
complexes with biologically active organic molecules. Thus, the thiolato-bridged complexes were 
coupled with propargyl bromide, the resulting conjugates being available for the 1,3-Huisgen 
addition with tumor targeting compounds. Conjugates with ibuprofen were synthesized to 
investigate the effect of the antiinflamatory agent on the activity and selectivity of the resulting 
complexes towards cancer cells. Finally, conjugates of dinuclear trithiolato arene ruthenium 
complexes with alkylating agent chlorambucil were synthesized to show the effect of the two 
different modes of action of the conjugates on their activity in vitro and in vivo.  
These results show the potential of the dinuclear thiolato-bridged arene ruthenium complexes as 
a versatile platform for the synthesis of anticancer agents with variable biological properties and 
modes of action. 
 
 
